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Abstract 
Due to the side-effects caused by regular chemotherapy, the development of drug delivery 
systems that can specifically target cancer cells and deliver the therapeutic dose is required. 
In this study, a folate-derivative of β-cyclodextrin has been studied as a vehicle for targeting 
folate receptors (FR) and delivering the chemotherapeutic drug methotrexate (MTX). FRs can 
be considered key cell membrane targets since they are commonly over-expressed in cancer 
cells and play an important role in cancer development and progression. Cyclodextrins (CDs) 
are cyclic oligosaccharides with a unique structure that allows them to form inclusion 
complexes with guest molecules, increasing their aqueous solubility and efficacy. MTX is a 
chemotherapeutic drug that acts by inhibiting folate metabolism and is used worldwide for 
the treatment of different types of cancer. 
Cellular uptake of folic acid is mediated with high affinity by FRs while the cellular uptake of 
antifolates, such as MTX, is mediated with high affinity by the reduced folate carriers 
(RFCs). This study addresses the gene (mRNA) and protein expression levels of FRs and 
RFCs in the carcinoma cell lines KB (cervical carcinoma), CaCo-2 (colon), SKOV-3 
(ovarian), HeLa (cervical), MCF-7 (breast), A549 (lung) and the normal cell line BEAS-2B 
(bronchial epithelial), quantified by real-time polymerase chain reaction (real-time PCR) and 
flow cytometry, respectively. Real-time PCR and flow cytometry data demonstrated that 
levels of FR protein in KB and CaCo-2 cells are high, while levels in SKOV-3, HeLa and 
MCF-7 cells are moderate. A549 and BEAS-2B cells express low levels of FR protein. These 
experiments have also shown that all cell lines ubiquitously express moderate levels of RFC. 
The cell lines KB, CaCo-2, MCF-7, A549 and BEAS-2B were used in cell viability assays to 
assess the cytotoxicity of the carrier CDEnFA, the free drug MTX and the drug complex 
CDEnFA:MTX. A 48-hour exposure to the compounds demonstrated that the carrier 
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CDEnFA caused minor cytotoxicity towards all cells indicating it is biocompatible to the 
cells tested. Free MTX is more toxic than the complex CDEnFA:MTX towards cell lines 
expressing low levels of FR, such as the BEAS-2B. More importantly, the results have 
demonstrated that the complex CDEnFA:MTX showed greater cytotoxicity than the free drug 
towards the high FR expressing KB and CaCo-2 cells, indicating that it has potential to target 
this receptor, enhancing the specificity and the efficiency of the drug.   
Protein inhibition was used to better understand the role of FRs and RFCs in the uptake and 
internalisation of the drug MTX from the complex CDEnFA:MTX. To elucidate whether the 
FR captures and internalises the whole complex or the β-cyclodextrin remains extracellular 
and the RFC is the responsible for the internalisation of the MTX, the drugs fumonisin-B1 
and sulfasalazine were used to inhibit FRs and RFCs, respectively. After a pre-treatment with 
these drugs, KB cells, which are high FR-expressing cells, were treated with MTX and 
CDEnFA:MTX to assess if the cytotoxicity caused by these compounds was decreased after 
inhibition of each transporter. The results demonstrated a decreased cytotoxicity caused by 
the MTX after inhibition of RFCs, confirming its internalisation through this transporter. The 
results also demonstrated that the cytotoxicity caused by CDEnFA:MTX is decreased after 
inhibition of each receptor and significantly decreased after a co-treatment that inhibits both 
transporters. This indicates that the cytotoxic effect from the complex CDEnFA:MTX can be 
a result of the drug uptake and internalisation through two routes: (1) after CDEnFA:MTX 
binds to the folate receptor on the cell membrane, MTX is released from the cyclodextrin 
cavity and internalised through the RFC. (2) The CDEnFA:MTX binds to the FR on the cell 
membrane and this receptor internalises the whole complex by endocytosis. By using both of 
these routes of internalisation, CDEnFA:MTX can amplify the cytotoxic effect of the drug 
MTX. 
iii 
 
In vivo studies in the larvae of the greater wax moth Galleria mellonella were performed to 
evaluate how tolerant the larvae were to the carrier CDEnFA, and also to compare its 
tolerance to the complex and the free drug. The results have demonstrated that CDEnFA 
treatment did not result in the death of the organism and did not increase the larval immune 
response. This is a positive result and indicates that CDEnFA is not toxic and therefore, is a 
safe drug carrier to be used with in vivo models. Mortality assays have also shown that the 
complex CDEnFA:MTX caused slightly more toxicity towards the larvae than the free drug. 
However, G. mellonella are strongly resistant to the drug MTX, and for that reason, 
mammalian studies would be necessary to further evaluate the in vivo response to 
CDEnFA:MTX and its comparison to the effect of MTX alone. 
 
Keywords: cancer, chemotherapy, cyclodextrins, folates, folate receptors, methotrexate, 
reduced folate carriers, targeted therapy.  
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1.1 Introduction to cancer therapy 
The defining feature of cancer is the rapid replication of abnormal cells, which proliferate 
uncontrollably, can invade adjoining parts of the body and spread to other organs. Cancer is a 
leading cause of death worldwide and was responsible for 8.9 million deaths in 2016.
1
 
According to the World Health Organisation, cancer of the lung, liver, colorectum, stomach 
and breast cause the most cancer deaths every year.
2
 
Under normal conditions, cells from a specific tissue can exchange information with other 
cell types. However, genetic mutations can disrupt intercellular signals, which can lead to a 
change in the proliferation profile of cells.
3
 Figure 1.1 displays the structure of DNA at 
nucleotide base level and shows the structure of genes as compacted strands of DNA called 
chromosomes within the nuclei of cells. The mutations involved in cancer development 
include the mispairing of nucleotide base pairs, insertions or deletions of nucleotides or 
various chemical base changes. Alteration of larger segments of DNA, often at a 
chromosomal level, includes rearrangements, deletions, or duplications of DNA segments. 
Other modifications related to cancer do not involve a mutation of the DNA itself but can 
involve the addition or removal of chemical markers, which can influence gene expression.
4
 
These changes and mutations may be inherited, induced by environmental factors, or result 
from endogenous DNA replication errors or metabolic processes.
5
 Abnormal conditions can 
be temporary and reversible, but under persistent inflammation, there is an upregulation of 
enzymes that can disrupt the extracellular matrix, and thus, invading immune cells can 
overproduce factors that promote abnormal proliferation.
6
 Cancer cells interact with their 
micro- and macro-environments changing surrounding tissues and enhancing abnormal 
interactions, as malignancy progresses. At this point, the tumour becomes its own organ, with 
distinct characteristics that now defines all its cellular responses.
7
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Figure 1.1. Nucleus of the cell with the genes arranged in long strands of tightly packed 
DNA called chromosomes. DNA is made up of four nucleotides: adenine (A), thymine (T), 
guanine (G), and cytosine (C). A binds with T, and G binds with C to form base pairs, which 
connect the two DNA strands.
8
 
 
 
As a result of the uncontrolled cellular replication, there is the formation of an initial visible 
mass, called the "primary" tumour. Cells from a primary tumour can colonise the same or 
different organ sites in a process called metastasis.
9,10
 Metastasis remains the principal cause 
of mortality in cancer patients despite decades of research aimed at restricting tumour 
growth.
11
 The type of cancer is determined by the organ in which the cancer starts, as well as 
the morphological cell type from which the cancer is derived i.e. cancers from connective 
tissue are known as sarcomas, cancers of epithelial cells are known as carcinomas and 
carcinoma derived from cells of glandular origin are called adenocarcinoma.
9
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Based on tumour behaviour, cancers can be classified according to their stage. Cancer staging 
systems describe how far the cancer has spread anatomically and attempt to characterise 
patients with a similar prognosis into the same staging group. There are generally five 
progressive stages for carcinoma, 0, I, II, III and IV. Stage I are small localized cancers, II 
and III are locally advanced and/or involve lymph nodes, while stage IV are inoperable or 
metastatic. There is also an additional staging system for some cancers, such as in colorectal 
carcinomas, which is denominated as “TNM”.9 The system describes three events, as they 
appear on clinical examination and indicates the anatomic extent of the cancer, where T 
represents local Tumour growth, N represents spread to regional lymph Nodes and M is 
metastasis. A number is added to each letter to indicate the size and/or extent of the primary 
tumour and the degree of cancer spread.
12
 
 
1.1.1 Cancer treatment options 
Cancer therapy is usually more effective when the cancer is diagnosed at an early stage of the 
disease and when the treatment option is specific for the diagnosed tumour. Combinations of 
treatments can be administered depending on the type of cancer and given at different times. 
Neoadjuvant and adjuvant therapies are combined therapies that have been shown as 
promising approaches in the search for curative treatments. Neoadjuvant therapy is the 
administration of therapeutic agents before the main treatment and aims to downstage the 
primary tumour by an early attack on systemic micro-metastatic disease. Adjuvant therapy is 
a strategy in which a treatment is given, in addition to and usually after, the primary or main 
therapy to maximize its effectiveness.
13
 
The most commonly used treatment options are surgery, radiotherapy, immunotherapy, 
hormone therapy and chemotherapy. Surgery can be used to remove or shrink the tumour and 
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works best for solid tumours that are contained in one area. For example, the primary 
treatment for invasive breast cancers is by surgical removal of the tumour. Surgery is also the 
first step in brain tumour treatment to remove as much of the tumour as is safe without 
affecting normal brain function.
14
 Radiation therapy is the use of high-energy particles or 
waves, such as x-rays, gamma rays, electron beams, or protons, to destroy or damage cancer 
cells. Radiation works by directly targeting cellular DNA, causing induced-cell death to 
eradicate or shrink the tumours.
15
 Radiotherapy can also help to reduce problems that may be 
caused by a growing tumour, such as breathing issues or loss of bowel and bladder control. 
Tumours are successfully treated with radiotherapy if they are at an early stage. It is 
commonly used to treat non-melanoma skin cancer, head and neck cancer, breast cancer, non-
small cell lung cancer, cervical and prostate cancer. Metastatic cancers are generally 
incurable with radiation therapy because it is not possible to treat the whole body.
16
  
Immunotherapy is a type of cancer treatment that activates and helps the cells from the 
immune system to fight cancer. The transfer of anticancer monoclonal antibodies and T cells 
from a donor to a cancer patient has been an effective treatment for a variety of 
haematological and solid malignancies.
17
 The success of immunotherapy reflects the ability 
of the donor cells or antibodies to induce an immediate immune reaction against the cancer, 
bypassing the requirement to activate endogenous immunity.
18
 A promising technology in 
immunotherapy that has shown impressive results in clinical trials for leukaemia, lymphoma 
and myeloma, is the use of genetically engineered T cells that express a Chimeric Antigen 
Receptor (CAR) on their membrane. These cells are designed to recognise a specific tumour 
antigen and combined with the T cell signalling domains, these cells can effectively target the 
tumour and activate the immune response.
19
 Hormone therapy is a treatment that can block 
the body’s ability to produce hormones, or can interfere with how hormones behave in the 
body. Hormone therapy is commonly used to treat some breast and prostate cancers. It is also 
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used for the treatment of endometrial cancer, as it is a hormone-dependent malignancy that 
proliferates in response to estrogen exposure. Hormones such as progesterone can be used to 
stop the estrogen to be released, and consequently, reduce the cancer’s proliferation 
response.
20
 Hormone therapy can stop cancer progression, slow its growth or reduce the 
chance of the cancer returning. It can also ease cancer symptoms, for example, hormone 
therapy may be used to reduce or prevent symptoms in men with prostate cancer who are not 
able to have surgery or radiation therapy.
21
 
Chemotherapy is the use of drugs to treat a disease.  Some chemicals can kill cancer cells and 
can be used as a treatment for primary tumours, and also when cancer has metastasized and 
has spread.
22
 Paul Ehrlich was the first researcher to coin the term “chemotherapy” as he used 
chemicals to treat infectious diseases, for example, arsphenamine (Salvarsan) to treat syphilis. 
He postulated that many more drugs could be synthesized chemically and be directed 
specifically against microbes or even against cancer cells.
23
 One of the first uses of a 
chemical to treat cancer was after World War I, when it was recognised that mustard gas (2-
chloroethyl sulphide), used as a weapon in the war, subsequently caused lymphoid and 
myeloid suppression in humans. 2-Chloroethyl sulphide was then used in a patient with 
lymphoma and it caused a high anti-tumour effect, but failed to produce durable 
remission.
24,25
 In 1948, folic acid was observed to stimulate cancer cell proliferation in 
children with leukaemia, and therefore, drugs with the ability to inhibit folic acid metabolism, 
such as aminopterin and methotrexate were introduced as chemotherapeutic agents.
24
 Folate 
and antifolate metabolism are discussed in more detail at the end of this chapter. In 1965, 
cisplatin was discovered by Barnett Rosenberg as a drug that could restrict cell division in 
bacterial cells and later reduce tumours and treat leukaemia in mice. This led to the use of 
cisplatin for a range of cancer types, but it was particularly effective for testicular cancer.
26
 
The mechanism of action reported for cisplatin was its ability to bind to DNA and cause cell 
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death.
27
 Since then, several other chemotherapeutic drugs have been identified for the 
management of cancer, with the majority of them used to damage DNA.
24,28
 These include 
cisplatin, doxorubicin, 5-fluorouracil, etoposide, and gemcitabine.
29
 DNA integrity is critical 
for cellular function and regular cell proliferation. Damage to DNA is detected by cell-cycle 
checkpoint proteins, whose activation induces cell-cycle arrest to prevent the transmission of 
damaged DNA during mitosis. DNA lesions that occur during the DNA synthesis phase can 
block replication progression and can lead to replication-associated DNA double-strand 
breaks. If the damaged DNA cannot be repaired, cell death can occur.
30
  
There are, however, limitations to chemotherapy, which include negative side effects and 
individual patient sensitivities to treatment. Table 1.1 below displays some examples of 
chemotherapeutic agents that affect DNA, their mode of action and their major side effects. 
These limitations occur due to a lack of specificity in delivery, as most chemotherapeutic 
agents target healthy and cancerous cells alike. As a consequence of this, the patient may 
suffer from side effects such as hair loss, appetite loss, fatigue, pain, diarrhoea, nausea, blood 
disorders etc. If the side effects are too severe, the patient may not be able to continue the 
treatment, and hence, chemotherapy can have an enormous impact on the control of cancer 
progression.
31
   
 
Table 1.1. Properties of DNA-damaging compounds used in the treatment of cancer.
29
 
Drug Mode of Action Major Side Effects 
Methotrexate 
Prevents DNA synthesis by inhibiting 
dihydrofolate reductase (DHFR) 
Myelosuppression; pulmonary toxicity; 
gastrointestinal toxicity; hepatotoxicity; 
nephrotoxicity; neurotoxicity 
Cisplatin DNA crosslinker 
Nephrotoxicity; neurotoxicity; 
ototoxicity 
Doxorubicin Topoisomerase II poison 
Cardiotoxicity; myelosuppression; 
neurotoxicity 
5-Fluorouracil 
Prevents DNA synthesis by inhibiting 
thymidylate synthase (TS) 
Neurotoxicity; gastrointestinal toxicity 
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Methotrexate (MTX) is the model drug that was applied in this work to damage and eliminate 
cancer cells. MTX is a chemotherapeutic drug used worldwide, on its own or combined with 
other chemotherapeutic agents, for the treatment of different types of cancer, such as breast 
cancer, osteosarcoma, head and neck cancers, lymphoma and leukaemia.
32
 MTX was 
originally developed in 1950 and its chemical structure is displayed in figure 1.2. 
 
 
Figure 1.2. Chemical structure of methotrexate. 
 
In low doses, it can also be used to treat autoimmune diseases, such as rheumatoid arthritis, 
lupus and Crohn’s disease. In 1951, Jane Wright demonstrated the use of MTX in solid 
tumours and reported remission of a breast tumour.
33
 Since then, there have been reports of 
MTX in the successful treatment of cancer of the marrow, choriocarcinoma and 
chorioadenoma.
34
  
Understanding the importance of folate for cell replication led researchers to speculate that 
folate analogues such as MTX could be useful in treating malignant tissues. MTX is a 
competitive inhibitor that stops folic acid metabolism by preferentially binding to the 
enzymes related to its metabolism. As shown in figure 1.3, MTX enters cells through the 
reduced folate carrier (SLC19A1) and acts by inhibiting the enzyme dihydrofolate reductase 
(DHFR), which results in accumulation of dihydrofolate (DHF) and depletion of cellular 
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folates. Cytosolic folylpolyglutamyl synthase (FPGS) adds glutamate residues to 
methotrexate to produce methotrexate polyglutamates (MTXPGs). The addition of glutamate 
residues to methotrexate increases its affinity for enzymes such as the thymidylate synthetase 
(TYMS) and enzymes of the de novo purine-synthesis pathway such as phosphoribosyl 
pyrophosphate amidotransferase (PPAT), phosphoribosylglycinamide formyltransferase 
(GAR transformylase), and IMP cyclohydrolase (ATIC). Other enzymes that are indirectly 
affected by methotrexate are 5,10-methylenetetrahydrofolate reductase (MTHFR) and 
methylenetetrahydrofolate dehydrogenase (MTHFD1). Hence, MTX interrupts the DNA 
synthesis process, and consequently, single (SSB) and double strand breaks (DSB) occur in 
the DNA helix. Repair mechanisms remove the damaged DNA and cell death then occurs via 
necrosis or apoptosis pathways.
35
 
 
Figure 1.3. Overview of methotrexate mechanism of action. Drugs and drug metabolites are 
indicated in yellow, transporters in pink, enzymes in green and cellular metabolites in blue. 
dTMP = deoxythymidine monophosphate; dUMP = deoxyuridine monophosphate; THF = 
tetrahydrofolate.
36
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However, to achieve high efficacy, high doses of MTX are required. To be effective MTX 
must be internalised into cells. However, MTX is anionic and cannot permeate negatively 
charged cell membranes due to repulsion, unless a high concentration is used. Also, the 
enzyme DHFR has a greater affinity for folate than for MTX unless the concentration of 
MTX is high.
37
  Besides the need for high doses, MTX has a narrow tumour spectrum and 
also does not cross the blood-brain barrier and therefore cannot be used for solid tumours and 
brain tumours. Resistance to MTX is also possible. A system for the delivery of MTX to the 
required site of action may avoid some of these disadvantages. 
To overcome the limitations of chemotherapy, drug delivery systems have been extensively 
studied, along with the identification of molecular biomarkers in cancer cells for targeted 
drug delivery systems. These targeted systems provide a novel exciting alternative 
therapeutic approach with long-term future benefits for cancer treatment. 
 
1.2 Drug delivery systems 
Drug delivery systems (DDS) can be used to increase the efficiency and specificity of the 
delivery process. DDS involve targeted delivery and/or controlled release of therapeutic 
agents. The efficiency of a treatment can be improved with the use of DDS as they may allow 
an increase in drug bioavailability, stability and aqueous solubility, improve cellular 
distribution and metabolic control. Higher specificity of the treatment can be achieved by 
targeting specific sites and pathways in the cells to be treated. These properties, when 
optimised, may help to reduce the side effects of the treatment.
38
 
The significant impact of targeted drug delivery lies in the ability to specifically guide a drug 
or drug carrier to minimize systemic toxic effects.
39
 In 1900, Paul Ehrlich postulated the 
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existence of specific cellular receptors and studied the possibility of binding to drugs. That 
was when he created the concept of a “magic bullet” to first describe targeted drug delivery. 
He envisioned that just like a bullet fired from a gun to hit a specific target, there could be a 
way to target microbes, or cancer cells, with the use of molecules or receptors.
23,24
 Specific 
properties of the targeted cells, the presence of molecular markers, characteristics of the 
environment and localisation of the cells are important factors that must be considered for the 
development of targeted DDS. 
The recognition of the target may be on various levels, including a whole organ, certain cells 
in an organ, or even individual components of specific cells, such as cell surface proteins. 
Recognition of the target on the molecular level is certainly the main form of recognition.
40
 
Molecular targets normally include receptors that are overexpressed or selectively expressed 
by particular cells or tissue components. These may include cell-surface carbohydrates 
(carbohydrate targeting), cellular antigens for antibodies (antibody targeting), and cell surface 
receptors (receptor targeting).
41
 Carbohydrates coat the surfaces of cells and have been used 
for cell recognition in antibacterial drug development. 3-deoxy-D-manno-2-octulosonic acid 
(KDO) and heptoses are examples of unique carbohydrates present on the cell surface of 
bacteria, that have been used in research for the development of antibiotics.
42
 In research and 
development for cancer therapy, antibody and receptor targeting are the most commonly 
explored potential targets. Antibodies bind to their targets with high specificity and binding 
efficiency, which makes them ideal candidates for targeted drug delivery. Antibody-drug 
conjugates (ADCs) are designed to direct a cytotoxic drug to cells expressing a cell-surface 
antigen recognized by an antibody.
43
 The approval of brentuximab vedotin in 2011, an ADC 
that targets tumour cells expressing the CD30 antigen in relapsed Hodgkin's lymphoma,  and 
the approval of ado-trastuzumab emtansine in 2013, an ADC that targets the human 
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epidermal growth factor receptor 2 in HER2-positive metastatic breast cancer, have sparked 
vigorous research in the field, with >65 ADCs currently in clinical evaluation.
44
   
An alternative strategy for developing a targeted drug is to design a receptor-targeted delivery 
system, which can identify and target tumour-associated receptors. These tumour-associated 
receptors or antigens can be derived from proteins synthesized by the tumour cell and are 
relatively restricted to or overexpressed in cancer cells when compared to the corresponding 
normal tissue.
45
 Folate receptors have been extensively studied as targets because of their 
high-affinity for the vitamin folic acid. These receptors are expressed in higher levels in 
cancer cells, and hence, appear to be promising targets for cancer treatment.
41
 The folate 
receptor is the target used in this study and will be discussed later in more detail. 
The specific ligand-receptor interaction can be utilized to concentrate a therapeutic agent at 
the diseased tissue, producing a preferred distribution profile.
46
 Successfully developed 
therapeutic agents are tailored to target specific receptors and can selectively attack malignant 
cells and avoid, for the most part, normal cells. As a result, these agents are expected to have 
very little associated toxicity. These therapeutic strategies have been shown to sensitize 
tumour cells to the effects of chemotherapy and radiotherapy.
47
 Efficient ligand-receptor 
interaction is dependent upon a variety of factors, such as the extent of expression of the 
receptor on targeted cells relative to non-target cells, receptor availability on the target cell 
surface, and the rate of internalization of that surface receptor following ligand binding. 
Furthermore, the expression of a promising tumour-targeting receptor may not be 
homogenously distributed within a tumour or may change its surface expression over time.
39
  
Receptor targeting involves attaching drugs to a ligand that binds to receptors expressed on 
the cell surface, thereby initiating receptor-mediated endocytosis.
41
 The development of 
receptor-targeted delivery systems is based on the direct coupling of an anti-cancer drug to a 
Chapter 1  Introduction 
13 
 
ligand or on encapsulation of the drug into a ligand-directed drug carrier.
48
  Figure 1.4 below 
shows the structure of ligand-directed/receptor-targeted drug conjugates. The construction of 
ligand-directed drug conjugates involves the association of targeting ligands to the drug using 
a linker system, or the drug can be encapsulated into a targeted drug-carrier through either 
chemical conjugation or physical interaction.
48
  
A   
B  
Figure 1.4. Ligand-directed drug delivery systems. (A) The drug is directly linked to the 
ligand through a linker system,
49
 or, (B) a drug-carrier system is used.
50
 
 
The carrier is a vehicle required to transport the loaded drug to the diseased tissue. Ideally, 
these systems should be non-toxic, non-immunogenic, biodegradable and stable, and should 
restrict drug distribution to target cells or tissues, through a molecular marker present in that 
site. In addition, the drug release rate should be controllable and predictable, and should not 
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affect the drug action.
51
 Their size and shape properties should be ideal for tissue penetration, 
cellular trafficking and facile control of cargo release.
52 Several different materials have been 
used as carriers for the purpose of delivering chemotherapeutics to tumours. These materials 
include cyclodextrins, lipids such as liposomes and exosomes, carbon such as nanotubes, 
graphene and nanocrystals, porous silica, polymers dendrimers, carbohydrates, iron oxide and 
proteins such as albumin or antibodies.
53
 Figure 1.5 depicts some of these materials. Each 
material has unique structural properties. For example, porous silica has uniform surface 
pores that allow easy functionalization of the surface to control drug loading and release.
54
 
Lipids have shown effective size-dependent properties and a high degree of biocompatibility 
and versatility.
55
 Cyclodextrins can form inclusion complexes with guest molecules to 
increase their solubility, stability and bioavailability.
56
 Hybrid material such as silica and 
cyclodextrins, for example, have also been studied for drug delivery and other applications.
57
 
Cyclodextrins are the proposed carrier used in this study and are discussed in more detail 
below.  
 
Figure 1.5. A range of drug delivery vehicles.
53 
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1.3 Cyclodextrins as carriers 
Cyclodextrins (CDs) were first identified in 1891 when Villiers isolated a crystalline 
substance from a culture medium of Bacillus amylobacter grown in the presence of 
starch.
58,59
 CDs are oligosaccharides that are produced by the cyclodextrin glucanotransferase 
(CGTase) enzyme in the degradation of starch. Their glucopyranose units form a truncated-
cone shaped structure and are linked by α-(1,4) bonds. α-Cyclodextrin consists of six of these 
glucose units while β-cyclodextrin and γ-cyclodextrin consist of seven and eight respectively. 
β-cyclodextrin is the most accessible and most used sub-type. 
X-ray studies identified that, in the cone-shaped structure of CD, primary hydroxyl groups 
(C6) are on the narrower edge of the structure while the secondary hydroxyl groups (C2, C3) 
are on the wider edge of the structure, as seen in figure 1.6 below, while ether-like oxygen 
atoms and hydrogen atoms, at C3 and C5, are on the inside of the cone.  This arrangement of 
atoms results in CDs having a hydrophobic cavity and hydrophilic exterior. These properties 
enable CDs both to form inclusion complexes and to dissolve in water.
59
 
 
A                                                                   B 
Figure 1.6. (A) Chemical structure of β-cyclodextrin and (B) a truncated-cone representation 
of cyclodextrins.
60
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For the formation of inclusion complexes, a guest molecule can be totally or partly included 
in the cavity and the weak non-covalent bond between the CD host and the guest results in 
the easy release of the guest molecule at the required site. The inclusion of a guest molecule 
in the CD cavity consists of the substitution of water molecules by a less polar molecular 
guest and is an energetically favoured process.
61
    
Because of their unique structure and properties, CDs have been used for different 
applications in industry. In the pharmaceutical industry, CDs have been used to increase drug 
solubility, bioavailability and stability, reduce irritation, prevent incompatibility and to mask 
odour and taste. Examples of the use of cyclodextrins in medicines on the European market 
are β-CD in cetirizine tablets, used to mask the unpleasant taste of the cetirizine 
dihydrochloride
62
 and γ-CD in minoxidil solution, used to increase drug solubility.63 
Cetirizine or zyrtec is an antihistamine and minoxidil is an antihypertensive vasodilator. 
Examples of β-cyclodextrin derivatives include SBE-β-CD (sodium salt of sulfobutylether-β-
cyclodextrin) used with intravenous antimycotic voriconazole to increase drug solubility
64
 
and RM-β-CD (randomly methylated β-CD) used in a nasal spray for hormone replacement 
therapy with 17β-estradiol for better drug absorption and enhanced bioavailability.65,66 CDs 
have also been used in the food and beverage industry as they can bind certain bitter materials 
or flavours in their cavity and stop them being perceived by the senses of taste and odour. For 
example, in non-alcoholic beverages based on green tea, cyclodextrins are used to mask the 
bitter taste of catechin, an antioxidant found in this type of tea.
67
 CDs have also been used in 
the agricultural industry to trap pesticides or herbicides and avoid the compound being lost 
through evaporation, hydrolysis, inactivation by wetness or degradation by light, and 
therefore, reduce the amount of pesticide needed in the formulation.
68,69
 
CDs can be derivatised through a multitude of hydroxyl groups and bound to other molecules 
which can then act as ligands, making these molecules interesting for targeted drug delivery. 
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For example, complexation of the drug doxorubicin with 2-hydroxypropyl-β-CD (HP-β-CD) 
was applied to increase permeability across the blood-brain barrier.
70
 Doxorubicin (DOX)‐
loaded β‐CDs equipped with multivalent mannose target units were efficiently taken up via 
receptor‐mediated endocytosis by MDA‐MB‐231 breast cancer cells that overexpress the 
mannose receptor.
71
 Diverse research groups have been working with the development and 
biological evaluation of folate derivatives of cyclodextrins. For example, Khattabi et al 
(2017) have worked on the synthesis and evaluation of a folic acid-carboxymethyl-β-
cyclodextrin aminated silica nanoparticle. These workers evaluated the activity of the CD-
conjugated nanoparticle with a combination of the anti-cancer drugs thymoquinone and 
melatonin in HeLa and MCF-7 cells, and showed an increased effect compared to 
unconjugated nanoparticles and the free drugs.
72
 Tao et al (2018) have investigated the in 
vitro and in vivo toxicity of a docetaxel/folic acid-β-cyclodextrin inclusion complex in KB 
cells and in mice, which indicated a favourable anti-tumour effect by inducing mitochondrial-
mediated apoptosis.
73
 
 
1.4 Folic acid as a ligand 
Folate is the generic term for a family of compounds that include folic acid and derivatives, 
such as tetrahydrofolate (THF), 5-methyltetrahydrofolate (5-methylTHF), 5-
formyltetrahydrofolate (5-formylTHF or folinic acid) and 5,10-methyleneTHF. Folic acid is 
the oxidized, synthetic form which does not exist in nature and its structure is displayed in 
figure 1.7 below. The terms folic acid and folate are sometimes used interchangeably. 
However, folic acid refers to the synthetic form of the molecule, while the term folate is used 
for naturally occurring folates, such as 5-methylTHF, shown in figure 1.8, which is a 
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biologically active form of folate. 5-MethylTHF is the most abundant form found in plasma 
and it is also the predominant active metabolite of ingested folate.
74
  
 
Figure 1.7. Chemical structure of folic acid. 
 
 
Figure 1.8. Chemical structure of sodium 5-methyltetrahydrofolate. 
 
Folate is one of the B vitamins and is essential for humans because of its important role in 
DNA synthesis and repair. Folate, amino acids and CO2 are the molecules required for the de 
novo synthesis of purines and pyrimidines, which are nitrogenous-ring, subunit structures of 
the nucleotides found in polymeric nucleic acids.
75
 The structures of purines and pyrimidines 
are displayed in figure 1.9 and are the nitrogenous bases paired as A-T and C-G within the 
DNA structure shown in figure 1.1. The synthesis of purines and pyrimidines is part of the 
DNA replication process, and therefore, folate is important for the cellular processes of cell 
replication and proliferation. In addition, the methylation of DNA, which is also a result of 
folate metabolism, plays a role in controlling gene expression and is important for cell 
differentiation.
76
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Figure 1.9. Purines and pyrimidines represent the nitrogenous bases within DNA. 
 
Natural folates must be enzymatically hydrolysed in the intestine to be absorbed, while folic 
acid can enter directly into the cell. As displayed in figure 1.10, after entering the cell, folic 
acid is converted into dihydrofolate (DHF) and then into tetrahydrofolate (THF) by the 
enzyme dihydrofolate reductase (DHFR). The natural folate, 5-methylTHF, is also converted 
into THF, which is the active form that carries one-carbon units required for DNA synthesis 
and repair. This conversion also generates methyl groups, which are required to regenerate 
methionine from homocysteine and are necessary for all genomic and non-genomic 
methylation reactions in the form of S-adenosyl methionine (SAM). The folate and the 
methionine cycles are essential to cellular function via interactions with other pathways.
77
 
Deficiencies in folate or aberrations in its metabolism can be a problem during pregnancy 
when the embryonic cells are differentiating and proliferating constantly and as a result, 
neural tube defects can occur.
78
 Folate deficiency can also be a problem for normal cell 
replication and can cause diseases, such as cancer.
79
 There are two principal mechanisms 
through which folate deficiency appears to be associated with the risk of cancer. The reduced 
intracellular levels of S-adenosylmethionine (SAM) in folate deficiency can alter cytosine 
methylation in DNA, leading to the activation of genes that are related to cancer 
development. Alternatively, folate deficiency may cause an imbalance in DNA precursors, or 
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the wrong incorporation of nucleotides into DNA, causing DNA damage.
80
 Results from 
animal studies on colorectal cancer suggest that folate plays a dual role. While it may protect 
against the initiation of cancer, it can also enhance the growth and progression of existent 
neoplastic cells.
81
 
 
Figure 1.10. Schematic of folate-mediated one-carbon metabolism. DHF = 
dihydrofolate, THF = tetrahydrofolate, DHFR = dihydrofolate reductase, MTHFD = 
methylenetetrahydrofolate dehydrogenase, MTHFR = methylenetetrahydrofolate reductase, 
dUMP = deoxyuridine monophosphate,  dTPM = deoxythymidine monophosphate, SAM = 
S-adenosyl methionine and MS = Methionine synthase.
82
 
 
In situations where cancer is already present, folate will contribute to rapid cell growth. 
Proliferating tumour cells have unique metabolic requirements characterized by enhanced 
nutrient uptake and metabolic pathways to support the biosynthesis of macromolecules 
needed for cell growth and division.
83
 This requirement of cancer cells for high levels of 
folate has made folate receptors (FR) the object of study for drug targeting purposes. FRs 
have been identified as molecular markers that have a higher expression in cancer cells than 
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in healthy cells.
49,84–88
 Folate has been used as a ligand associated with different carriers and 
chemotherapeutic drugs for DDS in cancer treatment and is the ligand used in this research. 
  
1.5 Folate receptors and reduced folate carriers  
Cells can uptake folate and antifolates (folate antagonists) through folate receptors (FRs) and 
reduced folate carriers (RFCs), although their transport kinetics and affinities differ. The FR 
is a membrane-bound protein with high binding affinity for folic acid. The RFC is an integral 
plasma membrane protein that has a high affinity for antifolates, such as methotrexate, but 
low affinity for folic acid.
89,90 While the RFC is expressed by various normal cells, there is a 
small proportion of FR in normal tissues. In contrast, FR is highly expressed on the 
membranes of many types of epithelial cancer, such as ovarian, cervical, lung, kidney, 
colorectal, and brain tumours.
41
 
The role of FR expression in tumours is not completely clear, but studies have suggested 
parallel roles for this receptor in both cell-growth regulation and signalling functions. 
According to Boshnjaku et al (2012), following uptake and internalization, FR can 
translocate to the nucleus and act as a transcription factor, which may directly regulate the 
expression of key developmental genes in cancer cells.
91
 Cells treated with an inhibitor of FR 
reduced their cell surface expression and showed subsequent impaired tumour cell 
proliferation, reduced colony formation and deregulated adhesion.
92
 Furthermore, folate 
uptake can promote cancer cell proliferation, migration and loss of adhesion through down-
regulation of the cell-cell adhesion molecule, E-cadherin, promoting cell motility and 
metastasis.
93 FR expression may also induce drug resistance by enhancing the anti-apoptotic 
ability of tumour cells.
94
 Therefore, considering that FR levels are reported to be high in 
specific malignant tumours compared to normal cells, are positively associated with tumour 
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progression and are significantly expressed in a limited number of non-malignant cell types, 
FRs are considered to be promising anti-tumour targets. 
Several FR-targeting anticancer therapies have been developed, which include two main 
strategies, 1) synthesise conjugate compounds that use folic acid as a ligand or 2) humanized 
monoclonal antibodies (mAbs) that are reactive to FRs or that can be conjugated to a drug 
molecule.
95
 An example of a mAb reactive to human FR is farletuzumab (Morphotek, USA).  
In January 2018, the Food and Drug Administration (FDA) accepted an Investigational New 
Drug (IND) application for MORAb-202, an antibody-drug conjugate (ADC), that uses a 
cathepsin-cleavable linker to combine farletuzumab with the microtubule inhibitor, eribulin. 
A phase 1 dose-escalation study will be conducted in the U.S. to evaluate the safety and 
preliminary efficacy of MORAb-202 in patients with solid tumours that express FR. The 
solid tumours to be studied include metastatic endometrial, ovarian, lung and triple-negative 
breast cancer.
96
 An example of a folic acid conjugate drug compound that is in development 
as a chemotherapeutic agent is vintafolide, which is composed of folic acid and the vinca 
alkaloid desacetylvinblastine hydrazide (DAVLBH, Endocyte Inc., USA). EC1456 is another 
conjugate molecule that targets FRs and consists of a folic acid molecule covalently linked to 
the cytotoxic agent, tubulysin B hydrazide (Tub-B-H, Endocyte Inc., USA).
97
 
Unlike FRs, which have a known key role in cancer development and can be used as 
biomarkers for targeted drug delivery, the RFC has not been as well investigated. However, it 
is known that RFC is a transport protein that is expressed, ubiquitously, in healthy tissues and 
tumours and is the major transporter for natural folates (5-methylTHF) and folate antagonists. 
RFC transports folate cofactors from the blood into cells of peripheral tissues. In human 
tissues, highly elevated human RFC transcripts are detected in placenta and liver, with 
significant levels in other tissues, including leukocytes, kidney, lung, bone marrow, intestine, 
and portions of the central nervous system and brain.
49
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Loss of RFC expression or function may have pathophysiologic consequences, including 
cancer. When antifolates are used for cancer treatment, loss of RFC transcripts and proteins 
results in antifolate resistance due to incomplete inhibition of cellular enzyme targets and 
insufficient substrate for polyglutamate synthesis.
98
 RFC transport is, therefore, a critical 
determinant of the anti-tumour efficacy of cytotoxic antifolates, such as the clinically relevant 
drugs currently used for cancer treatment, including MTX (methotrexate), PMX (pemetrexed) 
and pralatrexate.
99
 Given the importance of RFC to in vivo folate homoeostasis and the 
impact of folate deficiency on human health and disease, there is an interest in the study of 
RFC regulation in relation to exogenous folate levels. Liu et al (2005) have suggested a 
broad-reaching regulatory adaptation of mammalian cells to conditions of folate depletion or 
excess, involving mechanisms critical to folate cofactor uptake and retention.
100
 Hou et al 
(2014) demonstrated a novel post-transcriptional regulation of human RFC involving 
increased RFC transcripts and proteins, accompanying increased extracellular folates, 
attributable to differences in RFC transcript stabilities and also increased retention of RFC in 
the cell under conditions of folate excess, because of impaired intracellular trafficking and 
plasma membrane targeting.
99
 While antifolate drug conjugates are developed to selectively 
target FRs, RFC levels are nonetheless important determinants of the anti-tumour activities of 
these agents, since RFC impacts cellular folate pools, which compete for polyglutamylation 
and binding to intracellular enzyme targets. FR and RFC expression levels in different cell 
lines, regulation in response to a low folate environment, as well as the correlation between 
gene and protein levels of each receptor are discussed in detail in Chapter 2. 
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1.6 Uptake and internalisation of drug delivery systems 
Understanding the mechanisms of cellular uptake and internalisation is critical in developing 
drug delivery systems. An improved understanding of intracellular trafficking mechanisms 
allows for effective binding to specific locations within the targeted cells and can contribute 
to successful drug absorption, increasing the efficacy of certain drugs.
39
 Targeting cell 
surface receptors allows not only a drug carrier to deliver the therapeutic agent directly to the 
targeted site, but it also facilitates efficient internalisation. Research has demonstrated that 
targeting receptors that internalise can result in increased therapeutic activity in some tumour 
models.
101
 For example, Park et al (2002) demonstrated that anti-HER2 immunoliposomes 
containing doxorubicin bind efficiently to HER2-overexpressing cells in vitro, resulting in 
intracellular drug delivery and produce enhance antitumor efficacy in animal models.
102,103
 
Liposomal doxorubicin-loaded nanoparticles, that target the CD19 surface antigen on a B-cell 
lymphoma line, showed significant improvement over nanoparticles coupled to a non-
internalising receptor.
104 Similar results were achieved with folate receptor-targeted 
cyanoacrylate nanoparticles, which were internalised more efficiently in folate receptor 
expressing tumour cells than cells lacking the receptor.
105
 
The molecular mechanisms mediating the internalisation of particles are mainly dependent on 
their size. Large particles can be internalised via an energy-dependent process, which is 
inhibited by drugs that affect membrane vesicle formation. Smaller particles are generally 
internalised via protein (clathrin)-coated pits, while larger particles are internalized via 
caveolae membrane invaginations. In addition, there are mechanisms mediating the 
internalisation of particles that are independent of both clathrin and caveolae.
101
 These 
internalisation pathways are described in detail in Chapter 4. Membrane specific receptors 
most frequently enter the cell through endocytosis following the binding of a high-affinity 
ligand. Endocytosis is a mechanism common to all human cells because of the fluidity of the 
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plasma membrane surrounding cells. Macromolecules are internalised by a change in 
phospholipid plasma membrane structure which invaginates inwards and then separates into 
distinct transport vesicles with the macromolecules contained inside the vesicle. These 
vesicles then traffic along the endolysosomal scaffold.
106
 Figure 1.11 displays different 
internalisation pathways involved in the uptake of drugs. Through passive diffusion, drug 
molecules move from an area of high concentration to one of low concentration, in a process 
that requires no energy to proceed. Other particles are too large to use small channels to 
transport by passive diffusion through the plasma membrane. In this case, cells engulf the 
larger particles through endocytosis, which is an active energy requiring process that includes 
phagocytosis, pinocytosis and receptor-mediated endocytosis.
107
 Phagocytosis is a process 
wherein a cell binds to the particle on the cell surface and draws the item inward while 
engulfing it. Pinocytosis, also known as fluid endocytosis, is a mode of endocytosis in which 
small particles suspended in extracellular fluid are brought into the cell through 
an invagination of the cell membrane. In receptor-mediated endocytosis, a specific receptor 
on the cell surface binds tightly to its specific ligand and the plasma-membrane region 
containing the receptor-ligand complex then undergoes endocytosis, becoming a transport 
vesicle.108 
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Figure 1.11. Processes leading to cellular internalisation of delivered drugs. (A) Passive 
diffusion of free drug. (B) Non-specific phagocytosis of a nanoparticle. (C) Drug entrapped 
in fluid and uptake by pinocytosis. (D) Receptor-mediated endocytosis.
101
  
 
CDs are large hydrophilic molecules and cannot directly pass through the lipophilic plasma 
membranes of cells. Studies suggest that, in general, CD is only slightly absorbed in the 
stomach and small intestine.
109
 In the large intestine, it is absorbed after fermentation into 
smaller saccharides by colonic microbial flora. However, Fenyvesi et al (2014), demonstrated 
that fluorescently-labelled methyl-β-cyclodextrin was able to enter the intestinal epithelial 
cells, CaCo-2, by fluid-phase endocytosis from the apical side of the cell.
110,111
 Although CDs 
are generally not able to enter the cell through a passive mechanism, the use of a receptor-
targeted ligand coupled to the CD can trigger the endocytosis process. In that case, the cell is 
able to engulf and internalise a macromolecule such as the CD. The internalisation of the 
folate derivative of the β-cyclodextrin drug delivery system is further discussed in Chapter 4. 
As MTX is generally internalised through the RFCs and folic acid binds with high affinity 
and enters the cell through the FRs, the pathway for internalisation of a drug delivery system 
Chapter 1  Introduction 
27 
 
that includes both MTX and folic acid should be characterised. The pathways for molecule 
internalisation can be investigated through different methodologies. These include the use of 
fluorescent markers that can label molecules related to internalisation pathways and 
methodologies that involve the inhibition of genes and proteins responsible for these 
processes. 
 
1.7 Drug development approaches: In vitro and in vivo studies 
In drug development, pre-clinical tests include in vitro experiments with cell lines, followed 
by in vivo studies to verify pharmacological toxicity and safety. Cancer cell lines established 
and maintained in vitro have been effectively used in drug discovery and development, for 
example, to identify promising receptors for active drug targeting, to evaluate cytotoxic effect 
of compounds, or to analyse the mode of action of drugs. Understanding the cellular uptake 
and internalisation processes of a drug-conjugate candidate is important for the development 
of an effective drug delivery system. This can be analysed in vitro by using fluorescent 
molecules that can mark intracellular trafficking, which can then be detected through 
techniques such as flow cytometry, fluorescent microscopy and confocal microscopy. For 
analysis of a receptor-mediated uptake process, receptors can be inhibited using 
pharmacological inhibitors, which are chemicals that can block a protein function, or using 
methods that can inhibit gene and protein expression, such as gene knockdown or gene 
knockout methods. After inhibiting the expression or blocking the function of the receptor, 
the effect of the drug-conjugate candidate can be analysed to assess if the blocked receptor is 
responsible for the uptake.
112,113
 Assays that measure proliferation, viability and cytotoxicity 
are commonly used to monitor the response and health of cells after treatment with new drugs 
or drug delivery systems. After evaluating the cytotoxic effect of the drug to a range of cell 
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lines, animal models can be selected for screening of the toxicity effect, primarily to assess 
safety and biocompatibility.
114
  
The use of in vivo pre-clinical trials is essential to predict the clinical outcome of a specific 
drug in development. Adequate design, execution and reporting of animal model results, help 
to make pre-clinical data more reproducible and translatable to the clinic.
115
 Therefore, 
animal in vivo studies are performed to examine the preliminary efficacy, toxicity and 
pharmacokinetics of new drugs. Early in vivo testing specifically aims to demonstrate safety, 
which is important to determine whether a candidate drug has scientific merit to proceed with 
further development.
116
 In vivo pre-mammal models can be used for early in vivo screens and 
can be valuable in reducing problems when linking in vitro findings to in vivo readouts.
117
 
Animal testing is typically conducted in rodents, such as mice, followed by drug safety 
testing and certain efficacy evaluations in larger mammals, such as rabbits and dogs. When 
testing in mammalian models, large amounts of the drug candidate are necessary, which is 
not always feasible in the early stage of drug development.
118
 In addition, drug candidates 
may fail due to absorption, distribution, metabolic, elimination and toxicological properties. 
Invertebrate animal models have been used at this stage of pre-clinical trials as their use does 
not require specialised laboratory facilities, they are easy to manipulate, and do not require 
ethical approval. This makes invertebrate models ideal for use as in vivo models in place of or 
in advance of using mice and other vertebrate mammalian models. These models have 
demonstrated interesting use in toxicity and efficacy testing of new pharmaceuticals, sparing 
vertebrate animals from preliminary testing.
119
 Invertebrate organisms such as insects 
combine genetic amenability, low cost, and culture conditions compatible with large-scale 
screens. On the downside, protein divergence between invertebrates and humans causes a 
high rate of false negatives. Nevertheless, invertebrate models are a tool to bridge the gap 
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between in vitro and pre-clinical animal assays.
120
 Table 1.2 summarises some of the 
advantages and disadvantages of using invertebrate models in pre-clinical research. 
 
Table 1.2. Advantages and disadvantages of the invertebrate screening systems.
120
 
Advantages Disadvantages 
Numerous biological processes are conserved 
between mammals and invertebrates 
Some diseases cannot be modelled with 
invertebrates because the gene or organ does 
not exist 
Many genes are conserved between mammals 
and invertebrates 
Problems of molecule penetration 
Studies occur in a physiological context Concentration within an animal is unknown 
Low cost Protein conservation at the amino acid level 
is poor 
Genetics allow the identification of a drug 
effector pathway 
False negatives 
 
Insects such as the larvae of the wax moth, Galleria mellonella, have been used as screening 
tools in drug discovery as they are cheaper and easier to maintain when compared to 
mammalian models such as mice, rats and rabbits. They also have a convenient size for 
housing and manipulation, which makes them ideal for high-throughput studies.
121
 
Furthermore, although vertebrates have developed an adaptive immune response, their innate 
immune response still retains remarkable similarities with the immune response in insect 
models. In mammals and insects, the communication between and regulation of immune cells 
is carried out by cytokines.
122
 Therefore, similar pathogen recognition receptors and 
signalling pathways activate the immune response in both animals. In addition, in insects and 
mammals, the recognition of non-self cells and molecules happens through pathogen-
associated molecular patterns. Moreover, challenges in recognising and fighting pathogens 
are the same for any host.
122
 The similarities between the immune system in G. mellonella 
and mammals are described in detail in Chapter 5. G. mellonella larvae were used in this 
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work to assess drug tolerance. Although this is not a tumour model, a screening to evaluate 
the organism’s tolerance to the compounds, especially to the drug carrier without the 
chemotherapeutic agent is important to further confirm its biocompatibility and safety as a 
targeted-drug delivery vehicle. 
 
1.8 Aims of research 
Over the past 20 years, significant expertise has been developed at DIT in the synthesis and 
characterisation of cyclodextrin derivatives for various pharmaceutical applications. Recent 
work has involved the development of a folate-modified cyclodextrin, 6-deoxy-6-[(1-(2-
amino)ethylamino)folate-β-cyclodextrin (CDEnFA) for drug delivery.123 Cyclodextrins were 
chosen as carriers since they have a favourable structure as its hydrophobic cavity allows it to 
form inclusion complex with poorly soluble drug molecules. In addition, they can be 
modified so a ligand can be linked to it, which may increase the specificity of delivery. Folic 
acid was chosen as the tether in order to target folate receptors on cell membranes which 
provide a route for internalisation of folates into the cytosol of the cell. The literature is not 
completely clear on the levels of expression of FR and RFC in various cells lines. Therefore, 
the aim of this study was to assess FR and RFC levels in different cell lines and to evaluate 
the effectiveness of the drug delivery system, CDEnFA:MTX, towards a range of cancer cell 
lines. CDEnFA was used in this work as a targeted carrier to deliver the drug methotrexate 
and figure 1.12 shows the proposed chemical structure of CDEnFA:MTX.  
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Figure 1.12. The proposed structure of the targeted drug delivery system CDEnFA:MTX. 
Folic acid is shown in blue, the cyclodextrin is shown in red and the drug, MTX, is included 
in the CD cavity. 
 
The specific objectives of this work were to: 
1) Compare FR and RFC gene levels in a range of human cell lines grown in folate-
replete and folate-free medium to standardise the culture conditions. Then, to assess 
the gene and protein expression of FR and RFC in a range of untreated cell lines to 
address the conflicting reports of expression of these transporters and allow for 
selection of in vitro models for subsequent experiments using real-time PCR and flow 
cytometry. 
2) Evaluate the cytotoxicity of CDEnFA to certify that the carrier alone is not toxic to 
the cells, and then evaluate the cytotoxicity of free MTX and the complex 
CDEnFA:MTX towards selected cell lines with high, medium and low FR levels, 
comparing the outcomes between the complex and the drug alone and confirm FR 
targeting. 
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3) Investigate the cellular route of uptake and internalisation of the drug complex 
CDEnFA:MTX, using fumonisin-B1 and sulfasalazine as inhibitors of FRs and RFCs, 
and with this, clarify the roles of each transporter in these processes. 
4) Evaluate the in vivo toxicity of the targeted carrier CDEnFA to the larvae of the 
greater wax moth Galleria mellonella, to assess its safety to be used in invertebrate 
models, and assess its tolerance to the free drug and to the complex. 
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2.1 Introduction 
Cellular uptake of folate molecules is mediated by folate receptors (FRs) and reduced folate 
carriers (RFCs), although their transport kinetics and affinity differ between these routes. FRs 
bind with high affinity to folic acid (Km ~ 1 nM), 10 times higher than their affinity for 
antifolates, while RFCs function with high affinity for antifolates such as methotrexate (Km = 
5-10 µM) but low affinity for folic acid (Km = 200-400 µM).
1–4
 As mentioned in Chapter 1, 
studies have demonstrated that over-expression of FRs may provide a growth advantage for 
cancer cells through mechanisms related to folate uptake.
5
 FRs are highly expressed in a 
variety of cancers such as ovarian, cervical, lung, kidney, colorectal, and brain tumours, 
while their distribution in normal human tissues is restricted to low level expression on the 
apical surfaces of some organs, such as the kidney, lung and choroid plexus.
2,6,7
 However, 
levels of FRs differ between cell lines and contradictory reports of different levels are found 
in the literature for the same cell line. For example, Zhang et al (2015) demonstrated that 
MCF-7 cells (breast cancer cell line) express high levels of FR while Chen et al (2009) 
reported no significant levels when compared to cell lines such as KB and HeLa.
8
 Hartmann 
et al (2007) and O'Shannessy et al (2012) reported that breast cancer cell lines over-express 
FRs while Kelley et al (2003) reported low expression in this tissue.
9–11
 Some authors have 
used breast cancer cell lines such as MCF-7 and ZR75-1 as FR-negative controls.
12–15
 In 
addition, it can be found in the literature that the cervical cancer cell line HeLa highly 
expresses FR, as reported by Grove et al (2012), or that HeLa cells express low levels of FR, 
as shown by Bongartz et al (2013).
16,17
 Therefore, more studies are required to identify the 
cell lines which over-express these receptors and ideally identify the conditions required or 
responsible for such gene and protein expression regulation. 
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RFC is reported to have widespread tissue expression in mammalian cells. Whetstine et al 
(2002) have demonstrated that human RFC is ubiquitously expressed and reported high levels 
of RFC mRNA expression in placenta and liver tissue, followed by lower levels in kidney, 
bone marrow, and intestine. Of the tumour cell lines analysed, the highest levels of transcripts 
were detected in erythroleukaemia (K562) cells.
18
  
The levels of proteins, such as receptors and transporters in a cell, reflect the balance between 
synthesis and degradation. Protein synthesis starts at the transcription of DNA to RNA and 
continues with the translation of RNA to protein, and the regulation of these two processes, 
as well as post-translational modifications, are important in determining which proteins are 
present in a cell and in what amounts. The expression of FRs, for example, can be regulated 
in relation to intracellular homocysteine levels. Figure 2.1 illustrates folate metabolism and 
shows that, when folic acid or the natural folate, 5-methyltetrahydrofolate (5-methylTHF), is 
converted to tetrahydrofolate (THF), a methyl group is transferred to homocysteine. The 
homocysteine can then be converted to methionine, which plays a role in DNA methylation, 
or can be degraded to cysteine.
19
 When there is folate deficiency, homocysteine accumulates 
in the cell and it mediates the translational regulation of FR expression. Homocysteine binds 
covalently to the mRNA binding protein, hnRNP-E1 (heterogeneous nuclear 
ribonucleoprotein-E1), forming a protein-mRNA complex, for which FRs have high affinity. 
This interaction between mRNA and protein triggers FRs biosynthesis.
20
 Figure 2.2 shows 
how homocysteine accumulation stimulates folate receptor expression. Homocysteine build-
up induces a direct post-translational homocysteinylation of the protein hnRNP-E1, which 
results in the unmasking of a high-affinity FR-α mRNA cis-element binding site and leads to 
increased translation of FR.
21
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Figure 2.1. Overview of folate (one-carbon) metabolism. DHF=dihydrofolate; 
THF=tetrahydrofolate; MTHFR=methylenetetrahydrofolate reductase; MS=methionine 
synthase; SAH=S-adenosylhomocysteine; SAM=S-adenosylmethionine.
19
 
 
 
Figure 2.2. Effect of homocysteine accumulation. (A) Post-translational homocysteinylation 
of the protein hnRNP-E1 results in upregulation of FR mRNA. (B) mRNA-binding site in 
hnRNP-E1 protein with the covalent binding of L-homocysteine, through the replacement of 
a cysteine disulfide bond.
21
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Folate receptors are cell-surface glycoproteins that mediate folate uptake through 
endocytosis. There are three main subtypes of FR, FR-α, FR-β and FR-γ. FR-γ is a secretory 
protein while FR-α and FR-β are membrane-associated forms. FR-β is expressed in normal 
hematopoietic cells, but it is only functional for folate binding in activated monocytes and 
macrophages.
22
 FR-α is the most widely expressed receptor isoform23 and since it is the focus 
of this study, FR is used to refer to the FR-α form in this thesis. This receptor is a 38-40 kDa 
molecule anchored to the cell membrane through a glycosylphosphatidylinositol moiety.
24
 
Investigators have demonstrated increased FR levels when extracellular levels of folate are 
low.
25–27
 Moreover, Miao Guo et al (2011) evaluated the uptake of a folate-conjugated drug 
delivery system in both folate-replete medium and folate-free medium and their results 
indicated greater uptake by cells grown in a folate-free medium.
28
 
The reduced folate carrier (RFC) is an integral plasma membrane protein with a molecular 
mass of ~65 kDa. RFC is a bidirectional anion exchanger and it transports natural folates and 
antifolates. The detailed mechanism of RFC transport is not firmly established but it is 
expected to involve a physical translocation of the carrier within the plasma membrane which 
occurs due to a large intra- to extracellular anion concentration gradient.
29
 Unlike the FR, 
RFC is a bidirectional transporter and it is responsible for the efflux of folates to normalise 
folate levels in the cell. Therefore, RFC can be regulated according to folate levels in the cell 
or in the medium. Ilan Ifergan and colleagues (2008) have demonstrated that, when there is a 
lack of extracellular folate, RFC becomes a unidirectional transporter and the efflux of folates 
can cause cell death.
4
  
This chapter will focus on the gene and protein expression levels of FRs and RFCs while the 
uptake and internalisation processes of folate molecules through these receptors are discussed 
in more detail in Chapter 4. In the first part of our work, gene expression of FR and RFC was 
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assessed for a range of cell lines grown in a folate-replete and a folate-free medium. From the 
results of this experiment, we expected to standardise the experimental conditions with 
respect to the culture medium. A folate-free environment is favourable to avoid competition 
for folate, though how a folate-free environment affects the cellular levels of folate 
transporters should be evaluated. Then, both gene and protein levels of FR and RFC were 
assessed in a range of untreated cell lines, including six cancer cell lines and also a healthy 
(non-cancer) cell line, and the correlation between mRNA and protein levels is presented and 
discussed. Quantifying the expression levels of these receptors is important, since the 
literature is controversial, as discussed above. In addition, we can select a smaller range of 
cell lines, based on FR levels, for the in vitro cytotoxicity evaluation, to demonstrate the 
potential to selectively target FRs and to study the correlation between the levels of each 
receptor and the cytotoxicity of our complex. 
FOLR1 is the gene that encodes for the FR-α protein. FR-α is the most studied member of the 
family of folate receptors, as it is present on epithelial cells, while other members of this 
family, such as FR-β and FR-γ are selectively present in hematopoietic cells. The high 
expression of FR-α in cancer tissues has led to extensive research regarding its potential role 
as a target for receptor-specific drug delivery systems. As mentioned previously, in this study 
FR refers to the FR-α, and therefore, FOLR1 is the gene used to assess gene expression of 
FRs in the studied cell lines.
30
 The RFC is a member of the solute carrier (SLC) group of 
membrane transport proteins. The SLC gene group includes 52 families and 395 transporter 
genes in the human genome. The RFC is the member 1 of the family 19 of this group, and is 
encoded by the SLC19A1 gene, and therefore, this is the gene used to assess gene expression 
of RFCs in the studied cell lines.
31
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2.2 Materials and methods  
2.2.1 Cell lines and culturing conditions 
A range of cancer cell lines was obtained from the RESC cell culture bank in DIT, having 
previously been purchased from the American Type Culture Collection (ATCC) and 
European Collection of Authenticated Cell Cultures (ECACC). These were SKOV-3 (ovarian 
carcinoma), HeLa (cervical carcinoma) and MCF-7 (breast carcinoma), which were cultured  
in both regular (folate-replete) RPMI-1640 (Sigma-Aldrich) and folate-free RPMI-1640 
media (Life Technologies), supplemented with 10% Foetal Bovine Serum (FBS) (Sigma-
Aldrich) and maintained in a sterile environment at 37 °C and 5% CO2 atmosphere. Gene 
levels of FR and RFC in cells was investigated by real-time PCR.  
From this, the folate-free RPMI-1640 medium was established as the optimum medium and 
used for cell culture in all experiments. The cell lines KB (subline of HeLa cells, cervical 
carcinoma), CaCo-2 (colorectal carcinoma), A549 (lung carcinoma) and BEAS-2B (normal 
lung) were added to the range to investigate mRNA and protein expression levels of FR and 
RFC by real-time PCR and flow cytometry, respectively. For this, all cells were cultured in 
folate-free RPMI-1640 medium supplemented with 10% FBS in T75 cell culture flasks 
(Sarstedt, Ireland) and also maintained in a sterile environment at 37 °C and 5% CO2 
atmosphere.  
In all experiments, when the cells reached 70–80% confluency, they were subcultured either 
for routine maintenance or experimentation. Subculturing involved first removing the cell 
culture medium from the monolayer of cells, then adding 10 mL of trypsin:EDTA (1:1) 
(Invitrogen, Ireland) solution to wash and remove any dead or detached cells from the 
population. A further 10 mL of trypsin solution was added and the cells were incubated at 37 
°C for 2-4 min to detach cells from their monolayer on the base of the flask. Cells were then 
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placed in 10 mL of fresh culture medium to deactivate the trypsin enzyme and produce a 20 
mL stock cell suspension. This stock cell suspension was used to seed different cell densities 
in T75 stock flasks to maintain the cells in culture. The stock cell suspension was also used 
for the subsequent experiments of real-time PCR or flow cytometry described below.  
 
 2.2.2 Gene expression by real-time PCR  
RNA isolation 
KB, CaCo-2, SKOV-3, HeLa, MCF-7, A549 and BEAS-2B cells were cultured in 3 x T25 
cell culture flasks (Starsedt, Ireland). When cells achieved 80% confluency, 1 mL of TRI 
Reagent® (Sigma-Aldrich) was added to each flask, homogenised and transferred to a 1.5 
mL centrifuge tube. For the phase separation step, 0.2 mL of chloroform was added,  
incubated for 5 minutes at room temperature and then centrifuged at 4 ºC for 15 minutes at 
12,000 g. The upper aqueous phase was transferred to a fresh tube and the same volume of 2-
propanol was added to give a 1:1 ratio, incubated for 10 minutes at room temperature, and 
then centrifuged at 4 ºC for 10 minutes at 12,000 g. The supernatant was discarded and the 
RNA pellet was washed with 75% ethanol. The RNA pellet was resuspended in 30 µL of 
RNase-free water and incubated in a water bath at 55 °C for 10 minutes for RNA 
solubilization. 
RNA quantification 
The purity and concentration of the RNA samples were measured using the micro-volume 
spectrophotometer MaestroNano™ (MaestroGen, USA). After an initial blank with 0.1% 
diethyl pyrocarbonate (DEPC) treated water, the concentrations, as well as the absorbance 
ratios of the samples, were recorded to allow for the cDNA synthesis step. The ratio of 
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absorbance at 260 and 280 nm (the A260/280 ratio) is used to assess the purity of nucleic 
acid preparations, and according to the literature, an A260/A280 absorbance ratio of 1.8 to 
2.1 is indicative of a pure, i.e. protein free, RNA sample,
32
 and therefore, this was the ratio 
range considered acceptable for proceeding with the cDNA synthesis and further 
experiments.  
cDNA synthesis 
Based on the RNA concentrations previously obtained, a standardised value of 435 ng of 
RNA was chosen based on the smallest measured concentration, and all subsequent samples 
were normalised to this concentration in a 5 μL volume. The same amount of total RNA from 
each sample was reverse-transcribed in a 20 µL reaction using the qScript™ cDNA synthesis 
kit (Quanta Biosciences). Briefly, a master mix was prepared using the qScript™ reaction 
mix (4 µL/20 µL) and qScript™ reverse transcriptase (1 µL/20 µL). Then a 5 μL volume of 
each RNA sample was added to 15 µL of master mix. The reverse transcription PCR was 
performed in a Thermocycler (Techne, UK) and the program consisted of 5 min at 22 °C, 30 
min at 42 °C, and 5 min at 85 °C. 
Primer design for Real-Time qPCR 
Gene-specific primers corresponding to the targets FOLR1 and SLC19A1, and housekeeping 
genes (endogenous reference genes) β-tubulin and β-actin were designed in-house using 
NCBI/Blast
33
 and Primer3 software,
34,35
 and purchased from Genosys (Sigma-Aldrich). Table 
2.1 below shows the forward and reverse primer sequences for each gene primer set. All 
primers used were desalted and scaled to 0.05 µM.  
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Table 2.1. Primer sequences for quantification of the target genes folate receptor (FOLR1) 
and reduced folate carrier (SLC19A1), and the housekeeping genes, β-tubulin and β-actin. 
Primer Direction Sequence (5’ – 3’) 
FOLR1 (FR) Forward ACTCCCTGCCTGTCTCCTAG 
FOLR1 (FR) Reverse CAGCCACCCACACTAGAAGG 
SLC19A1 (RFC) Forward ACTGACGTAGAATGAAGAACTGC 
SLC19A1 (RFC) Reverse ACACTTCAGAAGGACAGACAGG 
β-tubulin Forward TTGGCCAGATCTTTAGACCAGACAAC 
β-tubulin Reverse CCGTACCACATCCAGGACAGAATC 
β-actin Forward ACTCTTCCAGCCTTCCTTCC 
β-actin Reverse GTTGGCGTACAGGTCTTTGC 
 
Real-time quantitative PCR assay conditions 
The real-time quantitative PCR (qPCR) reaction was standardised using the KAPA SYBR 
FAST Universal 2X qPCR Master Mix (Kapa Biosystems), which consisted of 1 µL of each 
primer (forward and reverse at 500 nM per µL), 10 µL of Kapa SYBR Master Mix (2X), and 
6 µL of PCR-grade water. This master mix was used in a reaction with 2 µL of cDNA 
template for a total reaction volume of 20 µL. Four PCR master mixes were prepared, one for 
each gene primer set (forward and reverse) including the target genes FOLR1 and SLC19A1, 
and the housekeeping genes β-tubulin and β-actin, which were used as reference genes to 
normalise the data. Each sample was aliquoted in duplicate, in a 96 well plate (plate design 
can be seen in Appendix 1) and read using the 7500 Fast Real-Time PCR System (Applied 
Biosystems®). The amplification program consisted of 1 cycle of 95 °C with a 5-minute hold 
followed by 45 cycles of 95 °C with a 10-second hold, 60 °C with a 30-second hold and 72 
°C with a 10-second hold. A negative control without cDNA template was run with every 
assay to assess the overall specificity. 
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qPCR data analysis 
Real-time qPCR is based on the use of dyes to monitor and report DNA amplification and the 
SYBR® family of cyanine dyes is widely used for this purpose. Briefly, the SYBR® green 
dye fluoresces when bound to double-stranded DNA and the cycle of amplification in which 
significant fluorescence is detected above a threshold is then reported. The reported cycle of 
amplification is called the CT value (threshold cycle). The CT value is inversely proportional 
to the amount of nucleic acid in the sample. Therefore, lower CT values indicate high 
amounts of nucleic acid, while higher CT values mean lower amounts of nucleic acid.
36
 
Amplification plots are created when the fluorescence signal from each sample is plotted 
against cycle number. Therefore, amplification plots represent the accumulation of product 
over the duration of the real-time PCR experiment.
37
  
Relative quantitative PCR can be used to determine gene expression when analysing the 
effect of a treatment or to compare two different conditions such as disease and non-disease. 
In such cases, the PCR signal of the target transcript in the treated sample is quantified 
relative to that of an untreated or non-disease control.
38
 In this work, the data was analysed 
using the relative 2
-CT
 method, described by Livak and Schmittgen (2001).
39
 In this 
method, the PCR data are normalised to an endogenous reference gene and are relative to a 
calibrator control. CT, the threshold cycle, is the cycle number at which the amount of 
amplified target reaches a fixed threshold. The equation below describes the 2
-CT
 method: 
XT = X0 • (1 + EX)
CT
 = K   Equation 2.1 
where XT = threshold number of target molecules 
 X0 = initial number of target molecules 
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 EX = efficiency of target amplification 
 CT = threshold cycle number for target 
 K = constant 
In our work CT is normalised with respect to β-tubulin and β-actin as endogenous reference 
genes (internal control genes, also called housekeeping genes) and therefore the equation for 
these references is: 
RT = R0 • (1 + EX)
CTR
 = K   Equation 2.2 
where RT = threshold number of reference molecules 
 R0 = initial number of reference molecules 
 ER = efficiency of reference amplification 
 CTR = threshold cycle number for reference 
 K = constant 
 
Therefore, if EX = ER 
XT/ RT = X0/ R0 • (1 + E)
CTX - CTR
   Equation 2.3 
And 
XN • (1 + E)
ΔCT
= K     Equation 2.4 
Or 
XN = K • (1 + E)
-ΔCT
     Equation 2.5 
where XN = X0/ R0 = amount of target normalised to the endogeneous reference 
 ΔCT = CTX - CTR = difference in threshold cycle of target and endogenous reference 
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In each experiment, a calibrator sample was used as the basis for comparing results. Thus, to 
measure the difference in the gene expression levels of FR and RFC in cells grown in folate-
replete and folate-free media, samples of cells grown in folate-replete medium were used as 
calibrator samples. To measure the difference in the gene expression levels of FR and RFC in 
different cancer cell lines, the normal cell line BEAS-2B was used as calibrator.  
Therefore,  
XNS/ XNC = K • (1 + E)
-ΔCTS
 / K • (1 + E)
-ΔCTC
 = (1 + E)
-ΔΔCT
 Equation 2.6 
where -ΔΔCT is the difference in threshold cycle of the sample target and endogenous 
reference genes relative to the calibrator.  Normally the efficiency is close to one, giving: 
XNS/ XNC = 2
-ΔΔCT
      Equation 2.7 
Therefore, the amount of target normalised to the endogenous reference and relative to the 
calibrator sample is given by 2
-ΔΔCT
 which is referred to as the fold change or fold 
difference. Values of the fold change above 1 indicate that the target sample is upregulated in 
relation to the calibrator sample while values under 1 indicate that it is downregulated.  
To determine significant upregulation and significant downregulation, a t-test was performed, 
and to calculate significant difference between cell lines, a 2-way ANOVA was performed 
using GraphPad Prism® software. Post-ANOVA Bonferroni’s test was used in multiple 
comparisons, i.e. to assess the significant difference in the gene expression between each cell 
line, as in the Bonferroni’ test, the significance level applies to the entire family of 
comparisons. Statistical significance was accepted as p ≤ 0.05 at 95% confidence levels for 
all tests. The standard deviation was calculated according to the method described in Applied 
Biosystems User Bulletin No. 2 (P/N 4303859).
40
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2.2.3 Protein expression by flow cytometry 
The number of cells per mL  for each cell line KB, CaCo-2, SKOV-3, HeLa, MCF-7, A549 
and BEAS-2B, was counted using the particle counter Beckman COULTERTM Z1 Coulter® 
(Beckman-Coulter, USA) and 1 mL of cell suspension was placed into 20 mL of isoton 
electrolyte solution (BD, Ireland). The volume required to give a cell solution with a 
concentration of 5 x 10
5
 cells/100 µl was calculated and the cell suspension was aliquoted 
into three centrifuge tubes: (1) unstained cells with no antibodies, (2) negative control with 
secondary antibody, and (3) immunoassay sample with both primary and secondary 
antibodies for FR or RFC detection.  
For the immunoassay, cells were incubated at 4 °C for 1 hour with the primary antibody, i.e. 
a mouse monoclonal anti-folate receptor antibody, LK26 purchased from Abcam (ab3361), at 
a final concentration of 2 µg/100 µL for FR detection, or with a chicken polyclonal anti-
reduced folate carrier SLC19A1 antibody, purchased from Thermo Scientific (PA1-9553), at 
a final concentration of 2 µg/100 µL for RFC detection. Flow cytometry staining (FCS) 
buffer, containing PBS, 1% bovine serum albumin (BSA) and 0.1% sodium azide, was used 
in the dilution of the antibodies. After incubation, the cells were washed and incubated at 4 
°C for 30 minutes in the dark with the respective secondary antibodies, i.e. a goat anti-mouse 
Alexa Fluor® 488-conjugated from Life Technologies (A11017) at a 1:800 final dilution, and 
a goat anti-chicken Alexa Fluor® 488-conjugate from Fisher Scientific (10286672) at a 1:800 
final dilution. After incubation, the cells were washed and examined on the Accuri C6 (BD 
Biosciences) flow cytometer. The unstained cells sample was incubated with FCS buffer 
only. Negative controls were samples of cells with the secondary antibody which were 
incubated with FCS buffer without the primary antibody, to define positive populations and 
to eliminate any background fluorescence from the conjugated secondary antibody. All 
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antibodies were previously titrated to determine the optimal dilution for the assay. 1% BSA 
was used in the staining buffer to avoid non-specific binding. Three independent experiments 
were carried out for all samples. In the flow cytometer, an excitation laser line of 488 nm, 
filter 530/30 and FL-1 detector were used for excitation and detection of fluorescence from 
the green dye Alexa Fluor® 488. All samples were gated to eliminate debris and undesired 
subpopulations. Aggregates were removed by gating single cells on the analysis of the height 
versus the area of the forward scattered light (FCS-H x FCS-A) and 10,000 events were 
recorded as single cells. All cells were healthy and alive at the moment of detection, which 
was determined through analysis of the cell size and complexity in the side scattered light 
versus forward scattered light (SSC x FSC) histograms and with the use of propidium iodide 
(PI), a dye which binds to the DNA that is exposed from dead cells. Data were analysed using 
BD Accuri C6 software. 
 
2.3 Results and discussion 
2.3.1 Folate-replete and folate-free media  
To confirm the upregulation of FR gene expression levels and to assess if RFC levels were 
also regulated by the lack of extracellular folate, three cell lines, SKOV-3, HeLa and MCF-7, 
were grown in both folate-replete and folate-free RPMI-1640 media. Gene (mRNA) levels 
were quantified by real-time quantitative PCR and cells grown in the folate-replete RPMI-
1640 medium were used as calibrator samples to calculate the relative fold change in the 
expression levels of the genes for cell lines grown in a folate-free medium. Figure 2.3 below 
shows the relative fold change in the mRNA levels of these cells when grown in folate-free 
medium, compared to their mRNA levels when grown in folate-replete medium.  
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A                                                                        B 
Figure 2.3. Relative fold-change in (A) folate receptor and (B) reduced folate carrier gene 
expression levels. Fold-change = 2
-Ct
 where CT = CT of folate-free medium sample - 
CT of folate-replete medium sample. Error bars represent standard deviation. Asterisks 
indicate results which are significantly different to the calibrator sample where * is p<0.05 
and ** is p<0.01 at 95% confidence.  
 
It can be seen from figure 2.3A that there is an upregulation (fold-change > 1) of FR for all 
cell lines grown in folate-free medium, with a statistically significant difference for SKOV-3 
and MCF-7 cells. The complete statistical analysis is given in Appendix 2. The fold increase 
observed in FR levels confirms the findings indicated in the literature. For example, Luhrs et 
al (1992) found that FRs are upregulated in mouse embryonic fibroblast cells grown in low 
folate conditions. They proposed that these conditions stimulate the cells to upregulate its FR 
levels in order to maintain the necessary levels of intracellular folate. This is also supported 
by Necela et al (2014) who reported higher FR expression in triple negative breast cancer 
cells grown in low folate conditions, and Yang et al (2007) who reported an upregulation of 
FR expression after human bone osteosarcoma cells were transferred to low-folate media.
41–43
 
According to Antony et al (2004), folate deficiency results in homocysteine cellular 
accumulation, and since homocysteine interacts with a protein-mRNA complex which 
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stimulates FR expression, there are higher levels of FR in the membrane to capture folate 
molecules and to normalise the cellular levels of folate.
20
 Folate-free medium was used in 
subsequent experiments since the drug delivery system studied in this work is proposed to 
specifically target FR. 
From figure 2.3B, it can be seen that there is a significant upregulation of RFC for SKOV-3 
but downregulation (fold-change < 1) for HeLa and MCF-7 cells, although this is not 
significant. The complete statistical analysis is given in Appendix 3. Reports of both up and 
downregulation can be found in the literature. Hou et al (2014) found less expression of RFC 
mRNA and protein in RFC-expressing HeLa cells grown in low extracellular folate levels, 
and found that it increased when folate was added to the medium.
44
 Subramanian et al (2003) 
found upregulation of RFC mRNA and protein in CaCo-2 cells while Ilan Ifergan et al (2008) 
found downregulation of RFC levels in MCF-7 cells in response to folate deficiency. Ifergan 
suggests that when there is a lack of extracellular folate, the cellular efflux of folates needs to 
decrease for cell survival and that can trigger RFC downregulation.
45,46
 
 
2.3.2 Folate receptor and reduced folate carrier gene expression 
The expression levels of FR (FOLR1) and RFC (SLC19A1) genes were examined in KB, 
CaCo-2, SKOV-3, HeLa, MCF-7, A549 and BEAS-2B cells. β-Tubulin and β-actin were the 
housekeeping genes used in this study as reference gene controls for data normalisation. The 
aim of using quantitative PCR here is to measure the abundance of FR and RFC mRNA in 
this range of untreated cell lines. Table 2.2 shows the data for FR and RFC gene expression 
normalised to the endogenous controls (CT) in the seven cell lines analysed. As stated by 
Ramon Goni et al (2009), in every cycle of PCR (CT value) the amount of DNA is 
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approximately duplicated. CT is in the logarithmic scale and inversely proportional to the 
quantity of DNA or RNA. Therefore high ∆CT values represent low expression, while highly 
expressed genes have low ∆CT.
47
 
Table 2.2. Folate receptor (FR) and reduced folate carrier (RFC) mRNA expression values 
(CT ± standard deviation) normalised to the endogenous controls. Asterisks indicate results 
which are significantly different to the BEAS-2B normal cell line where *** is p<0.001, ** is 
p<0.01 and * is p<0.05 at 95% confidence. 
 
 
KB, CaCo-2 and SKOV-3 are the cell lines that express the highest levels of FR when 
compared to the other cell lines. KB, HeLa, MCF-7 and A549 cell lines express significantly 
higher levels of RFC than the other cell lines. BEAS-2B, the normal cell line, shows the least 
abundance of mRNA levels of both receptors. A complete statistical analysis, which includes 
a one-way ANOVA test comparing BEAS-2B cells to all other cell lines, is given in 
Appendix 4 and a one-way ANOVA with a Tukey’s multiple comparison test, which 
compares all cell lines, is given in Appendix 5. 
To better visualise the difference in FR and RFC levels between the cancer cell lines and the 
normal cell line, Ct was calculated using BEAS-2B as the calibrator sample.39 This 
difference (fold-change) is shown in figure 2.4.  
Cell line FR RFC 
KB 4.65*** ± 0.86 5.60*** ± 1.02 
CaCo-2 9.58*** ± 0.38 7.56 ± 0.47 
SKOV-3 10.56*** ± 0.18 7.58* ± 0.95 
HeLa 13.65* ± 0.53 5.26*** ± 0.10 
MCF-7 13.90 ± 0.59 6.08*** ± 0.44 
A549 14.44 ± 1.76 6.74** ± 0.97 
BEAS-2B 15.78 ± 0.47 9.75 ± 0.42 
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 A         B 
Figure 2.4. (A) Folate receptor and (B) reduced folate carrier gene expression in KB, CaCo-
2, SKOV-3, HeLa, MCF-7, A549 and BEAS-2B cell lines represented by the 2
-Ct
 method. 
The red line represents the normal cell line BEAS-2B used as the calibrator. Error bars 
represent standard deviation and asterisks indicate results which are significantly different to 
the calibrator sample where *** is p<0.001, ** is p<0.01 and * is p<0.05 at 95% confidence. 
 
It can be seen from the figures above that both FR and RFC are upregulated in all the cancer 
cell lines analysed, compared to the normal cell line BEAS-2B. A significantly higher 
expression is found for FR in KB, CaCo-2 and SKOV-3. Statistics can be seen in Appendices 
6 and 7. HeLa and MCF-7 cells can also be considered as having FR low expressing mRNA 
when compared to KB cells. As mentioned previously, there are conflicting reports in the 
literature with respect to expression of FR in cancer cell lines. However, some investigators 
have reported a similar overexpression of FR in cancer cells when compared to healthy cells. 
Siu et al (2012) reported overexpression of FR in various ovarian cancer cells and its 
association with tumour progression, demonstrating a progressive increase in FR levels from 
non-tumour tissues, benign and borderline tumours to carcinomas.
48
 The high FR (FOLR1) 
gene expression found here for KB, CaCo-2 and SKOV-3 is also consistent reports from 
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Sadasivan et al (1989), who found high mRNA expression in KB cells, particularly higher 
when grown in a folate-deficient environment, as in this study.
49
 Doucette and Stevens 
(2001), reported high FR mRNA levels in CaCo-2 cells and correlated this with cell growth, 
and Yang et al (2007) showed positive FR mRNA levels using real-time PCR data and a gel 
of the PCR product.
43,50
 Bongartz et al (2013) also found low levels of FRs mRNA in A549 
cells, which showed lower levels than in HeLa cells. At present, no information was found 
for FR gene expression in BEAS-2B cells but several authors have reported a low expression 
of FR in normal tissues, for example Parker et al (2005) and O’Shannessy et al (2015) found 
negligible FR expression in normal ovarian tissue.
7,51
 
RFC is ubiquitously expressed in normal mammalian tissues and tumours.
28
 From figure 
2.4B it can be seen that RFC is upregulated in the cancer cell lines compared to the BEAS-2B 
normal cell line with a significantly higher expression for HeLa cells. RFC (SLC19A1) gene 
expression has not been as widely investigated as the FR (FOLR1) gene. Hou et al (2014) 
describe HeLa as an RFC-expressing cell line, which is consistent with this work since HeLa 
was found to be the highest RFC mRNA-expressing cell line analysed. In addition, Westerhof 
et al (1995) describe KB cells as a RFC-expressing cell line, which also compares favourably 
with this work since KB cells were the second highest RFC mRNA-expressing cell line.
44,53
 
However, investigators, such as Siu et al (2012) and Ifergan et al (2008), reported 
downregulation of RFC in cancer cells.
4,48
 The normal cell line used here is the human lung 
cell line BEAS-2B, and no information was found in the literature about its expression of 
levels of RFC. Therefore, it is possible that BEAS-2B expresses lower levels than other 
normal cell lines, and thus, the cancer cells analysed may express high levels of RFC but only 
in comparison to this cell line in particular.  
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2.3.3 Folate receptor and reduced folate carrier protein expression 
Flow cytometry experimentation was performed to confirm FR and RFC protein expression 
levels and to identify the correlation with their gene mRNA levels. Figures 2.5 and 2.6 
display the median fluorescence intensity for FR and RFC protein detection, respectively, in 
the seven cell lines analysed.  
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Figure 2.5. Folate receptor protein expression in KB, CaCo-2, SKOV-3, HeLa, MCF-7, 
A549 and BEAS-2B cells where MFI=Median Fluorescence Intensity. Asterisks indicate the 
results which are significantly different to the rest of the cell lines where *** is p<0.0001 at 
95% confidence. 
 
Figure 2.5 shows that there is a variation in FR protein expression for the seven cells lines, 
with KB cells displaying significantly higher expression (MFI = 1,039,696), and the normal 
BEAS-2B cells displaying the lowest expression (MFI = 490) (statistics can be seen in 
Appendix 8). These results compare favourably with the literature. Forster et al (2007) 
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analysed KB, IGROV-1 (ovarian carcinoma) and JEG-3 (choriocarcinoma) cells and also 
found higher protein expression of FR in KB cells. Bongartz et al (2013) analysed HeLa and 
A549 cells and also found low expression of FR protein in A549 cells. Chen et al (2009) also 
described HeLa and MCF-7 as tumour cells with lower FR density on their surface when 
compared to KB cells. There is little information found in the literature with respect to FR 
protein expression in BEAS-2B, but authors have reported low expression in other healthy 
cell lines, for example, Weitman et al (1992) found low FR protein expression in MA104 
normal renal epithelium cells and in a number of normal tissues such as liver, intestines and 
muscle.
54
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Figure 2.6. RFC protein expression in KB, CaCo-2, SKOV-3, HeLa, MCF-7, A549 and 
BEAS-2B cell lines where MFI=Median Fluorescence Intensity. Asterisks indicate results 
which are significantly different to the other cell lines where * is p<0.05 at 95% confidence.  
Figure 2.6 shows that the cell lines studied all express RFC, which agrees with reports in the 
literature. Matherly et al (2008) and Whetstine et al (2002) reported that RFC is ubiquitously 
expressed between cell lines and tissues, such as placenta and liver.
18,55
 In this work, MCF-7 
Chapter 2                             Expression of Folate Receptors and Reduced Folate Carriers       
63 
 
has the highest expression of RFC protein (MFI = 5,446.17) although there is no significant 
difference between the cell lines (statistics can be seen in Appendix 9). SKOV-3 displays the 
lowest abundance of RFC (MFI = 1,436).  
RFC levels vary less than FR levels between the cell lines, which may suggest that RFC is 
required by all cells and is related to some physiological properties.
32
 RFC is called a folate 
transporter because of its important role in the uptake of natural folates such as 5-
methyltetrahydrofolate, while FR has higher affinity for folic acid, the synthesised oxidised 
form of folate.
33
 RFC is also responsible for balancing the intracellular levels of folate by 
mediating its efflux transport. Therefore, these results may indicate that RFC is necessary for 
folate internalisation when normal levels are required, and when higher levels of this vitamin 
are required, such as when there is lack of extracellular folate or a greater need for rapid cell 
replication, FR can be upregulated for higher uptake of folates.  
Using the results presented in figures 2.5 and 2.6, the fluorescence obtained for each cell line 
was compared with that obtained for unstained cells and control cells to which no primary 
antibody was added, as described in the Materials and Methods section. The results are 
presented in figure 2.8 for FR and figure 2.9 for RFC and show the fluorescence (filter 
530/30 for Alexa Fluor® 488) on the x-axis and the number of events (cell count) on the y-
axis.  
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Figure 2.7. Fluorescence levels for unstained cells (black peak), no primary antibody control 
(blue peak) and folate receptor levels (red peak) in KB, CaCo-2, SKOV-3, HeLa, MCF-7, 
A549 and BEAS-2B. 
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Figure 2.8. Fluorescence levels for unstained cells (black peak), no primary antibody control 
(blue peak) and reduced folate carrier levels (orange peak) in KB, CaCo-2, SKOV-3, HeLa, 
MCF-7, A549 and BEAS-2B. 
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In figures 2.7 and 2.8, the x-axis indicates the fluorescence intensity, and therefore, the more 
the peak shifts to the right, the higher is the fluorescence intensity and the higher is the 
amount of protein present in the sample. Each peak is represented by the number of cells 
(count) that display a determined amount of fluorescence. The results showed in the figures 
2.5 and 2.6 are represented by the median of fluorescence intensity while the figures 2.7 and 
2.8 show the distribution of this fluorescence between the cells analysed individually. 
2.3.4 Comparison of gene and protein expression levels 
Gene and protein levels were compared, and figure 2.9 shows the distribution of the cell lines 
according to their expression levels of mRNA and protein for FR and RFC. These levels were 
determined to be low, medium and high, which are relative terms, only comparing the cell 
lines analysed in this study. 
 
                           A                               B 
Figure 2.9. Distribution of the cell lines analysed according to their relative levels of 
expression. (A) Folate receptor (FR) mRNA and protein expression levels. (B) Reduced 
folate carrier (RFC) mRNA and protein expression levels. 
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Figure 2.9A above shows the difference between the levels of FR in the seven cells analysed. 
Gene and protein levels of FR were well correlated in KB, CaCo-2, A549 and BEAS-2B 
cells. MCF-7 and HeLa expressed higher protein than mRNA levels, which may be explained 
by different rates of protein synthesis in relation to the rates of mRNA synthesis in these cell 
lines. As stated by Abreu et al (2009) one mRNA molecule in the cell can be translated into 
protein several hundred to thousands of times before its degradation, eventually resulting in 
higher amounts of protein than mRNA.
34
 This difference of gene and protein expression may 
explain why contradictory reports can be found in the literature, particularly for FR 
expression. 
It can be seen from figure 2.9B that similar levels of RFC were found across all cell lines. As 
discussed previously, RFC plays an important role in maintaining intracellular concentrations 
of folate, and therefore, it is responsible for the influx and efflux of this vitamin. However, a 
poor mRNA-protein correlation is found between cell lines. According to Abreu et al (2009), 
changes in the concentration of a protein depend on the mRNA concentration, translation 
efficiency and degradation of the existing protein. Post-transcriptional and translational 
regulation, as well as protein turnover and protein degradation control, can all influence 
protein concentration which could explain the poor protein-mRNA correlation.
58,59
 According 
to Maier et al (2009), the correlation between mRNA and protein abundances in complex 
systems are known to be notoriously poor and the processes of transcription from DNA to 
RNA and translation from RNA to protein are far from having a linear relationship. There are 
regulatory proteins and small RNAs that can act as translational modulators by specifically 
binding to their mRNAs to stop translation. In addition, ribosomal density and ribosome 
occupancy, which denote the number of ribosomes per transcriptional unit and the individual 
mRNA fraction engaged in translation on ribosomes, are important measures for translational 
efficiency. The translational efficiency is the number of proteins synthesized per mRNA, and 
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different translation efficiencies for mRNA molecules directly influence the mRNA-protein 
correlation.
60
 Fortelny et al (2017) indicate that protein levels cannot be accurately predicted 
from mRNA levels and gene-specific translation rates, also demonstrating a poor correlation 
between mRNA and protein levels.
61
 
 
2.4 Conclusion 
The study presented in this chapter elucidated the gene and protein levels of FRs and RFCs in 
different cell lines. First, an upregulation in FRs was found when cells are grown in folate-
free media. Then, after comparing the gene expression levels in a range of cell lines, real-time 
PCR showed that FRs are more abundant in KB cells followed by CaCo-2 and SKOV-3 cells. 
RFC has higher expression in HeLa cells, followed by KB cells. BEAS-2B showed the least 
abundant mRNA levels of both receptors and, as it is a non-cancer cell line, seemed to be a 
good calibrator cell line to compare with the cancer cell lines. Cancer cells displayed 
upregulation of both FRs and RFCs when compared to the normal cell line BEAS-2B.  
The protein expression levels of FR and RFC assessed by flow cytometry showed that KB 
cells express significantly higher levels of FRs than all the other cell lines while BEAS-2B 
cells showed the lowest levels. HeLa cells showed the highest levels of RFCs while SKOV-3 
showed the lowest levels.  
The levels of FRs vary between very high and very low expression in different cell lines 
when compared to the levels of RFC, which are mostly in a lower range of expression. That 
can be an indicator that FRs are regulated according to the cell requirements. Therefore, even 
though FR is upregulated when folate is present in low concentrations, the function depends 
on the requirements of the cell during cell replication.
50
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The role of FRs and RFCs in the uptake of folic acid and antifolates is important in this work, 
since in the drug delivery system CDEnFA:MTX, folic acid and the antifolate, MTX, are 
present in the same complex. From their FR levels analysis, KB, CaCo-2, MCF-7, A549 and 
BEAS-2B cells were selected to be used in the cytotoxicity evaluation of the drug delivery 
system.  
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3.1 Introduction  
From the results of the work described in Chapter 2, five cell lines were selected for an in 
vitro cytotoxicity analysis according to their FR expression levels. These cell lines are KB, 
CaCo-2, MCF-7, A549 and BEAS-2B. KB and CaCo-2 cells were chosen due to their high 
levels of FR, MCF-7 cells were chosen due to their medium levels of both FR and RFC, 
while A549 and BEAS-2B cells were chosen due to their low levels of FR. These cells were 
tested against the carrier CDEnFA, drug methotrexate (MTX), and the inclusion complex 
CDEnFA:MTX.  
CDEnFA was developed by Tofzikovskaya et al (2012) at DIT, to be used as a drug vehicle 
that can target folate receptors on cancer cells and deliver the MTX.
1
 CDEnFA is a β-
cyclodextrin carrier vehicle, developed through a three-step synthesis that starts with the 
preparation of 6-o-monotosyl-6-deoxy-β-cyclodextrin (CDTs), which method was published 
by Potter et al (2007).
2
 The synthesis method and the characterisation of CDTs are presented 
in the supplementary information, Chapter 7, and figure 3.1 provides a schematic of the 
synthesis of the CDTs. 
 
Figure 3.1. Synthesis of 6-o-monotosyl-6-deoxy-β-cyclodextrin, CDTs. 
 
The second step in the synthesis involves the addition of an amino group to the CDTs, 
forming the derivative 6-deoxy-6-[1-(2-amino)ethylamino]-β-cyclodextrin, CDEn. This 
amino group functions as a linker between the β-CD and the folic acid. CDEn was prepared 
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according to the method published by Potter et al (2007).
2
 The synthesis method and the 
characterisation of CDEn are presented in the supplementary information, Chapter 7, and 
figure 3.2 gives a schematic of the synthesis.  
 
Figure 3.2. Synthesis of 6-deoxy-6-[1-(2-amino)ethylamino]-β-cyclodextrin, CDEn. 
 
The third step in the synthesis involves the addition of the folic acid to the CDEn, forming the 
6-deoxy-6-[(1-(2-amino)ethylamino)folate]-β-cyclodextrin, CDEnFA. This procedure was 
published by Tofzikovskaya et al (2012)
1
 and the full method and the characterisation of 
CDEnFA are given in the supplementary information, Chapter 7. Figure 3.3 below depicts the 
synthetic route to CDEnFA. 
 
Figure 3.3. Synthesis of 6-deoxy-6-[(1-(2-amino)ethylamino)folate]-β-cyclodextrin, 
CDEnFA. 
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MTX is the model drug that was used in conjunction with the carrier CDEnFA 
(CDEnFA:MTX) for this work. As described in Chapter 1, MTX is a well-known drug, used 
worldwide for treating rheumatoid arthritis and cancers, such as acute lymphoblastic 
leukaemia (ALL), osteosarcoma, breast, head and neck cancers, lymphoma, lung cancer, 
bladder cancer, and trophoblastic neoplasms.
3
 MTX acts by inhibiting the enzyme 
dihydrofolate reductase and potentially other enzymes in the one-carbon metabolism, which 
results in the inhibition of purine nucleotide synthesis, and consequently, DNA synthesis.
4
 
CDEnFA:MTX is the inclusion complex of CDEnFA and MTX. Although the CD cavity is 
hydrophobic, it normally contains 11 H2O molecules per cavity. Non-covalent bonds are 
involved in the inclusion complex formation in aqueous solution and it is energetically 
favourable for a less polar molecule, such as MTX, to replace the water molecules and 
preferentially bind to form the inclusion complex. The method for preparation of 
CDEnFA:MTX is described in the supplementary information, Chapter 7. Figure 3.4 displays 
the proposed structure of CDEnFA:MTX. 
 
Figure 3.4. The proposed structure of the targeted drug delivery system CDEnFA:MTX. 
Folic acid is shown in blue, the cyclodextrin is shown in red and the drug, MTX, is included 
in the CD cavity. 
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The work presented in this chapter provides an in vitro evaluation of the cytotoxicity of 
CDEnFA:MTX compared to the drug MTX alone, towards cell lines expressing varying 
levels of folate receptors. The carrier CDEnFA was also evaluated in terms of its 
biocompatibility. A correlation between cytotoxicity data and the expression levels of FR 
and RFC (from Chapter 2) in each cell line is analysed.   
 
3.2 Materials and methods  
3.2.1 Cell lines and cell culture  
The cell lines KB, CaCo-2, MCF-7, A549 and BEAS-2B were selected for the in vitro 
cytotoxicity analysis according to their FR expression levels. All cells were cultured in folate-
free RPMI-1640 medium (Life Technologies) supplemented with 10% FBS, grown to 80% 
confluency in T75 cell culture flasks (Sarstedt) and maintained in a sterile environment at 37 
°C and 5% CO2 atmosphere. Cells were then trypsinised with protease enzyme trypsin in 
EDTA solution (0.25%). Cells were neutralised with 1:1 trypsin EDTA:culture medium, 
centrifuged for removal of trypsin and retained as a cell suspension in culture medium for the 
cytotoxicity testing. Cells were counted using the Beckman Z1 Coulter Counter, as described 
in the section 2.2.3 of Chapter 2. For the purpose of achieving a uniform methodology, all 
cells were seeded at a density of 5,000 cells per well in 96 well plates, in a 100 μL volume. 
The plates were incubated at 37 °C in a 5% CO2 humidified atmosphere for the cells to attach 
to the culture plates, and after 24 hours, they were then exposed to each test compound 
CDEnFA, MTX and CDEnFA:MTX.  
Stock solutions of each test compound were prepared in NaOH (0.1 M pH 12). All solutions 
were then diluted in supplemented folate-free RPMI-1640 medium for a concentration range 
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of 1, 5, 10, 50 and 100 µM. Cells were seeded in 6 wells for each concentration of each 
compound and on triplicate plates for statistical validity. Fresh folate-free RPMI-1640 
medium was added to untreated cells as a negative control. After treating the cells, the plates 
were incubated at 37 °C in a 5% CO2 humidified atmosphere for 48 hours, which was the 
drug-exposure time chosen for this range of concentrations and this range of cell lines 
followed experimental optimisations. 
 
3.2.2 Cell viability assay 
The MTT assay was used to assess the cell viability after treatments with each test 
compound. The MTT assay, developed by Tim Mosmann (1981), is a rapid colourimetric 
assay that measures cell viability based on cell function. The assay detects living cells and the 
signal generated is proportional to the degree of activation and metabolic function of the 
cells. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) is a tetrazolium 
salt and its cleavage by the enzyme succinate-dehydrogenase results in the production of 
purple formazan crystals which accumulate in endosomal and/or lysosomal compartments of 
cells. These purple crystals can then be dissolved using an alcohol or dimethyl sulfoxide 
(DMSO) to produce a homogeneous solution suitable for measurement of cell viability by 
absorbance spectrophotometry.
5
  
For the procedure, the MTT salt was prepared in Phosphate Buffered Saline (PBS) at 5 
mg/mL as a stock solution and this was diluted 1:10 as a working (10 μL of MTT solution to 
90 μL of medium). Cells were incubated with MTT working solution at 37 °C in a 5% CO2 
humidified atmosphere for 3 hours. After incubation, the MTT was removed by washing with 
PBS. 100 μL of DMSO was added to each well, the plate was shaken for 10 minutes and the 
absorbance read on a SpectraMax® Plus384 Absorbance Microplate Reader at 570 nm. 
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Cell viability was calculated as a percentage of control groups according to the following 
formula:  
cell viability (%) = (OD of the test group/ OD of the control group) ×100 
where OD = optical density and test and control group are treated and non-treated cells, 
respectively. 
 
3.2.3 Statistics 
Cytotoxicity data were expressed as mean percentage cell viability relative to control (100%) 
± standard deviation (SD). Statistical analysis was carried out using two-way analysis of 
variance (ANOVA) followed by a post-ANOVA Dunnett’s test for assessing the difference 
between each sample concentration relative to the control. The two-way ANOVA compares 
the mean differences between groups that have been split on two independent variables and 
the Dunnett's test is a multiple comparison procedure used to compare each of a number of 
treatments with a single control. The post-ANOVA Bonferroni’s test was used to assess the 
difference between the same concentrations of two different compounds. Bonferroni 
correction is used when multiple comparisons need to be performed following two-way 
ANOVA as it can reduce the threshold for significance taking in consideration the number of 
comparisons to be made. With this, the significance level applies to the entire family of 
comparisons, not to each individual comparison. Statistical significance was accepted as p ≤ 
0.05 at 95% confidence levels for all tests. Statistical data and IC50 values were calculated 
using the GraphPad Prism software®.   
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3.3 Results and discussion 
3.3.1 Cytotoxicity of CDEnFA  
The cell viability of KB, CaCo-2, MCF-7, A549 and BEAS-2B cells after a 48-hour exposure 
to the carrier CDEnFA was assessed using the MTT assay and the results are presented in 
figure 3.5 below.  
 
Figure 3.5. Effect of CDEnFA on the cell viability of KB, CaCo-2, MCF-7, A549 and 
BEAS-2B cells. Results are expressed as percentage of untreated control (mean ± SD). 
Asterisks denote significant differences to the control where * is p < 0.05 and ** is p < 0.01 
at 95% confidence. 
Chapter 3                                           In Vitro Cytotoxicity Evaluation   
83 
 
The cell viability as a result of the effect of CDEnFA remains above 84% for all 
concentrations studied for CaCo-2 and A549 cell lines. A statistically significant cytotoxic 
effect of CDEnFA can only be seen at concentrations of 50 and 100 µM for KB cells, with a 
cell viability of 86.1% and 84.2%, respectively, and at 100 µM for both MCF-7 and BEAS-
2B, with a cell viability of 84.3% and 87.6% (statistics can be seen in Appendix 10). The 
international standard for biological evaluation of medical devices, ISO 10993-5, includes 
that from quantitative evaluations, a cytotoxic effect is considered when there is a reduction 
of cell viability more than 30%.
6
 The result obtained compares favourably with Varan et al 
(2018), who obtained a cell viability range between 70% and 100% for a non-ionic 
amphiphilic and a polycationic amphiphilic unloaded derivatives of β-CDs, exposed to a co-
culture of MCF-7 and the human dermal fibroblast cell line (HDF).
7
 Róka et al (2015) tested 
high concentrations of derivatives of α-CDs in CaCo-2 cells and found that the effect of α-
CDs derivatives resulted in concentration-dependent cytotoxicity. These authors suggest that 
the cytotoxicity may vary between cell types possibly due to the different mechanisms of 
membrane constituent extraction.
8
 Leclercq (2016) reviews the interactions between CDs and 
cellular components and suggests that the CDs have the capacity to draw phospholipids and 
cholesterol out of the biological membrane. According to Irie et al (1997) and Huang et al 
(2013), the suggested mechanism is that CDs interact with plasma membranes by the 
extraction of different components into their cavity via inclusion complex formation.
9 The 
removal of cholesterol components from the cells may result in an increase in membrane 
fluidity, which would lead to lysis of the cells.
10
 This can be a reason for the cytotoxicity seen 
for KB, MCF-7 and BEAS-2B cells. However, it should be noted that CDs lose their abilities 
to interact with cell membranes when their cavities are occupied with guest molecules.
11
 
Therefore, the carrier CDEnFA possibly interact with the cell membrane, but when MTX is 
included in the cavity, the cytotoxic effect is caused by the drug itself and CDEnFA has no 
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longer a toxic effect towards the cells. In addition, as discussed in Gidwani’s review (2015), 
although in vitro studies have reported haemolytic effects of CDs, the toxicological 
implication of in vivo studies is considered negligible.
12
 The in vivo tolerance of CDEnFA to 
the larvae of the greater wax moth Galleria mellonella is discussed in Chapter 5. Additional 
information on the biocompatibility of CDEnFA from in vitro cell viability measured by flow 
cytometry is presented in Chapter 4.   
 
3.3.2 Cytotoxicity of MTX  
The cell viability of KB, CaCo-2, MCF-7, A549 and BEAS-2B cells after a 48-hour exposure 
to the drug MTX was assessed using the MTT assay and the results are presented in figure 
3.6 as follows.  
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Figure 3.6. Effect of MTX on the cell viability of KB, CaCo-2, MCF-7, A549 and BEAS-2B 
cells. Results are expressed as percentage of untreated control (mean ± SD). Asterisks denote 
significant differences to the control where * is p < 0.05, ** is p < 0.01 and, *** is p < 0.0001 
at 95% confidence. 
 
It can be seen from these results that MTX is significantly cytotoxic to all cell lines studied, 
at least from concentrations above and including 50 µM (statistics can be seen in appendix 
11). MTX displayed higher cytotoxicity towards KB, CaCo-2 and A549 cells even at low 
concentration of 5 µM, and lower cytotoxicity towards MCF-7 and BEAS-2B. According to 
the results reported in Chapter 2, KB, CaCo-2 and A549 express higher protein levels of 
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RFC, than BEAS-2B. RFC is the receptor with high affinity for MTX, and therefore, higher 
RFC levels could result in higher MTX cytotoxicity. MCF-7 cells, even though they were not 
so sensitive to MTX, express the highest protein levels of this receptor. Ifergan et al (2008) 
investigated the association between RFC levels and cytotoxicity, and suggested that high 
RFC levels are associated to sensitivity to antifolates, such as MTX, while low RFC levels 
are associated to the resistance to antifolates.
13
 However, some investigators such as Huang et 
al (2008)
14
 and Kaufman et al (2004)
15
 have reported a low correlation between RFC levels 
and MTX toxicity. In addition to RFC levels, the expression of enzymes such as 
methylenetetrahydrofolate reductase (MTHFR), responsible for the reduction of 
methyleneTHF in the metabolism of folates may be correlated to MTX activity.
16,17
  
 
3.3.3 Cytotoxicity of CDEnFA:MTX 
The cell viability of KB, CaCo-2, MCF-7, A549 and BEAS-2B cells after a 48-hour exposure 
to the complex CDEnFA:MTX was assessed using the MTT assay and the results are 
presented in figure 3.7 as follows.  
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Figure 3.7. Effect of CDEnFA:MTX on the cell viability of KB, CaCo-2, MCF-7, A549 and 
BEAS-2B cells. Results are expressed as percentage of untreated control (mean ± SD). 
Asterisks denote significant differences to the control where * is p < 0.05, ** is p < 0.01 and, 
*** is p < 0.0001 at 95% confidence. 
 
The data shows that CDEnFA:MTX treatment results in cell viability significantly different 
to the control for all cells with p < 0.0001 at concentrations higher than and including 50 µM 
in all cases (statistics can be seen in appendix 12). CDEnFA:MTX demonstrated the greatest 
cytotoxicity towards KB and CaCo-2 cells at all concentrations studied and least cytotoxicity 
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towards BEAS-2B cells. KB and CaCo-2 cells express the highest levels of FRs while BEAS-
2B expresses the lowest. The results obtained for A549 and BEAS-2B compares favourably 
to previous work from Tofzikovskaya et al (2015).
18
 The comparison between cell viability 
after treatments with MTX alone and CDEnFA:MTX, as well as its correlation to FR levels 
in the cells, is discussed in the following section. 
 
3.3.4 Comparison of the cytotoxicity of MTX and CDEnFA:MTX  
Figure 3.8 below shows a comparison of the cell viability for each of the cell lines studied 
after a 48-hour exposure to MTX and CDEnFA:MTX. A figure which also includes the 
results for CDEnFA and the solvent control, NaOH, can be seen in appendix 13.  
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Figure 3.8. Effect of MTX (■) and CDEnFA:MTX (▲) on the cell viability of KB, CaCo-2, 
MCF-7, A549 and BEAS-2B cells. Asterisks denote significant differences between the two 
compounds where * is p < 0.05, ** is p < 0.01, *** is p < 0.0001 at 95% confidence. 
 
After a 48-hour exposure to free MTX and to the complex CDEnFA:MTX, the anti-
proliferative effect was observed and it can be seen from figure 3.7 that the complex was 
more cytotoxic towards the high-FR expressing cell lines, KB and CaCo-2, in comparison to 
the free MTX. The IC50 value, which is the concentration causing 50% inhibition of cell 
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proliferation, was calculated from the cell viability results. The IC50 value for KB cells was 
53.75 ± 1.57 µM for free MTX and 6.91 ± 1.49 µM for CDEnFA:MTX. This means that the 
complex was responsible for a 7.8 fold increase in the cytotoxicity of the drug towards this 
cell line. The IC50 value obtained for CaCo-2 cells was 76.48 ± 1.28 µM for MTX and 48.03 
± 1.16 µM for CDEnFA:MTX, which means that the complex resulted in a 1.6 fold increase 
in the cytotoxicity of the drug. Other investigators have also reported higher cytotoxicity of 
FR-targeted drug compounds towards high-expressing FR cell lines. For example, Chen et al 
(2015) assessed the cytotoxicity of an MTX-loaded nanoparticle in A549 and KB cell lines 
and also observed higher cytotoxicity of the complex than the free drug. 
19
 Roger et al (2012) 
reported that, in the FR expressing cell line, CaCo-2, folic acid functionalized poly(D,L-
lactide-co-glycolide)-nanoparticles loaded with the drug paclitaxel, showed an 8-fold increase 
in transport when compared to free drug.
20
 Anderson et al (2001) reported that the 
incorporation of folic acid conjugated liposomes for drug delivery resulted in a 5.7-fold 
increase in CaCo-2 cell uptake of the drug vancomycin.
21  
MCF-7 cells express medium levels of FRs when compared to the other cell lines analysed, 
and no significant difference was observed in cell viability between the complex and the free 
drug. The IC50 value obtained for this cell line was 79.72 ± 1.12 µM for MTX and 71.79 ± 
1.11 for CDEnFA:MTX. As discussed in chapter two, MCF-7 cells showed a poor correlation 
between mRNA and protein expression. FRs may be upregulated or downregulated 
depending on the experimental conditions, such as extracellular folate availability, 
intracellular homocysteine levels, and cell requirements of folate due to cell replication.
22,23
  
A549 and BEAS-2B cell lines express low levels of FR, and as shown in figure 3.7, these 
cells lines were more sensitive to free MTX than to the complex CDEnFA:MTX. The IC50 
values obtained for A549 were 30.59 ± 1.15 µM for MTX and 56.61 ± 1.13 for 
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CDEnFA:MTX. The IC50 values obtained for BEAS-2B were 82.46 ± 1.09 for MTX and 
127.1 ± 1.15 for CDEnFA:MTX. This means that the free MTX was 1.8 and 1.5 fold more 
toxic towards A549 and BEAS-2B, respectively, than CDEnFA:MTX. These are exciting 
findings as there was a lower effect towards the non-cancer cell line BEAS-2B. Several 
investigators have reported that cell lines expressing low levels of FRs are not as affected by 
FR targeted drug delivery systems as cell lines expressing high levels and reports also suggest 
that normal cell lines do not express significant levels of that receptor. For example, Oliveira 
et al (2016) reported that folate-amino-functionalized silica nanoparticles were significantly 
cytotoxic to a prostate cancer cell line (PC3 cells), whereas a normal prostate epithelial cell 
line (PrEC cells) was much less affected by this drug delivery system.
24
 Yang et al (2015) 
confirmed the significant tumour inhibition efficacy of drug-loaded poly(ethylene glycol)-
folate nanoparticles with lower cytotoxicity to the normal cells HEK293 (human embryonic 
kidney cells) than the drug alone.
25
    
The results presented here suggest that CDEnFA:MTX can selectively target FRs, enhance 
drug toxicity towards the high FR expressing cell lines, and also reduce the cytotoxicity of 
MTX against cells expressing low levels of this receptor. Barar et al (2015), also 
demonstrated a higher cytotoxicity of a folic acid conjugated nanoparticle towards MCF-7 
cells than A549.
26
 Sharma et al (2013) also found greater inhibition of CaCo-2 proliferation 
by MTX loaded folic acid conjugated nanoparticle than the non-folic acid MTX loaded 
nanoparticle.
27
 Muralidharan et al (2016) demonstrated that FR-targeted lipid nanoparticles 
were significantly less toxic towards a normal lung fibroblast cell line (CCD16 cells) than to 
a high FR expressing cancer cell line (H1299 cells).
28
  
These results indicate the potential of the drug delivery system CDEnFA in improving the 
cytotoxicity of the drug MTX in cell lines overexpressing FR, suggesting that a lower 
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concentration may be required to achieve the same dose response. Furthermore, 
CDEnFA:MTX was not as toxic as free MTX to the cell lines which express low levels of 
FRs, suggesting that the drug delivery system has some specificity towards cell lines that 
express high levels of FRs. 
The cell lines analysed express reduced folate carrier (RFC) protein levels as follows, MCF-7 
> KB > A549 > CaCo-2 > BEAS-2B and it did not seem to influence the cytotoxicity of 
MTX or CDEnFA:MTX. He et al (2014) analysed whether a polymorphism of the RFC gene 
(SLC19A1) may influence MTX acute toxicity in pediatric lymphoblastic leukaemia (ALL) 
and concluded that there is no correlation between RFC polymorphism and MTX toxicity in 
pediatric ALL.
29
 Chattopadhyay et al (2006) demonstrated an inverse relationship between 
RFC function and pemetrexed activity. Pemetrexed is also an antifolate that inhibits enzymes 
responsible for the folate metabolism. The author suggests that this inverse correlation may 
occur due to a cellular folate pool contraction which results in partial preservation of 
pemetrexed polyglutamylation and increased target enzyme inhibition.
30
 However, Matherly 
and Hou (2008) reviewed RFC structure and function and reported that loss of RFC 
expression results in antifolate resistance due to incomplete inhibition of cellular enzyme 
targets. Therefore, more studies are needed to investigate the correlation between RFC 
expression and antifolates activity.
31
  
 
3.4 Conclusion 
The results presented in Chapter 3 demonstrated that the drug delivery vehicle CDEnFA has a 
low cytotoxicity towards the cell lines analysed, suggesting that it is a good potential 
candidate as a novel drug delivery system. The inclusion complex CDEnFA:MTX showed 
greater cytotoxicity than free MTX towards the high FR expressing KB and CaCo-2 cells, 
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indicating that it has potential to target this folate receptor, enhancing the specificity and the 
efficiency of the MTX drug. Free MTX is more toxic towards cell lines expressing low levels 
of FR, such as the normal cell line BEAS-2B, than the complex CDEnFA:MTX, suggesting 
that the inclusion complex can potentially cause fewer side effects than the drug alone. The 
levels of RFC do not seem to influence MTX or CDEnFA:MTX activity. 
These are exciting findings and indicate that CDEnFA can be used as a drug delivery system 
to specifically target FR in cancer cells with better efficacy. Furthermore, the inclusion 
complex offers a system that causes less damage than the drug alone to cells that express low 
levels of FRs, such as healthy cells.  
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4.1 Introduction 
It has been previously demonstrated that folic acid enters the cell preferentially through the 
folate receptors (FRs) while methotrexate enters the cell preferentially through the reduced 
folate carriers (RFCs).
1
 Therefore, FRs may be responsible for the uptake of CDEnFA:MTX 
by the ligand, folic acid. Due to the relatively large size of the cyclodextrins (molecular 
weight >1000 Da), as well as hydrophilicity, it is predicted that these molecules, in general, 
are not able to permeate biological membranes. A guest molecule may be absorbed but only 
an insignificant amount of cyclodextrin is able to dissolve in lipids and is considered to be 
absorbed from the gastrointestinal tract.
2
 Therefore, it is thought that in general, the 
cyclodextrin delivers the drug to the surface of cell membrane, and the free form of the drug 
molecule is dissociated from the cyclodextrin complex and is internalised through the 
lipophilic membrane while the cyclodextrin remains extracellular.
3,4
 However, in vivo studies 
measured a high amount of β-cyclodextrins that were absorbed via the rectum of rats and 
excreted in the urine, suggesting that not only the free form of dissociated drugs but also 
cyclodextrin complexes may be absorbable through the rectal mucosa.
5
 In addition, Fenyvesi 
et al (2014), investigated the internalisation of fluorescently-labelled methyl-β-cyclodextrin 
by CaCo-2 cells and concluded that the compound was able to enter the intestinal epithelial 
cells by fluid-phase endocytosis from the apical side of the cell.
4
  
Although the cell membrane is naturally impermeable to complexes larger than 1000 Da, 
there are active mechanisms, such as a process called endocytosis, that allow for the 
internalisation of large molecules. In this process, the cell membrane invaginates to engulf 
molecules in an intracellular membrane-bound vesicle, or endosome, which will subsequently 
traffic through the cell. Molecules may reside near the membrane or directly interact with 
membrane proteins to enable their retention in these vesicles.
6
 Thus, in drug delivery 
Chapter 4  Cellular Uptake and Internalisation Studies 
99 
 
applications, the endocytotic pathway has always held significant promise for the 
investigation of targeted drug delivery systems and cellular uptake of macromolecules.
7
  
In the process of endocytosis, the macromolecules to be internalized first bind to specific cell 
surface receptors, which are usually concentrated in specialized regions of the plasma 
membrane, called clathrin-coated pits. These pits bud from the membrane to form small 
clathrin-coated vesicles containing the receptors and their bound macromolecules (ligands).
8
 
The clathrin-coated vesicles then fuse with early endosomes, in which their contents are 
sorted for transport to lysosomes or recycling to the plasma membrane. Another protein that 
is often needed in the endocytosis process is the GTPase dynamin, which is responsible for 
membrane fission which results in the pinching off of the vesicle from the parent membrane.
9
  
Clathrin- and dynamin-dependent endocytosis are endocytic pathways that are grouped 
according to the cell requirement for the self-polymerizing vesicle coated protein clathrin and 
the large enzyme GTPase dynamin.
10,11
 However, there are also many other pathways of 
clathrin-independent endocytosis. For example, those which have distinct coats called 
caveolae, formed by caveolin proteins, and others which function in the absence of 
specifically coated intermediates. Some clathrin-independent pathways are also independent 
of dynamin. Some of these routes likely overlap in their molecular requirements and their 
cargo.
12
 Most internalised cargo is delivered to early endosomes via vesicular (clathrin- or 
caveolin-coated vesicles) or tubular intermediates called clathrin- and dynamin-independent 
carriers (CLICs) that are derived from the plasma membrane.
13
 Some pathways may first 
direct traffic to intermediate compartments, such as the caveosome or 
glycosylphosphatidylinositol (GPI)-anchored protein-enriched early endosomal 
compartments (GEECs), en route to the early endosome.
14
 GEECs result from fusion of the 
CLICs, which are directly derived from the cell surface, in a process termed the CLIC/GEEC 
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pathway. A variety of GPI-anchored proteins are internalized by this pathway, including the 
FRs.
12
 Figure 4.1 below illustrates these types of endocytosis. 
 
Figure 4.1. Endocytic pathways present in cells. The left-side section shows dynamin-
dependent pathways. Clathrin- and caveolae-mediated endocytosis, along with endocytosis of 
the interleukin-2 receptor (IL2R) require dynamin. The right-side section shows dynamin-
independent trafficking pathways, including the clathrin-independent carrier and 
glycophosphatidylinositol-enriched endocytic compartment (CLIC/GEEC) pathway.
15
 
 
FRs are expressed at the cell surface and anchored in the cell membrane by a GPI domain, 
and therefore are examples of GPI-anchored proteins. Hence, FRs are GPI-anchored proteins 
selectively endocytosed via a non-clathrin, non caveolar, and dynamin-independent pinocytic 
(fluid) pathway to the recycling endosomal compartment of the cell.
16
 The RFC is an integral 
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membrane protein that belongs to the solute carrier family of transporters and functions as a 
bidirectional anion transporter of organic phosphates that are synthesised and retained within 
cells.
17
 This is an antiport transport system in which the downhill flow of organic phosphates 
is linked to the uphill transport of folate substrates into cells via the same mechanism at 
neutral pH.
18
 According to Hou and Matherly (2014), membrane transport of folate molecules 
by RFC is expected to involve a physical movement of the carrier within the plasma 
membrane. In addition, its substrate-binding cavity accessibility alternates between the intra- 
and extracellular compartments, allowing the efflux or the influx of reduced folates, 
respectively. For this carrier, transport is driven by extrusion of anions down a large 
concentration gradient.
19
 Sabharanjak and Mayor (2004) suggested that understanding the 
relationship between the FR and the RFC, and the nature of the compartment where the two 
come together for coordinating efficient folate uptake is an important issue that remains to be 
addressed. Furthermore, understanding the detailed mechanisms of the sorting propensities of 
FR will provide insight into the delivery of folate into cells, and may help in designing 
therapeutics based on folate-conjugates.
20
 
The inhibition of receptors, transporters and enzymes is a good strategy for the investigation 
of cellular uptake, internalisation processes and intracellular trafficking pathways. The use of 
uptake or endocytosis inhibitors can selectively knock-off individual mechanisms and the 
mode of uptake for a specific molecule, such as a drug carrier.
21
 Here, the FR was inhibited 
by the drug fumonisin-B1 (FB1) to confirm the drug targeting and cellular uptake process of 
FR. Stevens et al (1997) demonstrated that FB1 can inhibit FR function by causing changes 
in the membrane lipid composition. In their study, there was a decrease of 90% in the uptake 
by FRs in FB1-treated cells. Their findings suggest that FB1 treatment results in the depletion 
of cholesterol and sphingolipid levels vital for the structure of the cell membrane, and this 
appeared to decrease the total amount of FRs in the cells in a time- and concentration-
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dependent manner.
22
 Nour et al (2007) also used FB1 to investigate the expression of both FR 
and RFC and folate uptake. They demonstrated that FR levels are decreased after FB1 
treatment, while RFC levels are increased, as a potential protective effect in a folate-replete 
environment. However, the levels of both receptors decrease after FB1 exposure in a folate-
free environment.
23
  
According to Vandana and Sahoo (2012), the inhibition or loss of RFC leads to decreased or 
impaired transport of antifolates, which in turn, decreases the intracellular concentration and 
reduces the cytotoxic effect of the antifolates on cancer cells.
24
 In this work, the drug 
sulfasalazine (SSZ) was used as an inhibitor of RFC to investigate if the cytotoxicity caused 
by the drug-complex CDEnFA:MTX is affected. According to Jansen et al (2004), SSZ is an 
effective non-competitive inhibitor of RFC. These authors have demonstrated a marked loss 
of MTX efficacy when it was co-administered with SSZ. According to their findings, RFC 
protein expression appeared to be down-regulated in cell lines treated with SSZ in a dose-
dependent manner.
25
  
The primary objective of the work presented in this chapter is to elucidate the route of 
cellular uptake and internalisation of the complex CDEnFA:MTX. A possible route would be 
the total internalisation of the complex by the FR, triggered by the specific ligation of the 
folic acid to this receptor. This model is demonstrated in figure 4.2. Here, after the uptake and 
internalisation of the complex by the FR, the cyclodextrin releases the drug MTX into the 
endocytic vesicle in the intracellular compartment. The release of the MTX can be triggered 
by competitive compounds against the drug, such as the target enzyme, dihydrofolate 
reductase (DHFR).
26
 Another possible route would be the uptake of the MTX by the RFC. 
This model is demonstrated in figure 4.3. Here, the ratio of FR to RFC presumably needs to 
be ≈1 so that the CDEnFA can target FR and then deliver the MTX to be uptaken and 
internalised through the RFC.   
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Figure 4.2. Possible route of uptake of the complex CDEnFA:MTX through the folate 
receptor. The whole complex is internalised and the drug is released in endocytic vesicles 
(adapted from Endocyte, inc).
27
 
 
Figure 4.3. Possible route of uptake of the complex CDEnFA:MTX. Folic acid targets the 
folate receptor and, the cyclodextrin remains extracellular while MTX is internalised through 
the reduced folate carrier.  
The work described in this chapter utilises FB1 and SSZ to inhibit and reduce the levels of 
FR and RFC respectively. After treating the cervical carcinoma KB cells with FB1 and SSZ, 
and thereby, inhibiting FR and RFC, a comparison of the cytotoxic effect caused by the free 
drug and the complex is analysed to confirm the probable route of internalisation and release 
of the MTX from the complex CDEnFA:MTX.  
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4.2 Materials and Methods 
4.2.1 Cell culture and treatments 
KB cells were selected for this mechanistic study due to their previously demonstrated high 
levels of both FRs and RFCs compared to the other cell lines. The cells were cultured in 
folate-free RPMI-1640 medium (Life Technologies) supplemented with 10% foetal bovine 
serum (FBS) (Sigma-Aldrich), grown to 80% confluency in T75 cell culture flasks (Sarstedt) 
and maintained in a sterile environment at 37°C and 5% CO2 atmosphere. Cells were then 
trypsinised with protease enzyme trypsin made in Hanks Balanced Salt Solution (0.25%) with 
EDTA (1:1). Cells were neutralised in culture medium (1:1) and centrifuged. The supernatant 
was removed and the cell pellet was suspended in fresh culture medium. Cell counts were 
determined using the Beckman Z1 Coulter Counter, as described in section 2.2.3 of Chapter 
2.  
Cells were then seeded in 24-well plates at a concentration of 50,000 cells per well and 
incubated at 37°C and 5% CO2. After 24 hours, cells were exposed to FB1 for 48 hours at a 
concentration of 27.7 µM and to SSZ for 72 hours at a concentration of 250 µM (Sigma-
Aldrich for both). These were described as the optimum times and concentrations for 
inhibition of the receptors without any major cytotoxic effects, according to Stevens & Tang, 
and Jansen et al.
22,25
 The cells were then harvested with a trypsin-EDTA solution and 
prepared for detection of FR and RFC levels on the flow cytometer, as described below in 
section 4.2.2.  
For cytotoxicity evaluation of MTX, CDEnFA:MTX or CDEnFA, the cells were first treated 
with FB1 and SSZ as above and then exposed to each compound at concentrations of 10, 100 
and 1000 µM for 48 hours and then cell viability was measured using the flow cytometer and 
propidium iodide as a marker of dead cells as described in section 4.2.3 below.  
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4.2.2 FR and RFC protein expression  
Following treatment with FB1 or SSZ, the cells were prepared for protein detection analysis 
using flow cytometry. This procedure is detailed in section 2.2.3 in Chapter 2. Briefly, 5x10
5 
KB cells were resuspended in 100 µL of FCS buffer and incubated at 4°C for 30 minutes with 
a mouse monoclonal anti-folate receptor antibody LK26 (Abcam) at a final concentration of 2 
µg/100 µL for FR detection, or with a chicken polyclonal anti-reduced folate carrier 
SLC19A1 antibody (Thermo Scientific) at a final concentration of 2 µg/100 µL for RFC 
detection. After incubation, the cells were washed and incubated at 4°C for 30 minutes in the 
dark with the respective secondary antibodies, goat anti-mouse Alexa Fluor® 488-conjugated 
at a 1:800 final dilution and goat anti-chicken Alexa Fluor® 488-conjugated at a 1:800 final 
dilution. After incubation, the cells were washed and examined on the flow cytometer Accuri 
C6 (BD Biosciences). Each cell solution was divided into 3 samples (a) unstained sample, (b) 
negative control and (c) FR or RFC sample. Negative controls were samples of cells run with 
the secondary antibody without including a primary antibody, to define positive populations 
and to eliminate any background fluorescence from the conjugated secondary antibody. A 
total of 10,000 events of single cells were recorded for analysis. In the flow cytometer, the 
excitation laser line of 488 nm, filter 530/30 and the FL-1 detector was used for excitation 
and detection of fluorescence from the green dye Alexa Fluor® 488. Data was analysed using 
BD Accuri C6 software. Data from triplicate samples, run in parallel, were used for statistical 
analysis where a t-test was used to assess the significant difference between treated and 
untreated samples. GraphPad Prism software® was used for statistical analysis. 
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4.2.3 Cell viability  
KB cells were cultured in folate-free RPMI-1640 medium, supplemented with 10% FBS, 
seeded in 96-well plates at a concentration of 5,000 cells per well and incubated at 37°C and 
5% CO2. After 24 hours, the cells were treated with FB1 at a concentration of 27.7 µM for 48 
hours, or with SSZ at a concentration of 250 µM for 72 hours, or with a co-treatment FB1 + 
SSZ (where FB1 was added after 24 hours for a 48-hour treatment). The cells were then 
exposed to the compounds MTX, CDEnFA:MTX and CDEnFA for 48 hours at 
concentrations of 10, 100 and 1000 µM. The cells were harvested with a 1:1 trypsin-EDTA 
solution as before and centrifuged at 1800 rpm for 3 minutes. The supernatant was removed 
and 100 µL of flow cytometry staining (FCS) buffer (PBS, 1% BSA, 0.1% sodium azide) was 
added to each well. For the staining of dead cells, 4 µg/mL of propidium iodide (PI) was 
added to each well prior to analysis, incubated at room temperature for 1 minute in the dark. 
The samples were put through the Accuri C6 flow cytometer until 1,000 events were 
recorded for each sample. The experiment was performed with triplicate samples, run in 
parallel, for all treatment samples or control samples. The control samples are described in 
detail in table 4.1 below and consisted of live cells, dead cells, and cells treated with FB1, 
SSZ or FB1 + SSZ without further exposure to MTX, CDEnFA:MTX or CDEnFA.  
Table 4.1. Description of the control samples. 
Live cells Untreated KB cells 
Dead cells 
KB cells were incubated with 4% paraformaldehyde 
(PFA) for 20 minutes at room temperature (PFA is a 
polyoxymethylene that kills cells by quickly denaturing 
its proteins). 
No exposure to MTX, 
CDEnFA:MTX or 
CDEnFA  
(a) KB cells treated with FB1 with no further exposure. 
(b) KB cells treated with SSZ with no further exposure. 
(c) KB cells treated with a co-treatment of FB1 and 
SSZ, with no further exposure.  
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4.2.4 Data analysis 
The median fluorescence intensity (MFI) from PI was recorded. PI binds to the DNA of 
damaged cells, and therefore, the amount of PI fluorescence detected is proportional to the 
amount of dead cells in the sample, equivalent not only to the number of dead cells but also 
to how damaged the affected cells are. The data presented in the figures of sections 4.3.2 
onwards, represent the mean of three replicates ± standard deviation. Statistical analysis was 
performed using GraphPad Prism software®. T-test or one-way analysis of variance 
(ANOVA) followed by a post-ANOVA Dunnett’s test was used to assess the significant 
difference between live cells in control samples. Two-way ANOVA, followed by a post-
ANOVA Bonferroni’s test, was used to assess the significant difference between the 
untreated and treated samples for different concentrations. Statistical significance was 
accepted as p ≤ 0.05 at 95% confidence levels for all tests. 
 
4.3 Results and Discussion 
4.3.1 Protein levels of FR and RFC after treatment with fumonisin-B1 (FB1) and 
sulfasalazine (SSZ) 
KB cells were treated with FB1 and SSZ, followed by a protein detection assay for measuring 
FR and RFC levels on a flow cytometer. The ratios FSC-H/FSC-A and SSC-A/FSC-A plots 
are given in where FSC-H and FSC-A are the forward scattered light height and area, 
respectively, and SSC-A is the side scattered light area. These plots, from each analysed 
sample, report the particle’s size and complexity, and were used to discriminate cell debris 
and doublets or clumps of cells from single cells. Plots representing how samples are gated to 
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exclude debris or clumps and to determine positives are given in appendix 14. 10,000 events 
of single cells were recorded for each sample.  
 
FR levels after FB1 and SSZ treatments 
Figure 4.4 presents the results obtained for the determination of the FR protein levels in KB 
cells after treatment with FB1 and SSZ. 
 
        A         B 
Figure 4.4. Folate receptor protein levels in (A) fumonisin-B1 treated (red peak) and (B) 
sulfasalazine treated (pink peak) KB cells, determined by flow cytometry. Untreated samples 
are shown in green. 
 
As regards the effect of FB1 on FR levels, it can be seen from figure 4.4A that the red peak, 
representing FB1-treated samples, shifts to the left when compared to the green peak, which 
represents untreated samples. This indicates that less fluorescence is detected from the FB1-
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treated samples, and therefore, there are lower amounts of FRs in the KB cells. This is also 
indicated by the MFI (median fluorescence intensity) of the FB1-treated samples compared to 
the untreated samples, with a significant decrease of 64% in FR levels for FB1-treated KB 
cells. A complete statistical analysis is given in Appendix 15A. This data is consistent with 
literature and indicates that FB1 inhibits and reduces FR levels on cell membranes. Nour et al 
(2007) investigated the effect of FB1 on the protein and also on the mRNA levels of FRs in 
the human liver carcinoma (HepG2) cells, and found that in FB1-treated cells, both FR 
protein and mRNA expression were inhibited in a concentration- and time-dependent manner. 
They suggested that the decrease in FR levels occurred after the apoptosis event, confirming 
that the inhibition was not caused by a direct effect of the FB1, but as a consequence of the 
disruption of sphingolipid metabolism.
23
 Pellanda et al (2012) used a rat model to investigate 
the effect of FB1 administration during rat pregnancy, including the effect of FB1 on the 
mRNA levels of FRs. They also found that exposure to FB1 resulted in decreased FR mRNA 
and supported the hypothesis that FB1 alters folate transport by interfering with the 
metabolism of cell membrane lipids.
28
 
As regards the effect of SSZ, it can be seen from figure 4.4B that both the pink peak 
representing SSZ-treated samples, and the green peak representing untreated samples, cover 
the same region of fluorescence, and therefore, SSZ treatment causes no shift in the 
fluorescence peaks for FR levels. This is also indicated by the MFI of the treated versus the 
untreated samples which show a non-significant difference in the fluorescence intensity for 
the FR levels in KB cells (statistics are given in Appendix 15B). This indicates that SSZ does 
not inhibit FR protein expression levels. No recent information could be found in the 
literature describing the effect of SSZ directly on FR levels in cells. It was previously 
reported that SSZ inhibited the absorption of folic acid in four of seven patients with 
ulcerative colitis, although the process involved was not clear.
29
 Inoue et al (2008) 
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demonstrated that SSZ (0.2 mM) inhibits folic acid uptake into everted sacs of rat jejunum at 
pH 5.5. However, the proton-coupled folate transporter (PCFT) is responsible for the 
internalisation of folates into the cell under a low pH environment, with an optimum transport 
function at pH 5.5. Therefore, Inoue and colleagues suggest that SSZ can inhibit folic acid 
absorption by inhibiting the function of the PCFT transporter and not FRs.
30
 
 
 RFC levels after FB1 and SSZ treatments 
Figure 4.5 presents the results obtained for the determination of the RFC protein levels in KB 
cells after treatment with FB1 and SSZ. 
 
        A         B 
Figure 4.5. Reduced folate carrier levels in (A) fumonisin-B1 treated (purple peak) and (B) 
sulfasalazine treated (orange peak) KB cells, determined by flow cytometry. Untreated 
samples are shown in green. 
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As regards the effect of FB1 on RFC levels, it can be seen from figure 4.5A that both the 
purple peak, representing FB1-treated cells, and the blue peak, representing untreated cells, 
cover the same region of fluorescence, and therefore, FB1 treatment causes no shift in the 
fluorescence peak for RFC levels. This is also indicated by the MFI of treated versus 
untreated samples which showed similar values for the RFC levels of both samples. Nour et 
al (2007) studied whether FB1 modifies the expression of RFC levels in HepG2 cells grown 
in both folate-replete and folate-free media. Their results indicate that in cells grown in 
folate-replete media, protein expression of the RFC was increased while, when grown in 
folate-free media, protein expression of the RFC was decreased after treatment with FB1.
23
 In 
our work, KB cells were grown in folate-free medium, and a decrease in the levels of RFC is 
observed, although it was not significant (statistics are given in Appendix 16A). 
From figure 4.5B, it can be seen that the orange peak, representing SSZ-treated cells, shifts 
slightly to the left when compared to the blue peak for untreated samples. This indicates that 
less fluorescence is detected from the SSZ-treated sample, and therefore, there are lower 
amounts of RFC in that sample. This is also indicated by the MFI of the SSZ-treated sample 
compared to the untreated sample with a significant decrease of 14.5% in RFC levels for 
SSZ-treated KB cells (statistics are given in Appendix 16B). This result is consistent with 
Jansen et al (2004), who demonstrated that RFC protein expression was down-regulated in 
the human leukemic (CCRF-CEM) cells. According to these authors, RFC transport activity 
closely corresponded to RFC protein levels.
25
 
 
4.3.2 Effect of FB1 and SSZ on the cytotoxicity caused by the study compounds 
After confirming that FB1 and SSZ indeed affect FR and RFC levels respectively, KB cells 
were exposed to a pre-treatment with these drugs as well as with a co-treatment with FB1 + 
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SSZ, to assess if these pre-treatments affect the cytotoxicity caused by the compounds MTX, 
CDEnFA:MTX and CDEnFA . Control samples are important in order to demonstrate that 
any cytotoxic effect seen from the sample is not caused by the pre-treatments with FB1 
and/or with SSZ. The concentrations of FB1 (27.7 µM) and SSZ (250 µM) used for the pre-
treatments are optimum concentrations for inhibiting the transporters, without causing major 
damage to the cells, as determined by Stevens and Tang (1997) and Jansen et al (2004).
22,25
 
Figure 4.6 below shows the cell viability for control samples that were not exposed to 
CDEnFA, MTX or CDEnFA:MTX, and include untreated live KB cells and dead cells, which 
were KB cells that were fixed with 4% paraformaldehyde (PFA).  
 
 
 
 
 
Figure 4.6. MFI (Median Fluorescence Intensity) obtained for the controls where live 
cells=untreated KB cells, dead cells=fixed KB cells (4% PFA), FB1=KB cells treated with 
FB1 only, SSZ=KB cells treated with SSZ only, FB1+SSZ=KB cells treated with a co-
treatment of FB1 and SSZ. Asterisks represent significant difference to the live cells control. 
 
Median Fluorescence Intensity (MFI) of PI, detected by flow cytometry was used to measure 
cell viability. PI binds to the DNA when the cell membrane is damaged, hence higher 
fluorescence means higher cell death. There was no significant difference between untreated 
live cells and FB1, SSZ or FB1 + SSZ treated control samples (Appendix 17). Therefore, it 
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can be concluded that pre-treatment with FB1 and/or SSZ cause no cytotoxic effect on KB 
cells.  
 
4.3.2.1 Effect of FB1 on the cytotoxicity caused by the study compounds 
Figure 4.7 below displays the effect of a pre-treatment of KB cells with FB1 on the 
cytotoxicity of MTX, CDEnFA:MTX and CDEnFA, each at concentrations of 10, 100 and 
1000 µM for 48 hours. MFI of PI, detected by flow cytometry, was again used as a measure 
of cell viability.  
 
 
 
 
 
A                                 B 
 
 
 
    C 
Figure 4.7. Effect of pre-treatment with fumonisin B1 (FB1) on the cytotoxicity of (A) MTX, 
(B) CDEnFA:MTX and (C) CDEnFA towards KB cells. 
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The data shows that FB1 pre-treatment caused a decrease in the cytotoxic effect of MTX and 
CDEnFA:MTX, although the change was not significant for MTX. As seen previously, FB1 
treatment does not have a major effect on the expression levels of RFC protein, the 
transporter responsible for the uptake of MTX, which can explain why the change in the 
cytotoxicity of MTX was not significant. FB1 treatment caused a significant decrease in the 
cytotoxicity of CDEnFA:MTX at 100 µM (p < 0.05) and 1000 µM (p < 0.01), statistics are 
given in Appendix 18. As seen previously, FB1 treatment causes a down-regulation of FR 
protein expression, and it was  also demonstrated that FB1 treatment reduces the uptake of 
folates by the cell.
22,23
 Therefore, this can explain the significant decrease in the cytotoxicity 
caused by CDEnFA:MTX after treatment with FB1.  
Figure 4.7C shows that CDEnFA was not toxic to the cells, as reported previously, and a pre-
treatment with FB1 did not exert a significant effect on cell viability. This confirms that the 
carrier CDEnFA, without the drug, does not damage the cells, and also provides additional 
evidence that FB1 itself is not responsible for cell death.  
 
 
4.3.2.2 Effect of SSZ on the cytotoxicity caused by the study compounds 
Figure 4.8 displays the effect of a pre-treatment of KB cells with SSZ on the cytotoxicity of 
MTX, CDEnFA:MTX and CDEnFA, each at concentrations of 10, 100 and 1000 µM for 48 
hours.  
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A               B 
 
 
 
 
 
           C 
Figure 4.8. Effect of pre-treatment with sulfasalazine (SSZ) on the cytotoxicity of (A) MTX, 
(B) CDEnFA:MTX and (C) CDEnFA towards KB cells. 
 
Figure 4.8A shows that SSZ treatment caused a decrease in the cytotoxic effect of MTX, 
although not statistically significant (statistics are given in Appendix 19). It should be noted 
that pharmacological inhibition only blocks the function of a protein but the protein is still 
present, even if in reduced levels. Therefore, a pharmacologically inhibited protein lacks 
activity, but may still interact with some binding partners or partially internalise a substrate.
31
 
This may explain why the decrease was not statistically significant. In addition, MTX could 
still enter the cell through a different route by using the proton coupled folate transporter 
(PCFT). Although, MTX enters the cell through this route preferentially in an acidic 
microenvironment, with optimum transport at pH 5–5.5.19  
CDEnFA:MTX
10 100 1000
0
20000
40000
60000
80000
100000 No treatment
(CDEnFA:MTX only)
SSZ treated
Concentration of CDEnFA:MTX (µM)
M
F
I
MTX
10 100 1000
0
20000
40000
60000
80000
100000
No treatment
(MTX only)
SSZ treated
Concentration of MTX (µM)
M
F
I
CDEnFA
10 100 1000
0
20000
40000
60000
80000
100000
No treatment
(CDEnFA only)
SSZ treated
Concentration of CDEnFA (µM)
M
F
I
Chapter 4  Cellular Uptake and Internalisation Studies 
116 
 
From figure 4.8B it can be seen that the cytotoxicity of CDEnFA:MTX was increased at 
concentrations of 10 and 100 µM and decreased at 1000 µM, after SSZ treatment, although 
these changes were not statistically significant. Previously it was seen that SSZ pre-treatment 
does not inhibit FR expression. However, it has also been reported that SSZ can partially 
inhibit the uptake of folic acid when the concentration of folic acid is high.
32
 This may 
explain why the cytotoxicity of CDEnFA:MTX decreases only at the highest concentration of 
the compound. 
Figure 4.8C shows that SSZ pre-treatment did not exert significant effect on the cell viability 
of CDEnFA-treated cells, and also provides additional evidence that SSZ itself is not 
responsible for cell death.  
 
4.3.2.3 Effect of a co-treatment with FB1 + SSZ on the cytotoxicity caused by the study 
compounds 
Figure 4.9 displays the effect of a co-treatment of KB cells with FB1 and SSZ on the 
cytotoxicity of MTX, CDEnFA:MTX and CDEnFA, each at concentrations of 10, 100 and 
1000 µM for 48 hours.  
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        C 
Figure 4.9. Effect of a co-treatment with fumonisin-B1 and sulfasalazine on the cytotoxicity 
of (A) MTX, (B) CDEnFA:MTX and (C) CDEnFA towards KB cells.  
 
Figure 4.9A shows that co-treatment with FB1 and SSZ did not significantly affect the 
cytotoxicity of MTX (statistics are given in Appendix 20). Previously it was also shown and 
discussed that, independently, FB1 and SSZ pre-treatments showed only a non-significant 
decrease in MTX cytotoxicity, which may explain why co-treatment has also not caused 
major changes in the cytotoxic effect of MTX towards the cells.  
Figure 4.9B shows that co-treatment with FB1 and SSZ exerted an additive effect on the 
internalisation of CDEnFA:MTX, resulting in a very significant decrease in its cytotoxic 
effect towards KB cells. FB1 treatment is responsible for a decrease of FR levels on the cell 
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membrane, and, therefore, FB1 may be playing a key role in the co-treatment effect by 
reducing the number of sites for binding of CDEnFA. Once the CDEnFA is not able to bind 
to the FRs on the cell, it is also not able to deliver the drug through the RFC, nor it can be 
internalised through the FR itself. The effect of SSZ have certainly also contributed to the 
significant decrease in the cytotoxicity of CDEnFA:MTX as the effect of the co-treatment 
was remarkably stronger than the effect of the independent treatment with FB1. RFC is a 
bidirectional transporter responsible for the influx and efflux of reduced folates. The free 
intracellular levels of MTX and of reduced folates are determined by the relative activity of 
both influx and efflux transport pathways. When the intracellular levels of MTX are high, the 
influx of MTX through the RFC will stop, which may also happen due to the lack of folates 
in the extracellular environment.
33
 SSZ may reduce the influx of MTX, and together with 
blocking of FRs by FB1, the CDEnFA:MTX cannot exert its strong cytotoxic effect towards 
the co-treated cells.  
Figure 4.9C shows that the co-treatment of FB1 + SSZ, like the independent treatments with 
these drugs, did not exert any significant difference in the cell viability of CDEnFA treated 
cells. This also provides additional evidence that FB1 + SSZ co-treatment is not responsible 
for cell death.  
It is possible that, for cells treated with CDEnFA:MTX (with no other treatments), both FR 
and RFC function as internalisation routes for the complex. Even if the influx of MTX via 
RFC stops due to saturated intracellular levels of MTX, the cell may continue internalising 
the drug through the endocytic pathway of FRs. Therefore, the results presented here indicate 
that the complex, CDEnFA:MTX, can ameliorate the cytotoxic effect of the drug by using 
both RFC direct transport and FR endocytosis. 
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4.4 Conclusion 
The results presented in this chapter have demonstrated that FB1 treatment results in a 
decrease in FR protein levels in the cell, but it does not affect RFC protein levels. 
Conversely, SSZ treatment does not affect FR protein levels in the cell, but it results in a 
decrease in RFC protein levels. 
FB1 treatment resulted in a decrease in the cytotoxic effect of MTX and CDEnFA:MTX, 
although not significant for MTX, while it caused a significant decrease in the cytotoxicity of 
CDEnFA:MTX at 100 and 1000 µM concentrations. SSZ treatment caused a decrease in the 
cytotoxic effect of MTX, although not statistically significant. The changes caused by SSZ on 
the cytotoxicity of CDEnFA:MTX were also not statistically significant. 
The co-treatment of FB1 + SSZ has not affected significantly the cytotoxicity from MTX, 
while it drastically inhibited the cytotoxic effect of CDEnFA:MTX. The results indicate that 
FB1 prevents the CDEnFA:MTX to bind to FRs, reducing its potential to internalise the drug 
MTX. SSZ have contributed likely by blocking the influx of MTX which was released from 
the complex. Therefore, the data presented here indicate that the cytotoxic effect from the 
complex can be a result of the drug uptake and internalisation from both hypothetic routes 
displayed in figures 4.2 and 4.3 in the introduction: (1) the CDEnFA:MTX binds to the FR on 
the cell membrane and this receptor internalises the whole complex. (2) After CDEnFA:MTX 
binds to the folate receptor on the cell membrane, MTX is released from the cyclodextrin 
cavity and internalised through the RFC. By using both of these routes of internalisation, 
CDEnFA:MTX can amplify the cytotoxic effect of the drug MTX. 
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5.1 Introduction 
Animal models have contributed valuable insights that have permitted extensive growth in 
our knowledge of biology and medicine, including the discovery and development of new 
drugs.
1,2
 Traditional animal models such as mice, rats and rabbits require a specific laboratory 
structure, adequate expertise for handling the animals so as to minimize animal stress, and 
ethical approval for their use can be a lengthy process.
3
 In vivo tests in mammalian models 
also require the administration of a large amount of the compound, which is not always 
feasible at the early stage of drug development.
4
 Moreover, about 40-60% of drug 
candidates fail due to absorption, distribution, metabolic elimination and toxicological 
properties in clinical development. To screen drug candidates and reduce the costs to market 
for new drugs, a variety of complex in vitro models are applied as filters to select the most 
suitable compounds for the in vivo models. However, further pre-mammal screens are 
necessary in order to reduce problems when linking in vitro findings to in vivo readouts.
5
 
Therefore, invertebrate animal models have been used to bridge the gap between the 
traditional in vitro and pre-clinical animal assays. Invertebrate organisms combine genetic 
amenability, low cost, and culture conditions compatible with large-scale screens. Their main 
advantage is to allow high-throughput screening in a physiological context. On the down 
side, protein divergence between invertebrates and humans causes a high rate of false 
negatives.
6
 Despite these limitations, invertebrate models, including insect models, are a 
much needed tool to fill the gap between in vitro and in vivo studies and have been used as 
screening tools in drug discovery.  
Insect models give a better prediction of in vivo absorption, distribution, metabolic 
elimination and toxicological parameters than in vitro models, and at the same time are faster 
and cheaper than traditional vertebrate in vivo models.
5
 Particularly, the larvae of the greater 
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wax moth, Galleria mellonella, seen in figure 5.1, has become an increasingly popular model 
for investigating pathogenicity and drug tolerance.
7
 G. mellonella, is an insect from the order 
Lepidoptera and the family Pyralidae.
8
 The greater wax moth develops through four distinct 
life stages, egg, larva, pupa, and adult. The larva is the stage used for the drug screenings. 
When compared with traditional mammalian models, G. mellonella larvae are cheaper and 
easier to maintain, as specialised laboratories or equipment are not required. They have a 
convenient size for housing and manipulation, which makes them ideal for high-throughput 
studies.
7,9
 Additionally, the use of G. mellonella does not require ethical approval and allows 
the generation of high number of data in a short time.
10
 
 
Figure 5.1. Larvae of the greater wax moth, Galleria mellonella. 
 
Although vertebrates have developed an adaptive immune response, their innate immune 
response still retains remarkable similarities to the immune response in insects. For example, 
pathogens are recognized by mammalian innate immune cells in a very similar manner as in 
insects via cellular pattern recognition receptors. Pathogen-associated molecular patterns 
(PAMPs) are conserved structures of microbes, such as peptidoglycans, that allow for the 
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recognition of the pathogen. Peptidoglycan recognition proteins (PGRPs) activate 
intracellular pathways related to the immune response. Although the mechanisms of PGRPs 
seem to be different between insects and mammals, these proteins activate the humoral and 
cellular arm of the host defence in both of them.
11
 The pattern recognition molecule in 
insects, apolopophorin III (apoLp-III), is similar to the apolipoprotein E (apoE) found in 
mammals, which is involved in phagocytosis.
12
 Moreover, there are striking similarities 
between insect and mammalian innate immune signalling pathways. Mammals use Toll-like 
receptors (TLRs), which are transmembrane proteins that can directly recognize components 
of the pathogen. TLRs are named for their homologous leucine-rich repeat structures that are 
also present in insect Toll, to activate antibacterial and fungal immune responses.
13
 There is 
an evident pattern when comparing the signal transduction throughout the homologous 
pathway of insects and mammals due to their similar signalling components. However, the 
terminal molecules, the initiating receptors and the molecules that are produced as a result of 
gene expression, vary considerably.
14
 The innate immune cells of both insects and mammals 
are efficient producers of antimicrobial peptides and proteins (AMPs). However, the innate 
immune system of insects leads to the production of AMPs that fight the infection, whereas 
mammals generate cytokines and chemokines that amplify the immune response and recruit 
antigen-presenting cells that induce antibody production.
15
 Phagocytic cells engulf and kill 
pathogens. In insects, these cells are called plasmatocyte, and they have receptors on the 
surface which are similar to receptors on mammalian neutrophils. Neutrophils produce 
extracellular traps (NETs) containing nucleic acids and proteins to immobilize and kill 
pathogens.
12
 A similar process has been observed to occur in haemocytes of G. mellonella in 
response to infection, although the extracellular nucleic acids in the larvae exhibit weaker 
bacterial entrapment capacity.
16  
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The innate immune response of insects consists of two major parts, the cellular and the 
humoral immune response. The cellular response is mediated by haemocytes, which are 
phagocytic cells. These are found within the haemolymph, which functions in an analogous 
manner to mammalian blood. Indeed, cellular responses within the haemolymph are often 
activated by signal transduction systems comparable to those in mice, and results obtained 
using insects strongly correlate with results obtained from murine testing.
17,18
 Haemocytes are 
not only involved in phagocytosis, but also in encapsulation and clotting. Haemocytes can 
recognize foreign material and also distinguish self from non-self during the cellular immune 
response in a similar manner to human immune cells.
19
 The humoral response is orchestrated 
by soluble effector molecules that immobilize or kill the pathogen and includes complement-
like proteins, melanin, and anti-microbial peptides.
20
  
Larval death, changes in haemocyte density, and an increase in the concentration of melanin 
(melanisation) in the larvae are good indicators of virulence and of immune response or stress 
responses. Visual changes can occur to the larvae through the course of drug exposure. 
Throughout the exposure time period, the inoculated larvae may turn a brown/black colour, 
which represents the onset of melanisation, an insect immune response driven by the cleavage 
of prophenoloxidase to active phenoloxidase.
21
 Different stages of melanisation are shown in 
figure 5.2 as follows.  
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Figure 5.2. Photographic images of G. mellonella larvae showing different stages of 
melanisation starting from (a) the typical creamy colour of healthy larvae through to (e) 
complete melanisation. (Figure adapted from Ott et al
22
 representing melanisation as 
described by Loh et al
23
, detailed in table 5.1). 
 
The activity of the response is driven by a general damage to the organism where it responds 
to limit the growth of a potential pathogen within the haemocoel.
24
 Other characteristic 
changes can also be analysed in order to determine the effect of a drug, such as survival time 
and activity, for example, a slow movement response to a stimulus and slow development 
within the normal life-cycle.
23
 Besides similarities in immune response, the distribution and 
metabolism of an agent in G. mellonella are also comparable to that in humans.
12
 This was 
demonstrated by Hill et al (2013) and Thomas et al (2013), who used G. mellonella as a 
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model system to test the pharmacokinetics of antibiotics against Pseudomonas aeruginosa 
and Burkholderia pseudomallei infection, respectively. They determined pharmacokinetic 
parameters, such as dose, drug concentration, elimination and half-life, of clinically relevant 
antibiotics in this model, demonstrating that this model can be used for the initial screening of 
novel antimicrobials.
25,26
 Paudel et al (2017) used a silkworm infection model to perform 
structure-activity relationship studies on an antimicrobial agent, comparing the 
pharmacokinetic parameters to the metabolism of these antimicrobial agents in human 
liver fractions in vitro. They suggest that the therapeutic effectiveness of an antimicrobial 
agent in the insect model reflects appropriate pharmacokinetic properties in humans.
4
 
In this work, larvae of G. mellonella were used primarily to assess the larval tolerance to the 
carrier CDEnFA, and thereby assessing its safety and biocompatibility to this in vivo model. 
Larval response and overall health were assessed after treatments with CDEnFA, and also 
with the drug MTX and the complex CDEnFA:MTX. 
 
5.2 Materials and Methods 
5.2.1 Galleria mellonella toxicity assay  
In vivo toxicity of the carrier CDEnFA, MTX alone and the complex CDEnFA:MTX was 
examined in the larvae of the greater wax moth Galleria mellonella larvae. G. mellonella 
larvae of the 6
th
 instar development stage were sourced from Livefoods Direct Ltd (Sheffield, 
UK). All larvae were stored in the dark at 15 ⁰C prior to testing. Thirty-three healthy larvae 
(average weight 0.3±0.05 g) with no cuticle discolouration were used for each experiment, 
thirty for assessing the effect of the compounds on the larval health and three for the 
haemocyte density assay. Fresh solutions of the test compounds were prepared immediately prior 
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to testing under sterile conditions. Each compound (CDEnFA, MTX and CDEnFA:MTX) was 
dissolved in NaOH (1 mL of 0.1 M) and added to sterile water (9 mL) to give a stock solution of 5 
mg/mL. Each compound was tested across the concentration range 4 to 400 μg of compound per 
larva. Three controls were also employed in all assays. The first consisted of undisturbed larvae, 
maintained at the same temperature as the test larvae. The second, sham-inoculated larvae, was 
larvae with the pro-leg pierced with an inoculation needle but no solution injected. The third 
control was larvae that were inoculated with the solvent NaOH (0.1 M), following the dilutions as 
used for the test compounds. 20 μL of each test solution was administered per larva and they were 
inoculated by injection directly into the haemocoel through the last pro-leg (figure 5.3). Larvae 
were then placed in sterile Petri dishes and incubated at 30 °C for 72 hours.  
 
 
Figure 5.3. Procedure for inoculating G. mellonella larvae. The needle is inserted into the last 
left pro-leg in order to inject the compound.
27
 
 
Larvae were monitored after 24, 48 and 72 hours for the following attributes: activity, extent of 
silk production (cocoon formation), melanisation, and survival. A score was provided for each 
attribute that contributed toward an overall health index of an individual G. mellonella larva, as 
Chapter 5  In vivo Galleria mellonella Toxicity 
131 
 
described by Loh, et al (2013). A healthy larva typically scores between 9 and 10, and a dead larva 
typically scores 0. Scoring for each attribute has been summarised in table 5.1 below.  
 
Table 5.1. Scoring system for overall health of larvae.
23
 
Category Description Score 
Activity 
No movement 0 
Minimal movement on stimulation 1 
Move when stimulated 2 
Move without stimulation 3 
Cocoon 
formation 
No cocoon 0 
Partial cocoon 0.5 
Full cocoon 1 
 
 
Melanisation 
 
  
Black larvae 0 
Black spots on brown larvae 1 
≥3 spots on beige larvae 2 
<3 spots on beige larvae 3 
No melanisation 4 
Survival 
Dead 0 
Alive 2 
 
5.2.1.1 Measurement of haemocyte density 
Haemocyte density was measured in larvae, 24 hours post inoculation with CDEnFA, MTX 
and CDEnFA:MTX, along with the undisturbed, sham-inoculated and solvent controls. Three 
larvae were selected at random. The larvae representing each control or each concentration of 
each test compound were bled through the anterior region of the head (figure 5.4). The 
extracted haemolymph was diluted 1:10 with mercaptoethanol (0.37% in distilled water) 
(Sigma, Ireland). Cell counts were performed using a haemocytometer: 10 µL of the diluted 
haemolymph were loaded onto each side of the haemocytometer (Neubauer Tiefe, 0.002 
mm
2
), covered with a coverslip and visualised under the 40x objective lens of a light 
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microscope. Cells were enumerated from five squares of each grid on the haemocytometer. 
An average of three separate counts was obtained. The density was calculated by multiplying 
the total average by the dilution factor of both haemolymph and the haemocytometer. 
 
 
Figure 5.4. Piercing point (anterior portion) of the G. mellonella larvae for haemocyte 
extraction indicated by the black arrow. 
 
5.3 Results and Discussion 
5.3.1 Galleria mellonella toxicity assay  
G. mellonella larvae were exposed to CDEnFA, MTX, and CDEnFA:MTX, and the toxicity 
was assessed by the mean mortality (%) after 24, 48 and 72 hours of drug exposure. 
Undisturbed, sham-inoculated and solvent-inoculated controls were also assessed. Mortality 
was not detected after 24 and 48 hours of exposure to the administered dosages of each 
compound. Data for the survival of G. mellonella larvae (expressed as a %) as a function of 
administered dosages of the test compounds 72 hours post inoculation are displayed in table 
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5.2. No mortality was recorded at any time-point after incubation of undisturbed, sham-
inoculated and solvent (NaOH) controls.  
Table 5.2. Mortality (%) of G. mellonella larvae 72 hours post inoculation with a range 
of dosages of the test compounds. Non-marked percentages indicate larvae were active 
(moving without stimulation). 
 
 
Administered amount (μg per larvae) /  
% mortality 
 4 10 40 100 400 
CDEnFA 
% Mortality 
μmol 
mg kg
-1 
 
0 
2.16 
13.33 
 
0 
5.40 
33.33 
 
0 
21.61 
133.3 
 
0 
54.02 
333.3 
 
0 
216.1 
1,333 
 
MTX 
% Mortality 
μmol 
mg kg
-1 
 
0 
8.80 
13.33 
 
0 
22.00 
33.33 
 
0* 
88.02 
133.3 
 
3* 
220.0 
333.3 
 
3* 
880.2 
1,333 
 
CDEnFA:MTX 
% Mortality 
μmol 
mg kg
-1
 
 
0* 
1.95 
13.33 
3* 
4.87 
33.33 
3* 
19.47 
133.3 
6* 
48.68 
333.3 
6** 
194.72 
1,333 
* Move only when stimulated 
 ** Minimal movement on stimulation 
 
All of the larvae treated with the carrier CDEnFA survived at all concentrations and all time-
points indicating in vivo tolerance to the carrier. Treatment with MTX caused the death of 3% 
of larvae at concentrations of 100 and 400 μg after 72 hours of drug exposure. 
CDEnFA:MTX was responsible for the death of 3% of larvae at concentrations of 10 and 40 
μg, and 6 % at concentrations of 100 and 400 μg per larvae after 72 hours. It is important to 
note that, even though there was still a high survival after 72 hours of drug exposure to MTX 
and CDEnFA:MTX, the activity of the larvae and their ability to respond to stimulus was 
strongly compromised. At that time-point, larvae were static after MTX treatment at 
concentrations of 40 μg and above, and would only slowly move after stimulation by 
touching. After CDEnFA:MTX treatment at concentrations from 4 to 40 μg, larvae would 
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slowly move after stimulation, while at concentrations of 100 and 400 μg, larvae barely 
responded to the stimulus with only minimum movement. When viewed in terms of 
micromolar concentrations, it is clear that CDEnFA:MTX was more toxic than MTX. The 
carrier CDEnFA, even with a higher molecular weight than MTX, was not toxic towards the 
larvae at the concentrations tested. Because none of the inoculations resulted in the death of 
50% or more, LD50 values, which represent the dose of a substance that kills 50% of a test 
sample, could not be calculated. 
The chemotherapeutic, cisplatin, was used alone as a reference standard and the mortality 
caused, assessed by another PhD student at DIT, is presented in table 5.3 for comparison.
28
 At 
a dosage of 100 μg of per larvae, approximately 90% larvae treated with cisplatin were dead 
at all time-points. Thus, it is clear that cisplatin is considerably more toxic to G. mellonella 
than both MTX and CDEnFA:MTX.  
Table 5.3. Mean larval mortality (%) after 72 hours of inoculation 
with 20 μL of cisplatin at a range of dosages of test compounds.28 
                              Cisplatin (µg per larvae) 
 4 µg 6 µg 8 µg 10 µg 100 µg 
% Mortality 
μmol 
mg kg
-1
 
0 
0.013 
13.33 
0 
0.019 
19.99 
0 
0.026 
26.66 
6 
0.033 
33.33 
90 
0.333 
333.33 
 
 
It is possible that G. mellonella is much less sensitive to MTX and CDEnFA:MTX than to 
cisplatin, due to a low affinity of MTX for the enzyme, dihydrofolate reductase (DHFR), in 
insects. In humans, antifolate drugs, such as MTX, can tightly bind to DHFR, inhibiting this 
enzyme’s activity, consequently inhibiting DNA synthesis and cell proliferation. However, 
Walker et al (2000) found that DHFRs in insects have significantly reduced sensitivity to 
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inhibition by MTX, when compared with the enzyme in vertebrate animals. This reduction is 
also reflected in the total binding energy of MTX to these enzymes. These authors 
demonstrated that DHFRs in insects show the lowest affinity for this inhibitor of any wild-
type DHFR, such as mammalian and chicken, studied to date. Four of the 17 amino acid 
residues involved in MTX binding, Met32, Ala33, Thr36 and Cys60, are not well conserved 
between the insect and mammalian or chicken enzymes and it is possible that these residues 
contribute to the reduced sensitivity, by several orders of magnitude, of the insect DHFRs to 
methotrexate.
29
 
Although a low mortality was seen even for the highest concentrations of MTX and 
CDEnFA:MTX, the activity of the larvae was compromised and some melanised lesions on 
the cuticle were observed. These changes were particularly evident from CDEnFA:MTX. 
Figures 5.5 and 5.6 display photographic images of the larvae at day 0 (just after inoculation) 
and day 3 (72 hours after inoculation) at the highest administered concentration. In order to 
obtain more subtle differences in larvae health status, the larvae were scored according to the 
scoring index system displayed previously in table 5.1 for activity, cocoon formation, 
melanisation, and survival.  
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Figure 5.5. G. mellonella larvae on day 0 (immediately after inoculation, left) and on day 3 
(72 hours post-inoculation, right) for (A) undisturbed control, (B) sham-inoculated control and 
(C) solvent control. 
                      Day 0                                  Day 3 
Chapter 5  In vivo Galleria mellonella Toxicity 
137 
 
 
 
 
 
 
Figure 5.6. G. mellonella larvae on day 0 (immediately after inoculation, left) and on day 3 
(72 hours post-inoculation, right) for (D) CDEnFA treated, (E) MTX treated and (F) 
CDEnFA:MTX treated larvae. 
Day 0                                  Day 3 
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Higher activity and cocoon formation correspond to healthier larvae, though cocoon 
formation was not observed as the three days of incubation were not enough for the larvae to 
achieve this stage of development. Production of melanin by the larvae occurs as a result of 
an immune response against infection, as melanin aids to trap and kill pathogens.
30
 As there 
was no pathogenic infection, the effect of the compounds did not result in major melanised 
lesions or major skin discolouration. Each G. mellonella larva was monitored based on the 
characteristics presented in table 5.1 and an overall health index score was calculated for each 
sample. Higher health index scores, which indicate healthy larvae, correlated well with the 
control samples and samples inoculated with CDEnFA. Scores are an overall health 
description after observing the larvae individually. After 72 hours of inoculation, undisturbed, 
sham-inoculated, solvent control and CDEnFA inoculated larvae had an outcome score of 9, 
MTX inoculated larvae had an outcome score of 7, while CDEnFA:MTX inoculated larvae 
had an outcome score of 5. These scores are described in table 5.4 below.  
Table 5.4. Health index scores calculated after 72 hours of inoculation with 
the study compounds. 
Compound Category Score Description 
Controls 
Activity 3 Move without stimulation 
Melanisation 4 No melanisation 
Survival 2 Alive 
Total 9 - 
CDEnFA 
Activity 3 Move without stimulation 
Melanisation 4 No melanisation 
Survival 2 Alive 
Total 9 - 
MTX 
Activity 2 Move when stimulated 
Melanisation 3 Cuticle discoloration 
Survival 2 Alive 
Total 7 - 
CDEnFA:MTX 
Activity 1 Minimal movement when stimulated 
Melanisation 2 Cuticle discoloration 
Survival 2 Alive 
 Total 5 - 
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The health of the larvae was more compromised after inoculation with CDEnFA:MTX than 
inoculation with MTX alone, which was indicated mainly by lack of activity and/or slow 
reaction to a stimulus. This indicates that CDEnFA:MTX may facilitate the delivery of MTX 
and increase the intracellular amounts of the drug, which can contribute to the slightly 
increased toxicity.  
5.3.2 Measurement of haemocyte density
 
Haemocytes were enumerated from the haemolymph extracted from 3 larvae per treatment 
(per dose at 24 h). The results are displayed in figure 5.7 below. Controls include undisturbed 
larvae, sham-inoculated larvae, which were larvae pierced with an inoculation needle but with 
no solution injected, and the solvent control, which was larvae that were inoculated with the 
solvent NaOH (0.1 M) with the same dilutions used for the test samples. Significant differences 
(p values) between the test samples and sham-inoculated control were obtained. 
Haemocytes density
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Figure 5.7. Haemocyte density 24 hours post-inoculation with CDEnFA, MTX, 
CDEnFA:MTX and the controls (undisturbed larvae, sham-inoculated and solvent NaOH). 
Asterisks represent significant difference where ** is p < 0.01 and * is p < 0.05, to both 
undisturbed and sham-inoculated controls. 
Chapter 5  In vivo Galleria mellonella Toxicity 
140 
 
No significant difference compared to the controls, was obtained in the haemocyte density for 
24 hours post-inoculated G. mellonella, with both CDEnFA and MTX at all concentrations 
studied. The haemocyte density, obtained for the 40 and 400 µg concentrations of the 
complex CDEnFA:MTX were significantly different to both controls, which suggests that 
treatment the complex may lead to activation of immune responses in larvae of G. mellonella. 
A similar range of haemocyte count was obtained by Dubovsky et al (2013) using an 
organophosphate as an insecticide, and they reported 1.1 x 10
7
 cells/mL for the control and 
1.5 x 10
7
 cells/mL for 24 hours post-insecticide treated G. mellonella.
31
 According to these 
authors, concentrations of drug compounds that are not lethal for all individuals in a sample 
may stimulate the insect immunity and, as a consequence, enhance the larvae protective 
response.
32
 Mowlds et al (2010) reported a range of 3 x 10
6
 (control) to 0.75 x 10
7 
for 24 
hours post-β-glucan treated G.mellonella.33 Rochford et al (2018) assessed the toxicity of 
Cu(II) phenanthroline-phenazine complexes in this in vivo model and reported a haemocyte 
density with counts ranging from 3.8 to 4.5 x 10
7
, 24 hours post inoculation with the copper 
based complexes.
28,34
 
Although there is only moderate toxicity towards the G. mellonella in vivo model observed at 
high doses, compared to other therapeutics, the effect may be mediated by a role in the innate 
immune response. From in vivo studies, it was reported that MTX acts on the immune 
response with significant effects on neutrophil chemotaxis in a dose-dependent manner.
35
 
Methotrexate is also known to suppress tumour necrosis factor (TNF) activity, in part related 
to a reduction in the degradation and inactivation of an inhibitor of this factor, and probably 
related to the release of adenosine, a potent endogenous anti-inflammatory mediator.
36
 
Further investigation would be necessary to demonstrate the effect of CDEnFA:MTX on the 
immune response of G. mellonella. In relation to the folate transporters or folate metabolism 
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in insects, little information can be found in the literature. However, it has been reported that 
folate intake has increased the growth of several insects, while some insects, such as the fruit 
fly Drosophila melanogaster, do not require folate as they can synthesize it. Several studies, 
using mice models, have demonstrated positive results for FR-targeted compounds. For 
example, Güliz et al (2018) demonstrated that a folate receptor-targeted doxorubicin delivery 
system was significantly more effective for therapy of xenografted nude mice than free 
doxorubicin, based on tumour shrinkages and biochemical parameters.
37
 Peng et al (2017) 
demonstrated using in vivo experiments that arsenic trioxide, loaded onto FA-labelled human 
serum albumin, significantly alleviates side effects and improves the therapeutic efficacy of 
arsenic trioxide on xenograft tumor models.
38
 And Alibolandi et al (2016) demonstrated that 
the in vivo tumour inhibitory effect of folic acid quantum dots (QD) and doxorubicin (DOX)-
encapsulated PEG-PLGA nanopolymersomes showed an augmented therapeutic efficacy of 
the targeted formulation over the non-targeted and free drug.
39
  
 
5.4 Conclusion 
The aim of this study was to assess the biocompatibility of the drug delivery system, 
CDEnFA, using G. mellonella larvae and to assess the response of the larvae to the inclusion 
complex, CDEnFA:MTX, to the free drug, MTX. The health of the larvae, assessed by a 
health index score based on larvae activity, melanisation and survival, compared well among 
undisturbed larvae, sham-inoculated or the solvent inoculated controls and CDEnFA treated 
larvae. CDEnFA treatment did not cause larval death at any concentration or time-point and 
did not result in any significant difference in haemocyte density compared to the controls. 
This is an exciting result and indicates that CDEnFA is not toxic to the larvae, and therefore, 
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is a safe drug carrier to be used in in vivo models. Further studies in mice could be used to 
demonstrate the safety and biocompatibility of this targeted-drug vehicle in mammal models.  
The mortality assay demonstrated that G. mellonella are tolerant to the drug MTX. MTX acts 
by binding to and inhibiting the enzyme DHFR. However, this enzyme is not well conserved 
between insect and mammalian enzymes and this may explain the reduced sensitivity of the 
insect to this drug. The complex CDEnFA:MTX caused a slightly higher toxicity towards the 
larvae, which was observed particularly in compromised activity, where the larvae were 
barely responding to stimulus after 72 hours of treatment at the highest administered 
concentration. Besides compromised activity, the haemocyte density was also higher for 
CDEnFA:MTX treated G. mellonella, which can be an indicator of activation in immune 
responses and an attempt to enhance the larvae protective response as a result of the 
treatment. However, due to the high tolerance of the larvae to the drug MTX, mammal in vivo 
studies would be necessary to further evaluate the in vivo response to CDEnFA:MTX and its 
comparison to MTX alone.  
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6.1 Conclusions 
In this work, a new folate derivative of β-cyclodextrin has been evaluated in its potential to 
target folate receptors (FRs) in cancer cells. The objectives of this work were successfully 
achieved and they include: 
 
1) Compare FR and RFC gene levels in a range of human cell lines grown in folate-replete 
and folate-free medium to standardise the culture conditions. Then, to assess the gene and 
protein expression of FR and RFC in a range of untreated cell lines to address the conflicting 
reports of expression of these transporters and allow for selection of in vitro models for 
subsequent experiments using real-time PCR and flow cytometry. 
Folate-free culture medium was chosen as a standard culture medium for all experiments 
since there was the interest of avoiding possible competition for folate in the environment. In 
addition, a folate-free environment is favourable for the cellular expression of FRs. Real-time 
PCR and flow cytometry were used to assess the gene and protein expression of FRs and 
RFCs in the seven cell lines. The data from the real-time PCR experiments demonstrated that 
FR mRNA (gene) levels are more abundant in KB cells followed by CaCo-2 and SKOV-3 
cells. HeLa and MCF-7 cells express medium levels of FR mRNA while A549 and BEAS-2B 
express low levels. RFCs mRNA has higher expression in HeLa cells, followed by KB cells, 
and then by MCF-7, A549, SKOV-3 and CaCo-2. BEAS-2B showed the least abundant 
mRNA levels of both receptors and, therefore, seemed to be a good normal control cell line to 
compare with the cancer cell lines. Cancer cells displayed upregulation of both FRs and 
RFCs when compared to the normal cell line BEAS-2B.  
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The protein expression levels of FR and RFC assessed by flow cytometry showed that KB 
cells express significantly higher levels of FRs than all the other cell lines and BEAS-2B 
express the lowest levels. From highest to lowest levels of FR protein, the cell lines 
expression order is as follows: KB > CaCo-2 > MCF-7 > HeLa > SKOV-3 > A549 > BEAS-
2B. MCF-7 cells showed the highest levels of RFCs while SKOV-3 showed the lowest levels. 
From highest to lowest levels of RFC protein, the cell lines expression order is as follows: 
MCF-7 > KB > HeLa > A549 > CaCo-2 > BEAS-2B > SKOV-3. 
From their FR and RFC levels, five cell lines were selected for an in vitro cytotoxicity 
analysis against the drug methotrexate (MTX), the carrier CDEnFA and the inclusion 
complex CDEnFA:MTX. These cell lines are KB, CaCo-2, MCF-7, A549 and BEAS-2B. 
KB and CaCo-2 cells were chosen due to their high levels of FR, MCF-7 cells were chosen 
due to their medium levels of both FR and RFC, while A549 and BEAS-2B cells were 
chosen due to their low levels of FR.  
 
2) Evaluate the cytotoxicity of CDEnFA to certify that the carrier alone is not toxic to the 
cells, and then evaluate the cytotoxicity of free MTX and the complex CDEnFA:MTX 
towards selected cell lines with high, medium and low FR levels, comparing the outcomes 
between the complex and the drug alone and confirm FR targeting. 
The results from the cytotoxicity evaluation demonstrated that the drug delivery vehicle 
CDEnFA has a low cytotoxicity towards the cell lines analysed, indicating it is biocompatible 
and safe. The results also indicate that the inclusion complex CDEnFA:MTX can specifically 
target FR in cancer cells enhancing the efficacy of the drug. This is because CDEnFA:MTX 
showed greater cytotoxicity than free MTX towards the high FR expressing KB and CaCo-2 
cells. Free MTX is more toxic towards cell lines expressing low levels of FR, such as the 
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normal cell line BEAS-2B than the complex CDEnFA:MTX, suggesting that the inclusion 
complex can potentially cause fewer side effects than the drug alone. These are exciting 
findings and indicate that CDEnFA:MTX can be used as a drug delivery system to target FR 
in cancer cells providing the treatment with a better efficacy. Furthermore, offering less 
damage than the drug alone to cells that express low levels of FRs, such as healthy cells, as 
demonstrated and as reviewed from the literature.  
After the cytotoxicity evaluation, a study was conducted in order to investigate the route of 
uptake and internalisation of the complex CDEnFA:MTX. FRs are responsible for the uptake 
of CDEnFA:MTX due to the ligand, folic acid. However, whether the FR captures and 
internalises the whole complex or the β-cyclodextrin remains extracellular and the RFC is the 
responsible for the internalisation of the MTX, was a question to be elucidated. 
 
3) Investigate the cellular route of uptake and internalisation of the drug complex 
CDEnFA:MTX, using fumonisin-B1 and sulfasalazine as inhibitors of FRs and RFCs, and 
with this, clarify the roles of each transporter in these processes. 
FB1 treatment resulted in a decrease in the FR protein levels in the cell, but it did not affect 
the RFC protein levels. SSZ treatment did not affect the FR protein levels in the cell, while 
resulted in a decrease in the RFC protein levels. After inhibition with pre-treatments with 
FB1, SSZ and a co-treatment with FB1 + SSZ, KB cells were treated with CDEnFA, MTX 
and CDEnFA:MTX and the cytotoxicity was evaluated. The results demonstrated that 
CDEnFA alone did not cause cell death confirming its biocompatibility to the cells. When 
comparing the effect of the pre-treatments in the cytotoxicity caused by MTX and 
CDEnFA:MTX, the results confirmed (a) the uptake of the complex through the FRs as FB1 
treatment resulted in a significant decrease in the cytotoxic effect of high doses of 
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CDEnFA:MTX; (b) the indicative internalisation of MTX through the RFC as SSZ treatment 
caused slightly decreased cytotoxic effect of MTX; and (c) in addition, the results indicated 
that the extensively increased cytotoxic effect from the complex CDEnFA:MTX in KB (FR+) 
cells can be an additive result of the drug uptake and internalisation through two routes: (1) 
after CDEnFA:MTX binds to the folate receptor on the cell membrane, MTX is released from 
the cyclodextrin cavity and internalised through the RFC. (2) The CDEnFA:MTX binds to 
the FR on the cell membrane and this receptor internalises the whole complex. By using both 
of these routes of internalisation, CDEnFA:MTX can amplify the cytotoxic effect of the drug 
MTX. This is indicated due to the dramatic decrease in the cytotoxic effect of CDEnFA:MTX 
after a co-treatment with FB1 + SSZ. 
 
4) Evaluate the in vivo toxicity of the complex in the larvae of the Galleria mellonella to 
assess drug tolerance, and thereby proving its safety to be used in in vivo models. 
The in vivo toxicity evaluation of CDEnFA, MTX and CDEnFA:MTX in the Galleria 
mellonella larvae demonstrated that CDEnFA treatment did not cause larvae’s death and did 
not increase the larvae’s immune response, which is an indicator that CDEnFA is not toxic 
and therefore, is a safe drug carrier to be used in in vivo models such as invertebrates. The 
mortality assay also demonstrated that G. mellonella are strongly resistant to the drug MTX. 
This is because the enzyme targeted by MTX, dihydrofolate reductase, is not well conserved 
between the insect and mammalian enzymes, so the sensitivity of the insect’s enzyme to 
MTX is significantly reduced when compared to the mammal’s enzyme. The complex 
CDEnFA:MTX caused slightly more toxicity towards the larvae, which was observed 
through survival and particularly to a compromised activity where the larvae were barely 
responding to stimulus after 72 hours of treatment at the highest administered concentration. 
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Besides compromised activity, the haemocytes count indicated that CDEnFA:MTX may 
activate the organism’s immune response in an attempt to enhance the larvae protective 
response. However, due to the high resistance of the larvae to the drug MTX, mammalian in 
vivo studies would be necessary to further evaluate the in vivo response to CDEnFA:MTX 
and its comparison to MTX response.  
 
6.2 Future scope and perspectives 
From the 5
th
 European Conference on Cyclodextrins in Lisbon, our group and researchers 
from the Hungarian company Cyclolab demonstrated a mutual interest in developing a 
collaborative work. Cyclolab is a Research & Development company based in Budapest, 
specialised in the development of derivatives of cyclodextrins. Researchers at Cyclolab are 
pioneers in Cyclodextrin R&D and have been working since 1972 in the fields of 
pharmaceuticals, cosmetics and the food, agrochemical and environmental industries and also 
analytical applications of cyclodextrins. The research plan for this collaborative work 
involves the biological evaluation of a range of folate-modified cyclodextrins for delivery of 
therapeutics. The cyclodextrins are synthesised and characterised by researchers at Cyclolab 
while the biological work is being developed in-house. This work includes a biological 
evaluation of folate derivatives of cyclodextrins and the chemotherapeutic agents as inclusion 
complexes, which include native α-cyclodextrin, methylated cyclodextrins, sulfobutyl eter 
cyclodextrin, as well as our complex CDEnFA. The chemotherapeutic agents to be used may 
include 5-fluorouracil, tamoxifen, docetaxel, doxorubicin and pemetrexed. Assessing the 
biological effect of these complexes will allow further investigation on the possibilities and 
combinations of folate-derivatives of cyclodextrins with different drugs, expanding the work 
on their use as targeted drug carriers for cancer treatment. 
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The following experiments are suggestions and may be performed for the evaluation of these 
new complexes: 
A. Cytotoxicity screening of the complexes using MTT assays, as the work described in 
Chapter 3 of this thesis, optimising concentrations and time-points for accurate 
obtaining of IC50 values.  
B. For the most promising drug-conjugate combinations, prove complex uptake through 
FRs by inhibiting FR expression and assessing drug and complex effect, in a similar 
way as described in Chapter 4. Although, using a gene knockdown method such as 
RNA interference; or a gene knockout method such as CRISPR, could be a good 
alternative as it would guarantee the lack of FR protein on the cell membrane. 
C. Investigate intracellular trafficking by visualization of endosomes using confocal 
microscopy. Endosomes are pockets of cellular membrane that form to internalise 
components into the cell and form part of the endocytic pathway. Larger drug 
molecules and/or drugs bound to receptors are internalised within cells by this 
mechanism.
1
 The process of endocytosis can be investigated using CellLight® Early 
Endosomes-GFP, BacMam 2.0 (Thermo Scientific) to observe early endosomes, 
which serve as a focal point of the endocytic pathway.  
D. Investigate if the drug-complex can help enhance the effect of the drug. This would 
depend on each drug’s mode of action. For example, doxorubicin acts by damaging 
the DNA in the cell. DNA damage can be measured as an indicator of genotoxicity 
using an antibody against phosphorylated H2AX. When DNA damage, it forms 
double-stranded breaks (DSBs), which is always followed by the phosphorylation of 
the histone, H2AX.
2
 Therefore, the amount of H2AX is proportional to the amount of 
damaged DNA in the cell and can be quantified by flow cytometry. The data 
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comparison for complex vs drug alone and FR+ vs FR- cell line would allow 
concluding whether the complex can facilitate drug activity. 
E. Carry out an in vivo evaluation using the larvae of the insect Galleria mellonella to 
assess toxic tolerance and cellular response as the work described in Chapter 5 of this 
thesis.  
 
6.3 General conclusion 
CDs have an extensive potential for use in therapeutics, and the synthesis of derivatives of 
CDs for targeted therapy has allowed the elaboration of more effective and stable drug 
products with potentially reduced side effects. The work detailed in this thesis describes the 
positive results obtained in the biological evaluation of the folate derivative of β-cyclodextrin 
CDEnFA, and has recently opened the opportunity for collaborative work to test a broader 
range of new complexes based on cyclodextrins for cancer therapy.  
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7.1 Synthesis and characterisation of the carrier CDEnFA  
The carrier, 6-deoxy-6-[(1-(2-amino)ethylamino)folate]-β-cyclodextrin (CDEnFA), is a 
diaminoalkane derivative of β-cyclodextrin, 6-deoxy-6-[1-(2-amino)ethylamino]-β-
cyclodextrin (CDEn), that was linked to folic acid (FA) by a covalent peptide bond.
1
 The 
synthesis involves the preparation of an aminoderivative of CD by using 6-o-monotosyl-6-
deoxy-β-cyclodextrin (CDTs) as an intermediate. Preparation of CDTs involves the reaction 
of β-CD with p-toluenesulphonyl chloride in pyridine, with recrystallisation from water.2 
The synthesis used in this study is a modified version of an aqueous-based method reported 
by Brady et al (2000).
3
 From the CDTs, a diaminoalkane derivative 6-deoxy-6-[1-(2-
amino)ethylamino]-β-cyclodextrin (CDEn) was prepared according to the method published 
by Potter et al (2007).
4
 Tofzikovskaya et al (2012) proposed to link CDEn to folic acid (FA) 
by a simple covalent peptide bond for obtaining CDEnFA. This procedure involves the use of 
N,N’-dicyclohexylcarbodiimide (DCC) as a coupling agent and N-hydroxysuccinimide 
(NHS) as an acid activator. Hence, the activation of folic acid with N-hydroxysuccinimide to 
produce the ester of folic acid, followed by the conjugation with the CDEn through an amide 
bond formation with the ester of folic acid, results in the CDEnFA. The synthesis of 
CDEnFA was firstly reported by Clementi et al (2001)
5
 with a 5% yield while 
Tofzikovskaya et al (2012)
1
 achieved a 60% yield with this improved method. CDEnFA and 
MTX are combined to form the inclusion complex, CDEnFA:MTX. The MTX replaces the 
water molecules present in the CD’s cavity and forms non-covalent bonds for the guest–host 
complex formation. 
For the experimental procedures, all materials were purchased from commercial sources and 
were used without further purification. β-cyclodextrin was supplied by Wacker Chemie UK.  
The characterisation of CDTs, CDEn and CDEnFA was performed using nuclear magnetic 
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resonance (NMR) spectroscopy, which is a technique that allows for a complete analysis of 
the structure of organic compounds.  
NMR is a phenomenon that occurs when the nuclei of certain atoms are immersed in a static 
magnetic field.
6
 Some nuclei experience this phenomenon and others do not, depending upon 
whether they possess a property called spin or angular momentum. Atomic nuclei with even 
numbers of protons and neutrons have zero spin and all the other atoms with odd numbers 
have a non-zero spin. In the NMR experiment, a spin flip between the energy levels occurs. 
The energy difference between two states corresponds to the energy of the electromagnetic 
radiation that causes the nuclei to change their energy levels. The energy absorbed by the 
nuclear spins induces a voltage that can be detected, amplified, and the signal displayed as a 
free induction decay.
7
 The most common types of NMR spectroscopy are carbon-13 NMR 
(
13
C NMR) and proton NMR (
1
H NMR), which provide information on the amounts and 
types of carbons and protons in the molecule, respectively. A 2D Heteronuclear Single-
Quantum Correlation (HSQC) NMR experiment permits to obtain a 2D heteronuclear 
chemical shift correlation between directly-bonded 
1
H and 
13
C. The NMR characterisation 
was performed on a Bruker (Boston, MA) Avance 400 NMR spectrometer operating at 400 
MHz for 
1
H and 100 MHz for 
13
C. Bruker Icon NMR software was used with a HP x1100 
Pentium 4 workstation. 
1
H and 
13
C spectra of CDTs and folic acid were recorded in DMSO-
d
6
 due lack of solubility in D2O. All other samples were recorded in D2O and were referenced 
to TMS at 0 ppm. Samples were of approximate concentrations of 15-50 x 10
-3
 mol dm
-3
. 
Figure 7.1 shows the numbering system used for β-CD when assigning NMR shifts, while the 
additional numbering systems for the substituents in its derivatives CDTs, CDEn and 
CDEnFA are shown in the next figures in this section. 
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Figure 7.1. Numbering system for the substituted glucose unit of β-cyclodextrin, where x is 
the substitutent. 
 
Step 1) Synthesis and characterisation of 6-o-monotosyl-6-deoxy-β-cyclodextrin (CDTs) 
β-cyclodextrin hydrate β-CD (10.01 g, 7.61 mmol) was dissolved in NaOH (100 cm3 of 0.4 
mol dm
-3
). The solution was cooled in ice and p-toluenesulfonyl chloride TsCl (3.0 g, 15.79 
mmol) was added. The mixture was stirred for 3 hours at 0 – 4 oC. The mixture was then 
filtered and the pH of the filtrate adjusted to 6.5 using HCl (1 mol dm
-3
, 20 cm
3
) and a 
precipitate formed. The filtrate was then cooled at 4 
o
C for 24 hours. The product was 
removed by filtration, washed with acetone and recrystallised from water several times. The 
solid was recovered by filtration, washed with acetone and allowed to dry at 60 °C for 4 
hours.  
Yield 2.63 g, 24% (based on hydrated material).  
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Figure 7.2. Numbering system for CDTs, where R is the glucose unit of the β-CD displayed 
in figure 7.1. 
 
1
H NMR (DMSO) δ (ppm): 7.7 (H8), 7.4 (H9), 5.8 (OH2, OH3), 4.8 (H1), 4.5 (OH6), 4.3 
(H6b), 3.6 (H6), 3.6 (H3), 3.5 (H5), 3.3 (H4), 3.3 (H2), 2.5 (H11). 
13C NMR (DMSO) δ (ppm): 144.7 (C10), 132.6 (C7), 129.8 (C9), 127.5 (C8), 102.1 (C1’), 
101.8 (C1), 101.2 (C1’’), 81.4 (C4’), 81.1 (C4’’), 80.7 (C4), 73.0 (C3), 72.6 (C2’ or C3’), 
72.3 (C2), 71.9 (C5), 68.8 (C6’), 69.8 (C5’), 59.8 (C6), 59.4 (C6’’), 21.1 (C11). 
 
13
C NMR     
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Step 2) Synthesis and characterisation of 6-deoxy-6-[1-(2-amino)ethylamino]-β-
cyclodextrin (CDEn) 
6-o-monotosyl-6-deoxy-β-cyclodextrin (CDTs 2.5 g, 1.74 mmol) was dissolved in 1,2-
diaminoethane (70 cm
3
, 1.05 mol) and refluxed under nitrogen for 24 hours at 70 
o
C. The 
mixture was concentrated under vacuum and gave a pale yellow viscous oil. The oil was then 
dissolved in a minimum volume of water: methanol (3:1) mixture. The solution was slowly 
added to cold acetone and a precipitate formed. The precipitate was recovered by filtration, 
washed with acetone and dried in air. The product was dissolved in a minimum volume of 
water (60 °C). A minimum volume of acetone was added to just initiate crystallisation and 
the mixture was cooled to 4 °C. The product was recovered by filtration, washed with acetone 
and dried at 60 °C for 4 hours.  
Yield: 1.4g, 60% (based on hydrated material).  
 
Figure 7.3. Numbering system for CDEn, where R is the glucose unit of the β-CD displayed 
in figure 7.1. 
 
1
H NMR (D2O) δ (ppm): 4.9 (H1β), 3.9 (H3), 3.8 (H6a,b), 3.8 (H5), 3.5 (H2), 3.5 (H4), 3.3 
(H4’), 3.0 (H6’α), 2.7 (H6’β, H8), 2.6 (H7). 
 13
C NMR (D2O) δ (ppm): 101.7 (C1), 101.4 (C1’), 83.4 (C4’), 81.0 (C4) 80.8 (C4’’), 73.0 
(C3), 72.9 (C2’/C3’), 71.9 (C2), 71.7 (C5), 70.3 (C5’), 60.1 (C6), 49.8 (C9), 49.1 (C6’), 39.3 
(C8). 
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1
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HSQC 
 
Step 3) Synthesis and characterisation of 6-deoxy-6-[(1-(2-amino)ethylamino)folate]-β-
cyclodextrin (CDEnFA) 
Folic acid (0.075 g, 0.17 mmol) was dissolved in dimethylsufoxide (DMSO, 10 cm
3
) along 
with N-hydroxysuccinimide (NHS, 0.021 g, 0.18 mmol). Dicyclohexylcarbodiimide (DCC, 
0.038 g, 0.18 mmol) was then added, and the reaction mixture was stirred overnight in 
darkness under nitrogen at room temperature. The insoluble by-product, dicyclohexylurea, 
was removed by filtration. The filtrate contained the DMSO solution of the N-
hydroxysuccinimide ester (NHS-FA) intermediate. CDEn (0.3 g, 0.22 mmol) was dissolved 
in pyridine (2 cm
3
) and added to the NHS-FA solution. The reaction was performed under a 
nitrogen atmosphere at 55 °C for 4 h. The resultant solution was diluted with a mixture of 
acetone:diethylether (1:1 vol/vol, 45 cm
3
) and the product was recovered by filtration 
followed by recrystallisation from water. 
Chapter 7 Supplementary Information 
163 
 
Yield: 0.23 g, 55 % (based on hydrated material).  
 
Figure 7.4. Numbering system for CDEnFA, where R is the glucose unit of the β-CD 
displayed in figure 7.1. 
 
1
H NMR (D2O) δ (ppm): 4.94 (H1β), 3.45 (H2), 3.79 (H3), 3.41 (H4), 3.71 (H5), 3.47 
(H6a,b), 2.07 (H7), 2.67 (H8), 2.59 (H10), 2.15 (H11a), 2.00 (H11b), 4.18 (H12), 6.53 
(H16/18), 7.51 (H17/19), 4.66 (H21), 8.46 (H23). 
13
C NMR (D2O) δ (ppm): 102.4 (C1), 102.4 (C1’), 82.8 (C4’), 82.1 (C4) 82.1 (C4’’), 72.9 
(C3), 72.9 (C2’/C3’), 72.4 (C2), 72.0 (C5), 69.9 (C5’), 59.8 (C6), 48.6 (C6’), 39.9 (C8), 
165.3 (C9), 32.2 (C10), 30.7 (C11), 48.6 (C12), 161.6 (C13), 156.3 (C14), 122.3 (C15), 111.6 
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(C16), 128.2 (C17), 111.6 (C18), 129.2 (C19), 150.5 (C20), 46.4 (C21), 148.2 (C22), 148.4 
(C23), 128.2 (C24), 154.3 (C25), 156.3 (C26), 161.6 (C27). 
13
C NMR    
 
 
1
H NMR 
 
 
 
 
 
 
 
 
Chapter 7 Supplementary Information 
165 
 
HSQC 
 
 
Preparation of the inclusion complex CDEnFA:MTX 
The inclusion complex was prepared by combining CDEnFA and MTX in a 1:1 molar ratio 
using the paste method. CDEnFA was placed in a glass beaker with a minimum volume of 
water and stirred to achieve a homogeneous paste. Then, MTX powder was added slowly 
and the mixture stirred for 45 minutes. The paste was dried in an oven at 45 
o
C for 48 hours.  
The resulting solid was ground and stored in the dark. The NMR characterisation of the 
inclusion complex was reported by Tofzikovskaya et al (2012).
8
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Appendix 1. Plate design for real-time PCR. 
 
 
Figure A.1. Plate design for real-time PCR. C=CaCo-2; S=SKOV-3; H=HeLa; A=A549; 
B=BEAS-2B. 1, 2 and 3 represent biological triplicates. Two plates were used for assessing 
all reference and target genes. (KB cells were added to another experiment). 
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Appendix 2. Significant difference of folate receptor gene expression between folate-replete 
and folate free media. 
FOLATE RECEPTOR 
Two-way ANOVA 
   
  
Source of Variation % of total variation P value 
 
  
Column Factor 96.3 0.0001 
 
  
Row Factor 0.04 0.9702 
 
  
Source of Variation P value summary Significant? 
 
  
Column Factor *** Yes 
 
  
Row Factor ns No 
 
  
Source of Variation Df Sum-of-squares 
Mean 
square F 
Column Factor 3 40.02 13.34 52.55 
Row Factor 2 0.01546 0.007728 0.03044 
Residual 6 1.523 0.2539   
Bonferroni posttests       
folate-replete vs HeLa folate free       
Row Factor folate-replete HeLa folate free Difference 95% CI of diff. 
Row 1 1 2.313 1.313 -1.695 to 4.320 
Row 2 1 3.062 2.062 -0.9455 to 5.070 
Row 3 1 3 2 -1.008 to 5.008 
Row Factor Difference t P value Summary 
Row 1 1.313 1.842 P > 0.05 ns 
Row 2 2.062 2.894 P > 0.05 ns 
Row 3 2 2.807 P > 0.05 ns 
folate-replete vs Skov folate free       
Row Factor folate-replete Skov folate free Difference 95% CI of diff. 
Row 1 1 4.296 3.296 0.2887 to 6.304 
Row 2 1 4.777 3.777 0.7698 to 6.785 
Row 3 1 4.3 3.3 0.2924 to 6.308 
Row Factor Difference t P value Summary 
Row 1 3.296 4.626 P < 0.05 * 
Row 2 3.777 5.301 P<0.01 ** 
Row 3 3.3 4.631 P < 0.05 * 
folate-replete vs MCF-7 folate free       
Row Factor folate-replete MCF-7 folate free Difference 95% CI of diff. 
Row 1 1 6.537 5.537 2.529 to 8.545 
Row 2 1 5.11 4.11 1.102 to 7.117 
Row 3 1 6 5 1.992 to 8.008 
Row Factor Difference t P value Summary 
Row 1 5.537 7.771 P<0.001 *** 
Row 2 4.11 5.767 P<0.01 ** 
Row 3 5 7.017 P<0.01 ** 
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Appendix 3. Significant difference of reduced folate carrier gene expression between folate-
replete and folate free media. 
REDUCED FOLATE CARRIER 
Two-way ANOVA 
   
  
Source of Variation % of total variation P value 
 
  
Column Factor 90.05 0.0007 
 
  
Row Factor 3.16 0.3183 
 
  
Source of Variation P value summary Significant? 
 
  
Column Factor *** Yes 
 
  
Row Factor ns No 
 
  
Source of Variation Df Sum-of-squares Mean square F 
Column Factor 3 9.606 3.202 26.5 
Row Factor 2 0.3369 0.1684 1.394 
Residual 6 0.725 0.1208   
Bonferroni posttests         
folate-replete vs HeLa folate free       
Row Factor reg rpmi HeLa Difference 95% CI of diff. 
Row 1 1 0.2693 -0.7307 -2.806 to 1.344 
Row 2 1 0.3687 -0.6313 -2.706 to 1.444 
Row 3 1 0.3 -0.7 -2.775 to 1.375 
Row Factor Difference t P value Summary 
Row 1 -0.7307 1.486 P > 0.05 ns 
Row 2 -0.6313 1.284 P > 0.05 ns 
Row 3 -0.7 1.424 P > 0.05 ns 
folate-replete vs Skov folate free       
Row Factor reg rpmi Skov Difference 95% CI of diff. 
Row 1 1 2.874 1.874 -0.2009 to 3.949 
Row 2 1 1.824 0.824 -1.251 to 2.899 
Row 3 1 2.8 1.8 -0.2750 to 3.875 
Row Factor Difference t P value Summary 
Row 1 1.874 3.812 P < 0.05 * 
Row 2 0.824 1.676 P > 0.05 ns 
Row 3 1.8 3.662 P < 0.05 * 
folate-replete vs MCF-7 folate free       
Row Factor reg rpmi MCF-7 Difference 95% CI of diff. 
Row 1 1 0.04126 -0.9587 -3.034 to 1.116 
Row 2 1 0.07002 -0.93 -3.005 to 1.145 
Row 3 1 0.8 -0.2 -2.275 to 1.875 
Row Factor Difference t P value Summary 
Row 1 -0.9587 1.95 P > 0.05 ns 
Row 2 -0.93 1.892 P > 0.05 ns 
Row 3 -0.2 0.4068 P > 0.05 ns 
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Appendix 4. Significant difference of Ct values for FR and RFC gene expression between 
each cell line and the BEAS-2B cell line. 
Folate Receptor CT   
      
One-way analysis of variance       
 
  
P value < 0.0001     
 
  
alue summary ***     
 
  
Are means signif. different?  
(P < 0.05) 
Yes     
   
Number of groups 7     
 
  
F 63.41     
 
  
R squared 0.9645     
 
  
        
 
  
ANOVA Table SS df MS 
 
  
Treatment (between columns) 264.6 6 44.11 
 
  
Residual (within columns) 9.739 14 0.6956 
 
  
Total 274.4 20   
 
  
Dunnett's Multiple Comparison Test 
Mean Diff. q 
Significant?  
P < 0.05? 
Summary 95% CI of diff 
BEAS-2B vs KB 11.13 16.34 Yes *** 9.143 to 13.11 
BEAS-2B vs CaCo-2 6.199 9.103 Yes *** 4.216 to 8.183 
BEAS-2B vs SKOV 5.215 7.658 Yes *** 3.232 to 7.199 
BEAS-2B vs HeLa 2.128 3.124 Yes * 0.1443 to 4.111 
BEAS-2B vs MCF-7 1.880 2.761 No ns -0.1034 to 3.863 
BEAS-2B vs A549 1.333 1.957 No ns -0.6507 to 3.316 
 
Reduced Folate Carrier CT 
            
One-way analysis of variance           
P value 0.0001     
  
    
P value summary ***       
Are means signif. different?  
(P < 0.05) 
Yes         
Number of groups 7         
F 10.96         
R squared 0.8245         
            
ANOVA Table SS df MS     
Treatment (between columns) 44.45 6 7.408     
Residual (within columns) 9.459 14 0.6757     
Total 53.91 20       
            
Dunnett's Multiple Comparison Test 
Mean Diff. q 
Significant?  
P < 0.05? 
Summary 95% CI of diff 
BEAS-2B vs KB 4.157 6.194 Yes *** 2.202 to 6.112 
BEAS-2B vs CaCo-2 1.760 2.622 No ns -0.1948 to 3.715 
BEAS-2B vs SKOV-3 2.187 3.258 Yes * 0.2319 to 4.141 
BEAS-2B vs HeLa 4.496 6.699 Yes *** 2.541 to 6.451 
BEAS-2B vs MCF-7 3.676 5.477 Yes *** 1.721 to 5.631 
BEAS-2B vs A549 3.014 4.490 Yes ** 1.059 to 4.968 
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Appendix 5. Significant difference of Ct values for FR and RFC gene expression between 
all cell lines. 
Folate Receptor CT 
      
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different?  
(P < 0.05) Yes         
Number of groups 7         
F 63.41         
R squared 0.9645         
            
ANOVA Table SS df MS     
Treatment (between columns) 264.6 6 44.11     
Residual (within columns) 9.739 14 0.6956     
Total 274.4 20       
            
Tukey's Multiple Comparison Test Mean Diff. q 
Significant?  
P < 0.05? Summary 95% CI of diff 
KB vs CaCo-2 -4.928 10.23 Yes *** -7.253 to -2.602 
KB vs SKOV -5.912 12.28 Yes *** -8.237 to -3.586 
KB vs HeLa -8.999 18.69 Yes *** -11.32 to -6.674 
KB vs MCF-7 -9.247 19.20 Yes *** -11.57 to -6.921 
KB vs A549 -9.794 20.34 Yes *** -12.12 to -7.469 
KB vs BEAS-2B -11.13 23.11 Yes *** -13.45 to -8.801 
CaCo-2 vs SKOV -0.9840 2.043 No ns -3.309 to 1.341 
CaCo-2 vs HeLa -4.071 8.455 Yes *** -6.397 to -1.746 
CaCo-2 vs MCF-7 -4.319 8.970 Yes *** -6.645 to -1.994 
CaCo-2 vs A549 -4.866 10.11 Yes *** -7.192 to -2.541 
CaCo-2 vs BEAS-2B -6.199 12.87 Yes *** -8.525 to -3.874 
SKOV vs HeLa -3.087 6.412 Yes ** -5.413 to -0.7621 
SKOV vs MCF-7 -3.335 6.926 Yes ** -5.661 to -1.010 
SKOV vs A549 -3.883 8.063 Yes *** -6.208 to -1.557 
SKOV vs BEAS-2B -5.215 10.83 Yes *** -7.541 to -2.890 
HeLa vs MCF-7 -0.2478 0.5145 No ns -2.573 to 2.078 
HeLa vs A549 -0.7951 1.651 No ns -3.120 to 1.530 
HeLa vs BEAS-2B -2.128 4.419 No ns -4.453 to 0.1976 
MCF-7 vs A549 -0.5473 1.137 No ns -2.873 to 1.778 
MCF-7 vs BEAS-2B -1.880 3.904 No ns -4.205 to 0.4454 
A549 vs BEAS-2B -1.333 2.768 No ns -3.658 to 0.9927 
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Reduced Folate Carrier CT 
      
One-way analysis of variance           
P value 0.0001         
P value summary ***         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 7         
F 10.96         
R squared 0.8245         
            
ANOVA Table SS df MS     
Treatment (between columns) 44.45 6 7.408     
Residual (within columns) 9.459 14 0.6757     
Total 53.91 20       
            
Tukey's Multiple Comparison Test Mean Diff. q 
Significant?  
P < 0.05? Summary 95% CI of diff 
KB vs CaCo-2 -2.397 5.052 Yes * -4.689 to -0.1056 
KB vs SKOV-3 -1.971 4.152 No ns -4.262 to 0.3211 
KB vs HeLa 0.3389 0.7141 No ns -1.953 to 2.631 
KB vs MCF-7 -0.4812 1.014 No ns -2.773 to 1.810 
KB vs A549 -1.144 2.410 No ns -3.435 to 1.148 
KB vs BEAS-2B -4.157 8.760 Yes *** -6.449 to -1.866 
CaCo-2 vs SKOV-3 0.4267 0.8992 No ns -1.865 to 2.718 
CaCo-2 vs HeLa 2.736 5.766 Yes * 0.4445 to 5.028 
CaCo-2 vs MCF-7 1.916 4.038 No ns -0.3756 to 4.208 
CaCo-2 vs A549 1.254 2.642 No ns -1.038 to 3.545 
CaCo-2 vs BEAS-2B -1.760 3.708 No ns -4.052 to 0.5318 
SKOV-3 vs HeLa 2.309 4.866 Yes * 0.01778 to 4.601 
SKOV-3 vs MCF-7 1.489 3.138 No ns -0.8023 to 3.781 
SKOV-3 vs A549 0.8270 1.743 No ns -1.465 to 3.119 
SKOV-3 vs BEAS-2B -2.187 4.608 No ns -4.478 to 0.1051 
HeLa vs MCF-7 -0.8201 1.728 No ns -3.112 to 1.472 
HeLa vs A549 -1.483 3.124 No ns -3.774 to 0.8092 
HeLa vs BEAS-2B -4.496 9.474 Yes *** -6.788 to -2.204 
MCF-7 vs A549 -0.6624 1.396 No ns -2.954 to 1.629 
MCF-7 vs BEAS-2B -3.676 7.746 Yes ** -5.968 to -1.384 
A549 vs BEAS-2B -3.014 6.350 Yes ** -5.305 to -0.7219 
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Appendix 6. Significant difference of folate receptor gene expression between each cell line 
and the calibrator sample BEAS-2B (relative fold-difference values). 
 
 
FR sig dif to BEAS-2B (set to 1) 
  
Two-way ANOVA 
Source of Variation 
% of total 
variation 
P value 
  
Column Factor 97.98 < 0.0001   
Row Factor 0.77 0.0922   
Source of Variation P value summary Significant?   
Column Factor *** Yes   
Row Factor ns No   
Source of Variation 
Df 
Sum-of-
squares 
Mean 
square 
F 
Column Factor 5 12910 2582 156 
Row Factor 2 101.1 50.56 3.054 
Residual 10 165.6 16.56  
Bonferroni posttests     
BEAS-2B vs KB         
Row Factor 
BEAS-2B KB Difference 
95% CI of 
diff. 
Row 1 
1.000 2557 2556 
-244.5 to 
5357 
Row 2 1.000 3915 3914 1113 to 6714 
Row 3 
1.000 1117 1116 
-1685 to 
3917 
          
Row Factor Difference t P value Summary 
Row 1 2556 3.421 P<0.001 *** 
Row 2 3914 5.238 P<0.001 *** 
Row 3 1116 1.493 P<0.001 *** 
 
BEAS-2B vs CaCo-2 
    
Row Factor 
BEAS-2B CaCo-2 Difference 
95% CI of 
diff. 
Row 1 
1.000 78.28 77.28 
55.25 to 
99.30 
Row 2 
1.000 76.85 75.85 
53.83 to 
97.88 
Row 3 
1.000 65.94 64.94 
42.91 to 
86.96 
     
  
Row Factor Difference t P value Summary 
Row 1 77.28 13.43 P<0.001 *** 
Row 2 75.85 13.18 P<0.001 *** 
Row 3 64.94 11.28 P<0.001 *** 
BEAS-2B vs SKOV-3         
Row Factor 
BEAS-2B SKOV-3 Difference 
95% CI of 
diff. 
Row 1 1.000 46.63 45.63 23.60 to 
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67.66 
Row 2 
1.000 34.59 33.59 
11.56 to 
55.61 
Row 3 
1.000 31.78 30.78 
8.758 to 
52.81 
     
  
Row Factor Difference t P value Summary 
Row 1 45.63 7.929 P<0.001 *** 
Row 2 33.59 5.837 P<0.001 *** 
Row 3 30.78 5.349 P<0.001 *** 
BEAS-2B vs HeLa         
Row Factor 
BEAS-2B HeLa Difference 
95% CI of 
diff. 
Row 1 
1.000 8.576 7.576 
-14.45 to 
29.60 
Row 2 
1.000 2.572 1.572 
-20.45 to 
23.60 
Row 3 
1.000 3.785 2.785 
-19.24 to 
24.81 
     
  
Row Factor Difference t P value Summary 
Row 1 7.576 1.316 P > 0.05 ns 
Row 2 1.572 0.2731 P > 0.05 ns 
Row 3 2.785 0.484 P > 0.05 ns 
BEAS-2B vs MCF-7         
Row Factor 
BEAS-2B MCF-7 Difference 
95% CI of 
diff. 
Row 1 
1.000 7.742 6.742 
-15.28 to 
28.77 
Row 2 
1.000 2.106 1.106 
-20.92 to 
23.13 
Row 3 
1.000 3.059 2.059 
-19.97 to 
24.08 
     
  
Row Factor Difference t P value Summary 
Row 1 6.742 1.172 P > 0.05 ns 
Row 2 1.106 0.1921 P > 0.05 ns 
Row 3 2.059 0.3578 P > 0.05 ns 
BEAS-2B vs A549         
Row Factor 
BEAS-2B A549 Difference 
95% CI of 
diff. 
Row 1 
1.000 0.9281 -0.07191 
-22.10 to 
21.95 
Row 2 
1.000 5.941 4.941 
-17.08 to 
26.97 
Row 3 
1.000 2.898 1.898 
-20.13 to 
23.92 
     
  
Row Factor Difference t P value Summary 
Row 1 -0.07191 0.0125 P > 0.05 ns 
Row 2 4.941 0.8586 P > 0.05 ns 
Row 3 1.898 0.3298 P > 0.05 ns 
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Appendix 7. Significant difference of reduced folate carrier gene expression between each 
cell line and the calibrator sample BEAS-2B. 
RFC sig dif to BEAS-2B (set to 1) 
 
Two-way ANOVA    
  
Source of Variation % of total variation P value  
  
Column Factor 80.7 0.0014  
  
Row Factor 2.47 0.504  
  
Source of Variation P value summary Significant?  
  
Column Factor ** Yes  
  
Row Factor ns No  
  
Source of Variation 
Df Sum-of-squares 
Mean 
square 
F 
Column Factor 5 956.7 191.3 9.589 
Row Factor 2 29.31 14.65 0.7344 
Residual 10 199.5 19.95   
Bonferroni posttests         
BEAS-2B vs KB         
Row Factor BEAS-2B KB Difference 95% CI of diff. 
Row 1 1.000 11.47 10.47 -20.05 to 40.98 
Row 2 1.000 29.65 28.65 -1.868 to 59.16 
Row 3 1.000 16.71 15.71 -14.80 to 46.22 
          
Row Factor Difference t P value Summary 
Row 1 10.47 1.286 P > 0.05 ns 
Row 2 28.65 3.519 P < 0.05 * 
Row 3 15.71 1.930 P > 0.05 ns 
BEAS-2B vs CaCo-2         
Row Factor BEAS-2B CaCo-2 Difference 95% CI of diff. 
Row 1 1 3.317 2.317 -21.86 to 26.50 
Row 2 1 4.563 3.563 -20.62 to 27.74 
Row 3 1 6.354 5.354 -18.82 to 29.53 
     
  
Row Factor Difference t P value Summary 
Row 1 2.317 0.3668 P > 0.05 ns 
Row 2 3.563 0.564 P > 0.05 ns 
Row 3 5.354 0.8475 P > 0.05 ns 
BEAS-2B vs SKOV-3         
Row Factor BEAS-2B SKOV-3 Difference 95% CI of diff. 
Row 1 1 9.863 8.863 -15.32 to 33.04 
Row 2 1 1.993 0.9934 -23.18 to 25.17 
Row 3 1 4.799 3.799 -20.38 to 27.98 
     
  
Row Factor Difference t P value Summary 
Row 1 8.863 1.403 P > 0.05 ns 
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Row 2 0.9934 0.1573 P > 0.05 ns 
Row 3 3.799 0.6013 P > 0.05 ns 
BEAS-2B vs HeLa         
Row Factor BEAS-2B HeLa Difference 95% CI of diff. 
Row 1 1 21.75 20.75 -3.424 to 44.93 
Row 2 1 16.59 15.59 -8.592 to 39.76 
Row 3 1 31.85 30.85 6.669 to 55.03 
     
  
Row Factor Difference t P value Summary 
Row 1 20.75 3.285 P < 0.05 * 
Row 2 15.59 2.467 P > 0.05 ns 
Row 3 30.85 4.883 P<0.01 ** 
BEAS-2B vs MCF-7         
Row Factor BEAS-2B MCF-7 Difference 95% CI of diff. 
Row 1 1 18.2 17.2 -6.979 to 41.38 
Row 2 1 9.007 8.007 -16.17 to 32.19 
Row 3 1 12.74 11.74 -12.44 to 35.92 
     
  
Row Factor Difference t P value Summary 
Row 1 17.2 2.723 P > 0.05 ns 
Row 2 8.007 1.267 P > 0.05 ns 
Row 3 11.74 1.858 P > 0.05 ns 
BEAS-2B vs A549         
Row Factor BEAS-2B A549 Difference 95% CI of diff. 
Row 1 1 5.632 4.632 -19.55 to 28.81 
Row 2 1 12.9 11.9 -12.28 to 36.08 
Row 3 1 7.248 6.248 -17.93 to 30.43 
     
  
Row Factor Difference t P value Summary 
Row 1 4.632 0.7333 P > 0.05 ns 
Row 2 11.9 1.884 P > 0.05 ns 
Row 3 6.248 0.9891 P > 0.05 ns 
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Appendix 8. Significant difference for the folate receptor protein expression between each 
cell line. 
FR Protein expression 
      
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different?  
(P < 0.05) Yes         
Number of groups 7         
F 62.82         
R squared 0.9642         
            
ANOVA Table SS df MS     
Treatment (between columns) 2601000000000 6 433500000000     
Residual (within columns) 96610000000 14 6901000000     
Total 2698000000000 20       
            
Tukey's Multiple 
Comparison Test Mean Diff. q 
Significant?  
P < 0.05? Summary 95% CI of diff 
KB vs CaCo-2 896400 18.69 Yes *** 664800 to 1128000 
KB vs SKOV-3 1035000 21.58 Yes *** 803400 to 1267000 
KB vs HeLa 1021000 21.28 Yes *** 789200 to 1252000 
KB vs MCF-7 936300 19.52 Yes *** 704700 to 1168000 
KB vs A549 1039000 21.67 Yes *** 807500 to 1271000 
KB vs BEAS-2B 1039000 21.67 Yes *** 807600 to 1271000 
CaCo-2 vs SKOV-3 138600 2.891 No ns -92970 to 370200 
CaCo-2 vs HeLa 124500 2.595 No ns -107100 to 356100 
CaCo-2 vs MCF-7 39910 0.8322 No ns -191700 to 271500 
CaCo-2 vs A549 142800 2.977 No ns -88830 to 374400 
CaCo-2 vs BEAS-2B 142800 2.978 No ns -88760 to 374500 
SKOV-3 vs HeLa -14160 0.2952 No ns -245800 to 217400 
SKOV-3 vs MCF-7 -98730 2.058 No ns -330300 to 132900 
SKOV-3 vs A549 4138 0.08628 No ns -227500 to 235700 
SKOV-3 vs BEAS-2B 4208 0.08773 No ns -227400 to 235800 
HeLa vs MCF-7 -84570 1.763 No ns -316200 to 147000 
HeLa vs A549 18300 0.3815 No ns -213300 to 249900 
HeLa vs BEAS-2B 18370 0.3829 No ns -213200 to 250000 
MCF-7 vs A549 102900 2.145 No ns -128700 to 334500 
MCF-7 vs BEAS-2B 102900 2.146 No ns -128700 to 334500 
A549 vs BEAS-2B 69.67 0.001453 No ns -231500 to 231700 
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Appendix 9. Significant difference for the reduced folate carrier protein expression between 
each cell line. 
RFC protein expression 
            
One-way analysis of variance           
P value 0.0298         
P value summary ns         
Are means signif. different?  
(P < 0.05) No         
Number of groups 7         
F 3.331         
R squared 0.5881         
            
ANOVA Table SS df MS     
Treatment (between columns) 43410000 6 7235000     
Residual (within columns) 30410000 14 2172000     
Total 73820000 20       
            
Tukey's Multiple  
Comparison Test Mean Diff. q 
Significant?  
P < 0.05? Summary 95% CI of diff 
KB vs CaCo-2 992.3 1.166 No ns -3117 to 5101 
KB vs SKOV-3 3399 3.995 No ns -709.9 to 7508 
KB vs HeLa 124.0 0.1457 No ns -3985 to 4233 
KB vs MCF-7 -611.2 0.7183 No ns -4720 to 3498 
KB vs A549 899.7 1.057 No ns -3209 to 5009 
KB vs BEAS-2B 3112 3.658 No ns -996.7 to 7221 
CaCo-2 vs SKOV-3 2407 2.828 No ns -1702 to 6516 
CaCo-2 vs HeLa -868.3 1.021 No ns -4977 to 3241 
CaCo-2 vs MCF-7 -1604 1.885 No ns -5712 to 2505 
CaCo-2 vs A549 -92.67 0.1089 No ns -4202 to 4016 
CaCo-2 vs BEAS-2B 2120 2.491 No ns -1989 to 6229 
SKOV-3 vs HeLa -3275 3.849 No ns -7384 to 833.9 
SKOV-3 vs MCF-7 -4010 4.713 No ns -8119 to 98.74 
SKOV-3 vs A549 -2499 2.937 No ns -6608 to 1610 
SKOV-3 vs BEAS-2B -286.8 0.3371 No ns -4396 to 3822 
HeLa vs MCF-7 -735.2 0.8640 No ns -4844 to 3374 
HeLa vs A549 775.7 0.9116 No ns -3333 to 4885 
HeLa vs BEAS-2B 2988 3.512 No ns -1121 to 7097 
MCF-7 vs A549 1511 1.776 No ns -2598 to 5620 
MCF-7 vs BEAS-2B 3723 4.376 No ns -385.6 to 7832 
A549 vs BEAS-2B 2213 2.600 No ns -1896 to 6321 
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Appendix 10. Significant difference in cell viability between control (fresh medium: 100% 
cell viability) and CDEnFA treatment. 
Control vs CDEnFA treatment 
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 17.29 0.2988     
Column Factor 29.42 < 0.0001     
Concentration 9.48 0.0177     
          
Source of Variation P value summary Significant?     
Interaction ns No     
Column Factor *** Yes     
Concentration * Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 20 876.1 43.81 1.185 
Column Factor 5 1490 298.1 8.060 
Concentration 4 480.3 120.1 3.247 
Residual 60 2219 36.98   
          
Number of missing values 15       
          
Bonferroni posttests         
          
Control vs KB         
Concentration Control KB Difference 95% CI of diff. 
1.000 100.0 91.34 -8.665 -25.01 to 7.685 
5.000 100.0 91.29 -8.708 -25.06 to 7.642 
10.00 100.0 90.19 -9.806 -26.16 to 6.543 
50.00 100.0 86.12 -15.88 -32.23 to 0.4676 
100.0 100.0 84.27 -19.53 -35.88 to -3.183 
          
Concentration Difference t P value Summary 
1.000 -8.665 1.745 P > 0.05 ns 
5.000 -8.708 1.754 P > 0.05 ns 
10.00 -9.806 1.975 P > 0.05 ns 
50.00 -15.88 3.199 P < 0.05 * 
100.0 -19.53 3.934 P<0.01 ** 
          
Control vs CaCo-2         
Concentration Control CaCo-2 Difference 95% CI of diff. 
1.000 100.0 93.91 -6.086 -22.44 to 10.26 
5.000 100.0 95.69 -4.310 -20.66 to 12.04 
10.00 100.0 91.88 -8.120 -24.47 to 8.229 
50.00 100.0 95.21 -4.793 -21.14 to 11.56 
100.0 100.0 93.82 -6.182 -22.53 to 10.17 
          
Concentration Difference t P value Summary 
1.000 -6.086 1.226 P > 0.05 ns 
5.000 -4.310 0.8681 P > 0.05 ns 
10.00 -8.120 1.635 P > 0.05 ns 
50.00 -4.793 0.9652 P > 0.05 ns 
100.0 -6.182 1.245 P > 0.05 ns 
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Control vs MCF-7 
Concentration Control MCF-7 Difference 95% CI of diff. 
1.000 100.0 102.9 2.940 -13.41 to 19.29 
5.000 100.0 102.4 2.431 -13.92 to 18.78 
10.00 100.0 100.3 0.2626 -16.09 to 16.61 
50.00 100.0 91.17 -8.830 -25.18 to 7.519 
100.0 100.0 84.32 -15.68 -32.03 to 0.6648 
          
Concentration Difference t P value Summary 
1.000 2.940 0.5922 P > 0.05 ns 
5.000 2.431 0.4895 P > 0.05 ns 
10.00 0.2626 0.05289 P > 0.05 ns 
50.00 -8.830 1.778 P > 0.05 ns 
100.0 -15.68 3.159 P < 0.05 * 
          
Control vs A549         
Concentration Control A549 Difference 95% CI of diff. 
1.000 100.0 97.04 -2.958 -19.31 to 13.39 
5.000 100.0 93.45 -6.552 -22.90 to 9.797 
10.00 100.0 94.96 -5.045 -21.39 to 11.30 
50.00 100.0 100.7 0.6704 -15.68 to 17.02 
100.0 100.0 96.31 -3.686 -20.04 to 12.66 
          
Concentration Difference t P value Summary 
1.000 -2.958 0.5958 P > 0.05 ns 
5.000 -6.552 1.320 P > 0.05 ns 
10.00 -5.045 1.016 P > 0.05 ns 
50.00 0.6704 0.1350 P > 0.05 ns 
100.0 -3.686 0.7423 P > 0.05 ns 
          
Control vs BEAS-2B         
Concentration Control BEAS-2B Difference 95% CI of diff. 
1.000 100.0 94.44 -5.558 -21.91 to 10.79 
5.000 100.0 92.66 -7.339 -23.69 to 9.010 
10.00 100.0 90.44 -9.563 -25.91 to 6.786 
50.00 100.0 91.54 -8.457 -24.81 to 7.892 
100.0 100.0 87.61 -14.85 -31.20 to 1.494 
          
Concentration Difference t P value Summary 
1.000 -5.558 1.119 P > 0.05 ns 
5.000 -7.339 1.478 P > 0.05 ns 
10.00 -9.563 1.926 P > 0.05 ns 
50.00 -8.457 1.703 P > 0.05 ns 
100.0 -14.85 2.992 P < 0.05 * 
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Appendix 11. Significant difference in cell viability between control (fresh medium: 100% 
cell viability) and MTX treatment. 
Control vs MTX treatment 
     
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 24.52 < 0.0001     
Column Factor 34.34 < 0.0001     
Concentration 37.14 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction *** Yes     
Column Factor *** Yes     
Concentration *** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 20 11970 598.4 18.38 
Column Factor 5 16760 3352 103.0 
Concentration 4 18130 4532 139.3 
Residual 60 1953 32.55   
          
Number of missing values 15       
          
Bonferroni posttests         
          
Control vs KB         
Concentration Control KB Difference 95% CI of diff. 
1.000 100.0 57.52 -42.48 -57.81 to -27.14 
5.000 100.0 59.40 -40.60 -55.94 to -25.26 
10.00 100.0 60.41 -39.59 -54.93 to -24.25 
50.00 100.0 56.53 -43.47 -58.80 to -28.13 
100.0 100.0 57.87 -42.13 -57.47 to -26.80 
          
Concentration Difference t P value Summary 
1.000 -42.48 9.119 P<0.001 *** 
5.000 -40.60 8.716 P<0.001 *** 
10.00 -39.59 8.499 P<0.001 *** 
50.00 -43.47 9.331 P<0.001 *** 
100.0 -42.13 9.045 P<0.001 *** 
          
Control vs CaCo-2         
Concentration Control CaCo-2 Difference 95% CI of diff. 
1.000 100.0 87.16 -12.84 -28.17 to 2.502 
5.000 100.0 77.94 -22.06 -37.39 to -6.718 
10.00 100.0 82.98 -17.02 -32.36 to -1.685 
50.00 100.0 77.89 -22.11 -37.44 to -6.769 
100.0 100.0 32.98 -67.02 -82.36 to -51.68 
          
Concentration Difference t P value Summary 
1.000 -12.84 2.756 P < 0.05 * 
5.000 -22.06 4.735 P<0.001 *** 
10.00 -17.02 3.654 P<0.01 ** 
50.00 -22.11 4.746 P<0.001 *** 
100.0 
 
 
 
-67.02 14.39 P<0.001 *** 
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Control vs MCF-7     
Concentration Control MCF-7 Difference 95% CI of diff. 
1.000 100.0 108.3 8.274 -7.065 to 23.61 
5.000 100.0 99.91 -0.09296 -15.43 to 15.25 
10.00 100.0 96.15 -3.847 -19.19 to 11.49 
50.00 100.0 55.28 -44.72 -60.06 to -29.38 
100.0 100.0 45.58 -54.42 -69.76 to -39.09 
          
Concentration Difference t P value Summary 
1.000 8.274 1.776 P > 0.05 ns 
5.000 -0.09296 0.01996 P > 0.05 ns 
10.00 -3.847 0.8259 P > 0.05 ns 
50.00 -44.72 9.600 P<0.001 *** 
100.0 -54.42 11.68 P<0.001 *** 
          
Control vs A549         
Concentration Control A549 Difference 95% CI of diff. 
1.000 100.0 91.02 -8.983 -24.32 to 6.355 
5.000 100.0 80.15 -19.85 -35.18 to -4.508 
10.00 100.0 67.36 -32.64 -47.98 to -17.30 
50.00 100.0 38.24 -61.76 -77.10 to -46.42 
100.0 100.0 36.23 -63.77 -79.11 to -48.43 
          
Concentration Difference t P value Summary 
1.000 -8.983 1.929 P > 0.05 ns 
5.000 -19.85 4.260 P<0.001 *** 
10.00 -32.64 7.007 P<0.001 *** 
50.00 -61.76 13.26 P<0.001 *** 
100.0 -63.77 13.69 P<0.001 *** 
          
Control vs BEAS-2B         
Concentration Control BEAS-2B Difference 95% CI of diff. 
1.000 100.0 98.21 -1.788 -17.13 to 13.55 
5.000 100.0 100.3 0.3266 -15.01 to 15.66 
10.00 100.0 91.17 -8.827 -24.17 to 6.511 
50.00 100.0 56.72 -43.28 -58.62 to -27.94 
100.0 100.0 48.38 -51.62 -66.95 to -36.28 
          
Concentration Difference t P value Summary 
1.000 -1.788 0.3839 P > 0.05 ns 
5.000 0.3266 0.07012 P > 0.05 ns 
10.00 -8.827 1.895 P > 0.05 ns 
50.00 -43.28 9.291 P<0.001 *** 
100.0 -51.62 11.08 P<0.001 *** 
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Appendix 12. Significant difference of cell viability between control (fresh medium: 100% 
cell viability) and CDEnFA:MTX treatment. 
Control vs CDEnFA:MTX treatment 
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 16.31 < 0.0001     
Column Factor 42.86 < 0.0001     
Concentration 39.04 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction *** Yes     
Column Factor *** Yes     
Concentration *** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 20 10030 501.7 27.36 
Column Factor 5 26360 5272 287.5 
Concentration 4 24010 6003 327.4 
Residual 60 1100 18.34   
          
Number of missing values 15       
          
Bonferroni posttests         
          
Control vs KB         
Concentration Control KB Difference 95% CI of diff. 
1.000 100.0 52.22 -47.78 -59.29 to -36.27 
5.000 100.0 46.33 -53.67 -65.18 to -42.16 
10.00 100.0 48.65 -51.35 -62.86 to -39.84 
50.00 100.0 39.50 -60.50 -72.02 to -48.99 
100.0 100.0 38.50 -61.50 -73.02 to -49.99 
          
Concentration Difference t P value Summary 
1.000 -47.78 13.66 P<0.001 *** 
5.000 -53.67 15.35 P<0.001 *** 
10.00 -51.35 14.69 P<0.001 *** 
50.00 -60.50 17.30 P<0.001 *** 
100.0 -61.50 17.59 P<0.001 *** 
          
Control vs CaCo-2         
Concentration Control CaCo-2 Difference 95% CI of diff. 
1.000 100.0 88.07 -11.93 -23.44 to -0.4143 
5.000 100.0 78.10 -21.90 -33.42 to -10.39 
10.00 100.0 77.25 -22.75 -34.26 to -11.24 
50.00 100.0 54.43 -45.57 -57.09 to -34.06 
100.0 100.0 35.61 -64.39 -75.91 to -52.88 
          
Concentration Difference t P value Summary 
1.000 -11.93 3.411 P<0.01 ** 
5.000 -21.90 6.265 P<0.001 *** 
10.00 -22.75 6.507 P<0.001 *** 
50.00 -45.57 13.03 P<0.001 *** 
100.0 -64.39 18.42 P<0.001 *** 
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Control vs MCF-7         
Concentration Control MCF-7 Difference 95% CI of diff. 
1.000 100.0 107.3 7.299 -4.214 to 18.81 
5.000 100.0 100.2 0.1645 -11.35 to 11.68 
10.00 100.0 92.69 -7.315 -18.83 to 4.198 
50.00 100.0 54.65 -45.35 -56.86 to -33.84 
100.0 100.0 41.75 -58.25 -69.77 to -46.74 
          
Concentration Difference t P value Summary 
1.000 7.299 2.088 P > 0.05 ns 
5.000 0.1645 0.04705 P > 0.05 ns 
10.00 -7.315 2.092 P > 0.05 ns 
50.00 -45.35 12.97 P<0.001 *** 
100.0 -58.25 16.66 P<0.001 *** 
          
Control vs A549         
Concentration Control A549 Difference 95% CI of diff. 
1.000 100.0 103.0 2.999 -8.514 to 14.51 
5.000 100.0 102.7 2.712 -8.801 to 14.22 
10.00 100.0 82.62 -17.38 -28.89 to -5.864 
50.00 100.0 45.84 -54.16 -65.68 to -42.65 
100.0 100.0 41.44 -58.56 -70.07 to -47.04 
          
Concentration Difference t P value Summary 
1.000 2.999 0.8576 P > 0.05 ns 
5.000 2.712 0.7757 P > 0.05 ns 
10.00 -17.38 4.970 P<0.001 *** 
50.00 -54.16 15.49 P<0.001 *** 
100.0 -58.56 16.75 P<0.001 *** 
          
Control vs BEAS-2B         
Concentration Control BEAS-2B Difference 95% CI of diff. 
1.000 100.0 106.6 6.583 -4.930 to 18.10 
5.000 100.0 106.7 6.712 -4.800 to 18.23 
10.00 100.0 100.8 0.8202 -10.69 to 12.33 
50.00 100.0 66.88 -33.12 -44.64 to -21.61 
100.0 100.0 55.01 -44.99 -56.50 to -33.47 
          
Concentration Difference t P value Summary 
1.000 6.583 1.883 P > 0.05 ns 
5.000 6.712 1.920 P > 0.05 ns 
10.00 0.8202 0.2346 P > 0.05 ns 
50.00 -33.12 9.474 P<0.001 *** 
100.0 -44.99 12.87 P<0.001 *** 
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Appendix 13. A comparison of the cell viability for each of the cell lines studied after a 48-
hour exposure to the solvent NaOH and to the compounds CDEnFA, MTX and 
CDEnFA:MTX 
 
Figure A.2. Effect of the solvent NaOH, the carrier CDEnFA, the drug MTX and the 
complex CDEnFA:MTX on the cell viability of KB, CaCo-2, MCF-7, A549 and BEAS-2B 
cells. 
 
 
Appendices 
187 
 
Appendix 14. Plots representing how samples are gated to exclude debris or clumps and to 
determine positives. 
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Appendix 15. Significant difference in the folate receptor MFI, between KB untreated 
sample and (A) FB1-treated or (B) SSZ-treated.  
 
 
Appendix 16. Significant difference in the reduced folate carrier MFI, between KB untreated 
sample and (A) FB1-treated or (B) SSZ-treated.  
(A) Reduced Folate Carrier  FB1 
Column A Untreated 
vs vs 
Column B FB1 
    
Unpaired t test   
P value 0.1202 
P value summary ns 
Are means signif. different?  
(P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.970 df=4 
    
How big is the difference?   
Mean ± SEM of column A 15480 ± 291.5 N=3 
Mean ± SEM of column B 14650 ± 303.8 N=3 
Difference between means 829.3 ± 421.1 
95% confidence interval -339.5 to 1998 
R squared 0.4924 
 
   
(B) Reduced Folate Carrier  SSZ 
Column A untreated 
vs vs 
Column B SSZ treated 
    
Unpaired t test   
P value 0.0469 
P value summary * 
Are means signif. different? 
(P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.840 df=4 
    
How big is the difference?   
Mean ± SEM of column A 15780 ± 274.8 N=3 
Mean ± SEM of column B 14380 ± 410.8 N=3 
Difference between means 1403 ± 494.2 
95% confidence interval 31.40 to 2775 
R squared 0.6684 
 
(A) Folate Receptor  FB1 
Column A Untreated 
vs vs 
Column B FB1 treated 
    
Unpaired t test   
P value 0.0049 
P value summary ** 
Are means signif. different?  
(P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=5.634 df=4 
    
How big is the difference?   
Mean ± SEM of column A 1351000 ± 47170 N=3 
Mean ± SEM of column B 637500 ± 117600 N=3 
Difference between means 713900 ± 126700 
95% confidence interval 362100 to 1066000 
R squared 0.8881 
(B) Folate Receptor SSZ 
Column A untreated 
vs vs 
Column B SSZ treated 
    
Unpaired t test   
P value 0.9841 
P value summary ns 
Are means signif. different?  
(P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.02124 df=4 
    
How big is the difference?   
Mean ± SEM of column A 1245000 ± 91170 N=3 
Mean ± SEM of column B 1247000 ± 89710 N=3 
Difference between means -2717 ± 127900 
95% confidence interval -357800 to 352400 
R squared 0.0001128 
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Appendix 17. Significant difference in the reduced folate carrier MFI, between KB untreated 
sample and (A) FB1-treated or (B) SSZ-treated.  
Controls 
      
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different?  
(P < 0.05) Yes         
Number of groups 5         
F 70.12         
R squared 0.9656         
            
ANOVA Table SS df MS     
Treatment (between columns) 13060000000 4 3264000000     
Residual (within columns) 465500000 10 46550000     
Total 13520000000 14       
            
Dunnett's Multiple  
Comparison Test Mean Diff. q 
Significant?  
P < 0.05? Summary 95% CI of diff 
Live cells vs Dead cells  -77290 13.87 Yes *** -93390 to -61190 
Live cells vs FB1  -518.8 0.09313 No ns -16620 to 15580 
Live cells vs SSZ  -8669 1.556 No ns -24770 to 7433 
Live cells vs FB1+SSZ -6925 1.243 No ns -23030 to 9177 
 
 
Appendix 18. Significant difference between untreated samples (test compound only) and 
FB1-treated samples. (A) MTX; (B) CDEnFA:MTX and (C) CDEnFA. 
(A) MTX FB1  
Two-way RM ANOVA         
Source of Variation % of total variation P value     
Interaction 6.64 0.4622     
Concentration 12.39 0.2624     
Column Factor 17.40 0.2165     
Subjects (matching) 32.3816 0.1760     
          
Source of Variation P value summary Significant?     
Interaction ns No     
Concentration ns No     
Column Factor ns No     
Subjects (matching) ns No     
          
Bonferroni posttests         
          
No treatment (MTX only)  
vs FB1 treated         
Column Factor 
No treatment (MTX 
only) FB1 treated Difference 95% CI of diff. 
10 37290 28210 -9088 -38710 to 20540 
100 54130 33700 -20430 -50050 to 9194 
1000 37820 33880 -3941 -33560 to 25680 
          
Column Factor Difference t P value Summary 
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10 µM -9088 0.8527 P > 0.05 ns 
100 µM -20430 1.917 P > 0.05 ns 
1000 µM -3941 0.3697 P > 0.05 ns 
 
(B) CDEnFAMTX FB1 
Source of Variation % of total variation P value     
Interaction 3.60 0.3869     
Concentration 7.15 0.1815     
Column Factor 67.72 0.0044     
Subjects (matching) 8.0849 0.3805     
          
Source of Variation P value summary Significant?     
Interaction ns No     
Concentration ns No     
Column Factor ** Yes     
Subjects (matching) ns No     
 
Bonferroni posttests 
         
No treatment (CDEnFA:MTX only)  
vs FB1 treated         
Column Factor 
 (CDEnFA:MTX 
only) FB1 treated Difference 95% CI of diff. 
10 58430 41260 -17160 
-34700 to 
373.8 
100 60590 40020 -20570 -38110 to -3031 
1000 72490 43070 -29410 -46950 to -11880 
          
Column Factor Difference t P value Summary 
10 µM -17160 2.720 P > 0.05 ns 
100 µM -20570 3.260 P < 0.05 * 
1000 µM -29410 4.661 P<0.01 ** 
     
(C) CDEnFA FB1 
Source of Variation % of total variation P value     
Interaction 1.01 0.7629     
Concentration 76.42 0.0006     
Column Factor 1.05 0.4839     
Subjects (matching) 7.0443 0.4729     
          
Source of Variation P value summary Significant?     
Interaction ns No     
Concentration *** Yes     
Column Factor ns No     
Subjects (matching) ns No     
  
Bonferroni posttests 
         
No treatment (CDEnFA only)  
vs FB1 treated         
Column Factor 
No treatment (CDEnFA 
only) FB1 treated Difference 95% CI of diff. 
10 3281 3461 180.2 -479.4 to 839.7 
100 2357 2316 -41.00 -700.5 to 618.5 
1000 3077 3252 174.7 -484.9 to 834.2 
          
Column Factor Difference t P value Summary 
10 µM 180.2 0.7593 P > 0.05 ns 
100 µM -41.00 0.1728 P > 0.05 ns 
1000 µM 174.7 0.7361 P > 0.05 ns 
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Appendix 19. Significant difference between untreated samples (test compound only) and 
SSZ-treated samples. (A) MTX; (B) CDEnFA:MTX and (C) CDEnFA. 
MTX SSZ 
Two-way RM ANOVA 
 
      
          
Source of Variation % of total variation P value     
Interaction 5.51 0.5787     
Concentration 13.52 0.2925     
Column Factor 29.50 0.0435     
Subjects (matching) 13.9067 0.5903     
          
Source of Variation P value summary Significant?     
Interaction ns No     
Concentration ns No     
Column Factor * Yes     
Subjects (matching) ns No     
          
Bonferroni posttests         
          
No treatment (MTX 
only)  
vs SSZ treated         
Column Factor 
No treatment (MTX 
only) SSZ treated Difference 95% CI of diff. 
10 37290 22830 -14460 -42280 to 13360 
100 54130 30630 -23500 -51320 to 4321 
1000 37820 30310 -7508 -35330 to 20310 
          
Column Factor Difference t P value Summary 
10 µM -14460 1.445 P > 0.05 ns 
100 µM -23500 2.348 P > 0.05 ns 
1000 µM -7508 0.7501 P > 0.05 ns 
     
     
CDEnFA:MTX SSZ 
Two-way RM ANOVA        
          
Source of Variation 
% of total 
variation P value     
Interaction 35.86 0.0107     
Concentration 7.70 0.2241     
Column Factor 0.44 0.8418     
Subjects (matching) 39.0281 0.0320     
          
Source of Variation P value summary Significant?     
Interaction * Yes     
Concentration ns No     
Column Factor ns No     
Subjects (matching) * Yes     
          
Bonferroni posttests         
          
No treatment 
(CDEnFA:MTX  
only) vs SSZ treated         
Column Factor 
No treatment 
(CDEnFA:MTX 
only) SSZ treated Difference 95% CI of diff. 
10 58430 70900 12470 -23160 to 48100 
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100 60590 81300 20710 -14920 to 56340 
1000 72490 46140 -26340 -61970 to 9288 
          
Column Factor  Difference t P value Summary 
10 µM 12470 0.9730 P > 0.05 ns 
100 µM 20710 1.615 P > 0.05 ns 
1000 µM -26340 2.055 P > 0.05 ns 
       
CDEnFA SSZ 
Two-way RM ANOVA 
 
      
          
Source of Variation 
% of total 
variation P value     
Interaction 5.66 0.5993     
Concentration 3.59 0.7170     
Column Factor 47.34 0.0006     
Subjects (matching) 1.9799 0.9810     
          
Source of Variation 
P value 
summary Significant?     
Interaction ns No     
Concentration ns No     
Column Factor *** Yes     
Subjects (matching) ns No     
          
Bonferroni posttests         
          
No treatment (CDEnFA 
only)  
vs SSZ treated         
Column Factor 
No treatment 
(CDEnFA only) SSZ treated Difference 95% CI of diff. 
10 3281 5159 1878 -2996 to 6751 
100 2357 6778 4421 -452.6 to 9294 
1000 3077 7764 4687 -186.9 to 9560 
          
Column Factor Difference t P value Summary 
10 µM 1878 1.071 P > 0.05 ns 
100 µM 4421 2.521 P > 0.05 ns 
1000 µM 4687 2.673 P > 0.05 ns 
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Appendix 20. Significant difference between untreated samples (test compound only) and 
FB1+SSZ co-treated samples. (A) MTX; (B) CDEnFA:MTX and (C) CDEnFA. 
MTX FB1+SSZ 
          
Two-way RM ANOVA       
          
Source of Variation % of total variation P value     
Interaction 10.21 0.4093     
Concentration 19.39 0.2110     
Column Factor 6.80 0.3363     
Subjects (matching) 22.8180 0.4117     
          
Source of Variation P value summary Significant?     
Interaction ns No     
Concentration ns No     
Column Factor ns No     
Subjects (matching) ns No     
          
Bonferroni posttests         
          
No treatment (MTX only)  
vs FB1 + SSZ          
Column Factor No treatment (MTX only) FB1 + SSZ  Difference 95% CI of diff. 
10 37290 36970 -325.0 -23130 to 22480 
100 54130 39480 -14650 -37450 to 8154 
1000 37820 36700 -1120 -23920 to 21680 
          
Column Factor Difference t P value Summary 
10 µM -325.0 0.03962 P > 0.05 ns 
100 µM -14650 1.786 P > 0.05 ns 
1000 µM -1120 0.1365 P > 0.05 ns 
 
CDEnFA:MTX FB1+SSZ 
Two-way RM ANOVA 
 
      
          
Source of Variation % of total variation P value     
Interaction 0.34 0.5599     
Concentration 2.44 0.0500     
Column Factor 93.52 < 0.0001     
Subjects (matching) 1.5049 0.3249     
          
Source of Variation P value summary Significant?     
Interaction ns No     
Concentration * Yes     
Column Factor *** Yes     
Subjects (matching) ns No     
          
Bonferroni posttests         
          
No treatment (CDEnFA:MTX  
only) vs FB1 + SSZ treated         
Column Factor 
No treatment  
(CDEnFA:MTX only) 
FB1 + SSZ 
treated Difference 95% CI of diff. 
10 58430 3175 -55250 -70950 to -39550 
100 60590 6952 -53640 -69340 to -37930 
1000 72490 10890 -61600 -77300 to -45900 
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Column Factor Difference t P value Summary 
10 µM -55250 9.779 P<0.001 *** 
100 µM -53640 9.494 P<0.001 *** 
1000 µM -61600 10.90 P<0.001 *** 
 
CDEnFA FB1+SSZ 
Two-way RM ANOVA 
 
      
         
Source of Variation % of total variation P value     
Interaction 17.16 0.0439     
Concentration 25.42 0.0174     
Column Factor 34.65 0.0149     
Subjects (matching) 8.2732 0.4029     
          
Source of Variation P value summary Significant?     
Interaction * Yes     
Concentration * Yes     
Column Factor * Yes     
Subjects (matching) ns No     
          
Bonferroni posttests         
          
No treatment (CDEnFA only) 
vs FB1 + SSZ treated         
Column Factor 
No treatment 
(CDEnFA only) 
FB1 + SSZ 
treated Difference 95% CI of diff. 
10 3281 4510 1229 219.8 to 2238 
100 2357 3802 1445 436.4 to 2454 
1000 3077 3090 13.17 -995.7 to 1022 
          
Column Factor Difference t P value Summary 
10 µM 1229 3.385 P < 0.05 * 
100 µM 1445 3.982 P<0.01 ** 
1000 µM 13.17 0.03627 P > 0.05 ns 
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Appendix 21. Significant difference between the test samples and sham-inoculated control 
for haemocytes count. 
Haemocytes  
  
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 12.90 0.0059     
Column Factor 65.88 < 0.0001     
Row Factor 4.71 0.0041     
          
Source of Variation P value summary Significant?     
Interaction ** Yes     
Column Factor ** Yes     
Row Factor ** Yes     
          
Bonferroni posttests         
          
Sham vs NaOH         
Row Factor Sham NaOH Difference 95% CI of diff. 
4 7500000 8333000 833300 -1739000 to 3406000 
10 7500000 8167000 666700 -1906000 to 3239000 
40 7500000 6833000 -666700 -3239000 to 1906000 
100 7500000 5833000 -1667000 -4239000 to 905800 
400 7500000 8500000 1000000 -1572000 to 3572000 
          
          
Row Factor Difference t P value Summary 
4 833300 1.047 P > 0.05 ns 
10 666700 0.8375 P > 0.05 ns 
40 -666700 0.8375 P > 0.05 ns 
100 -1667000 2.094 P > 0.05 ns 
400 1000000 1.256 P > 0.05 ns 
          
          
Sham vs CDEnFA         
Row Factor Sham CDEnFA Difference 95% CI of diff. 
4 7500000 7500000 0.0000 -2572000 to 2572000 
10 7500000 7500000 0.0000 -2572000 to 2572000 
40 7500000 7500000 0.0000 -2572000 to 2572000 
100 7500000 7500000 0.0000 -2572000 to 2572000 
400 7500000 7500000 0.0000 -2572000 to 2572000 
          
          
Row Factor Difference t P value Summary 
4 0.0000 0.0000 P > 0.05 ns 
10 0.0000 0.0000 P > 0.05 ns 
40 0.0000 0.0000 P > 0.05 ns 
100 0.0000 0.0000 P > 0.05 ns 
400 0.0000 0.0000 P > 0.05 ns 
          
          
     
Sham vs MTX         
Row Factor Sham MTX Difference 95% CI of diff. 
4 7500000 5933000 -1567000 -4139000 to 1006000 
10 7500000 5667000 -1833000 -4406000 to 739100 
40 7500000 6667000 -833300 -3406000 to 1739000 
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100 7500000 6667000 -833300 -3406000 to 1739000 
400 7500000 9667000 2167000 -405800 to 4739000 
          
          
Row Factor Difference t P value Summary 
4 -1567000 1.968 P > 0.05 ns 
10 -1833000 2.303 P > 0.05 ns 
40 -833300 1.047 P > 0.05 ns 
100 -833300 1.047 P > 0.05 ns 
400 2167000 2.722 P > 0.05 ns 
          
          
Sham vs CDEnFA:MTX         
Row Factor Sham CDEnFA:MTX Difference 95% CI of diff. 
4 7500000 9333000 1833000 -739100 to 4406000 
10 7500000 9833000 2333000 -239100 to 4906000 
40 7500000 10670000 3167000 594200 to 5739000 
100 7500000 7833000 333300 -2239000 to 2906000 
400 7500000 10170000 2667000 94190 to 5239000 
          
          
Row Factor Difference t P value Summary 
4 1833000 2.303 P > 0.05 ns 
10 2333000 2.931 P > 0.05 ns 
40 3167000 3.978 P<0.01 ** 
100 333300 0.4188 P > 0.05 ns 
400 2667000 3.350 P<0.05 * 
 
 
 
 
 
 
